CA2534342C - Amino acid prodrugs - Google Patents

Abstract

The present invention is directed to a prodrug comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The prodrug has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the prodrugs of the present invention enhance at least two therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Description

AMINO ACID PRODRUGS
SCOPE OF THE INVENTION
The invention relates to amino acid derivatives of pharmaceutical compounds, methods of treating particular ailments, which are ameliorated by the administration of these drugs and pharmaceutical compositions containing these drugs.
The current invention involves improving many physicochemical, biopharmaceutical, and clinical efficacy of various drugs using amino acids as covalently bonded carriers for these drugs.
The development of chemical compounds for the treatment of disorders, maladies and diseases has become increasingly difficult and costly. The probability of success for such development is often discouragingly low. Further, the time for development can approach or exceed ten years, leaving large numbers of patients without remedy for an extended period of time.
Even in cases in which effective pharmaceutical compounds have been developed, there are often disadvantages associated with their administration. These disadvantages can include aesthetic, and pharmacokinetic bafflers affecting the effectiveness of some existing pharmaceutical compounds, For example, unpleasant taste or smell of a pharmaceutical compound or composition can be a significant barrier to patient compliance with respect to the administration regimen. The undesirable solubility characteristics of a pharmaceutical compound can lead to difficulty in formulation of a homogeneous composition. Other disadvantages associated with known pharmaceutical compounds include: poor absorption of orally administered formulations; poor bioavailability of the pharmaceutical compounds in oral formulations; lack of dose proportionality; low stability of pharmaceutical compounds in vitro and in vivo; poor penetration of the blood/brain barrier; excessive first-pass metabolism of pharmaceutical compounds as they pass through the liver; excessive enterohepatic recirculation; low absorption rates; ineffective compound release at the site of action;
excessive irritation, H:\work\1652\17690\SPEC\17690.spec without claimsII.doc for example, gastro-intestinal irritability and/or ulceration; painful injection of parenterally administered pharmaceutical compounds and compositions;
excessively high dosages required for some pharmaceutical compounds and compositions, and other undesirable characteristics. Some pharmaceutical compounds are processed by the body to produce toxic by-products with harmful effects.
The art is continually seeking new chemical compounds for the treatment of a wide variety of disorders, with improved properties to overcome the disadvantages of known pharmaceutical compounds mentioned above.
The present invention has overcome many problems associated with currently marketed drugs by making prodrugs. The concept of prodrugs is well known, and there are a number of examples of such prodrugs enumerated in the literature and there are a number of prodrugs available in the market, including such diverse groups as statin drugs, ACE inhibitors, antiviral drugs such as Acyclovir and the like.
The present invention, however, uses amino acids as the moiety to make the prodrugs.
The prodrugs of the present invention have a number of advantages. For example, when amino acid prodrugs are administered by a number of routes such as oral, Iv, rectal or other such methods, these prodrugs are converted into active drug molecules. A
significant advantage of the amino acid prodrug is that it is non-toxic, and hence either assimilated into the body or safely excreted. This is quite unlike the characteristics exhibited by a number of prodrugs available in the market, where the promoiety itself is toxic, as is the case with statin drugs, Enalapril, Benazapril and the like group of ace inhibitors, and a number of antibiotics such as pivoxil, isopropyl, Axetil, Cilexetil and the like groups, which are highly toxic, thereby reducing the therapeutic index of the active drug.
On the other hand, the amino acid prodrugs of the present invention also impart a number of advantages as shown herein below.

2 11\work\1652\17690\SPEC\17690.spec without claimsadoc SUMMARY OF THE INVENTION
The present invention is directed to a pharmaceutically active prodrug, having amino acid covalently bonded to a pharmaceutical compound to form said acid prodrug, which is administered in this form to the subject, such as a mammal.
The amino acid is an ideal model to be used as a prodrug, because it is capable of forming various types of linkages between itself and the drug. By definition, an amino acid has at least two functionalities thereon, an amino group (NH2) and a carboxy group (COOH). For example, the a- amino acids have the well known structure H2N¨T_co0H

wherever R0 is the side group or chain of the amino acid. The H 2N ¨C¨ COOH
as defined herein, is the main chain of the amino acid. Thus, for example, beside the amino group and the carboxyl group on the main chain, the side chain may have functional groups thereon. It is the functional group on the amino acid moiety that permits the covalent linkage to occur between the amino acid and the drug.
The drug or medicament useful in the present invention contains functional groups thereon that permit the drug to react with and form a covalent bond with the amino acid.
Examples of functional groups present on the drugs include NH2, OH, COOH or acid derivatives thereof, such as esters, amides and the like.
The mode of attachment between the pharmaceutical compound and the amino acid can be via:
1) An ester bond (-00-0-) arising from condensation of a carboxylic acid and an alcohol or phenolic hydroxyl group, or through transesterification, for example:

3 H:\work\ 1652\17690 \SPEC\17690.spec without claimsII.doc a) Where the pharmaceutical compound has an aliphatic or aromatic hydroxyl group an ester bond can be formed with the backbone carboxylic acid group of the amino group under esterification conditions; or b) Where the pharmaceutical compound has an aliphatic or aromatic hydroxyl group and the amino acid has a side chain carboxylic acid group, an ester bond can be formed therebetween under esterification conditions; or c) Where the pharmaceutical compound has a carboxylic acid group and the amino acid has a side chain aliphatic or aromatic hydroxyl group, an ester bond can be formed therebetween under esterification condition; or d) Where the pharmaceutical compound has an ester group with a substituted or unsubstituted acyloxy (e.g., alkoxy- or arylalkoxy-, aryloxy carbonyl) substituent (compound-O-CO-substituent) and the amino acid has a backbone carboxylic acid group, an ester bond can be formed therebetween through transesterification; or e) Where the pharmaceutical compound has an ester group with a substituted or unsubstituted acyloxy (e.g., alkoxy- or arylalkoxy-, aryloxy carbonyl) substituent (compound-O-CO-substituent) and the amino acid has a side chain carboxylic acid group, an ester bond can be formed therebetween through transesterification; or Where the pharmaceutical compound has an ester group with a substituted or unsubstituted alkoxy- or arylalkoxy- or aryloxy carbonyl substituent (compound-00-0-Substituent) and the amino acid has a side chain aliphatic or aromatic hydroxyl group, an ester bond can form therebetween though transesterification; or The alcohol and carboxylic acid moieties may be on the same molecule such they can form an internal ester. For example, certain compounds like Gabapentin can form an internal ester under ester forming conditions, is also included with the scope of the present invention.
2) An amide bond (-CO-NH -) arising from condensation of a carboxylic acid and an amine, for example:

4 FI:\work\1652\17690 \SPEC\ 17690.spec without claimsli.doc

5 a) Where the pharmaceutical compound has an amino group and the amino acid has a backbone carboxylic acid group, an amide can be formed under amide forming conditions; or b) Where the pharmaceutical compound has an amino group and the amino acid has a side chain carboxylic acid group, an amide bond can form therebetween under amide forming conditions; or c) Where the pharmaceutical compound has a carboxylic acid group and the amino acid has a backbone amino group, an amide bond can form therebetween under amide forming conditions; or d) Where the pharmaceutical compound has a carboxylic acid group and the amino acid has a side chain amino group, an amide bond can be formed therebetween under amide forming conditions.
Thus, the present invention is directed to the prodrugs thus formed. As shown hereinbelow the prodrug thus formed has advantages not realized relative to the drug without the amino acid attached thereto. For example, it can improve bioavailability, efficacy, be less toxic, exhibit greater solubility in water and/or improve the ability of the drug to pass into the cell membrane or through blood brain barrier, exhibit less side effects, such as gastro-intestinal irritability, enhanced therapeutic index and the like.
Thus, the present invention is directed to a method of improving the therapeutic quality of a drug wherein the improvement in the therapeutic quality is selected from the group consisting of improved efficacy, enhanced therapeutic index, increased solubility in the mammal's internal fluid, improved passage through the cell membrane, improved passage through the blood brain barrier, decreased side effects, such as significantly decreased irritation and/or ulcerations, less toxicity, enhanced absorption ratio and the like relative to the corresponding drug administered to the patient in the non-prodrug form, said method comprising reacting the drug with an amino acid to form a covalent bond therebetween and administering the product thereof (hereinafter "prodrug") to a patient. The prodrugs of the present invention have at least one improved quality. In FlAwork\1652\17690\SPEC\17690.spec without claimsII.doc fact, they exhibit preferably at least two of the improved qualities cited hereinabove.
Other advantages of the prodrug include the wide availability of the amino acids and the ease in which the reactions take place. The reaction to form the amide is generally efficient and yield are very high, presumably above about 70% and more preferably above about 80% and most preferably above about 90%.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 graphically compares the efficacy of L- serine ester of (+) Ibuprofen (F1), L-threonine ester ft-) Ibuprofen (F2) and L-hydroxyproline ester of ( ) Ibuprofen (F3), (+) Ibuprofen (i.e., the racemic mixture) and Ibuprofen (S)(+), after one hour dosing, based on the antagonizing property of Acetylcholine induced writhe in Albino mice.
Figure 2 graphically compares the efficacy of L- serine ester of ( ) Ibuprofen, (F1), L-threonine ester of, (I) Ibuprofen (F2), L-hydroxyproline ester of ( ) Ibuprofen (F3), +
Ibuprofen and S(+) Ibuprofen after 3 hour dosing, based on the antagonizing property of Acetylcholine induced writhes in albino mice.
Figure 3 depicts graphically the dose response relationship to mean clotting time (MCT) in minutes for the L-serine ester of acetylsalicylic acid (Formulation 1).
Figure 4 depicts graphically the dose response relationship to mean clotting time (MCT) minutes for the L-hydroxyproline ester of acetylsalicylic acid (Formulation 2).
Figure 5 depicts the dose response relationship to mean clotting time (MCT) in minutes for the L-threonine ester of acetylsalicylic acid (Formulation 3) Figure 6 depicts the dose response relationship to mean clotting time (MCT) in minutes for control (acetylsalicylic acid).

6 H:\work\1652 \17690 \SPEC\ 17690.spec without claimsll.doc Figure 7 graphically compares the relative efficacy of L-serine (ester of acetyl salicyclic acid (F.1), L-threonine ester of acetyl salicylic acid (F.2), L-hydroxyproline ester of acetylsalicylic acid (F.3), and acetylsalicylic acid (PC) as a function of mean clotting time in minutes.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
As used here, the term "drug", "medicament ", and "pharmaceutical" are being used interchangeably and refer to the active compound that is administered to the patient without attachment of the amino acid thereto. Moreover, as used herein, the drug contains a functional group thereon capable of reacting with the amino acid, such as NH2, OH, COOH or acylating derivatives thereof (e.g., ester, anhydride, amide, and the like) and the like. When the drug is linked to an amino acid, the term "amino acid prodrug" or "prodrug of the present invention" or synonym thereto is utilized.
Among the amino acids useful as promoieties (i.e., reacting with the drugs) are those containing the free amino and/or carboxylic acid groups of all conventional amino acids.
Of those, some preferred embodiments include those amino acids having relatively high solubility in aqueous media, for example, in deionized water at unbuffered aqueous solution at 25 C, of at least 100 g/L, and more preferably, at least 250 g/L, and even more preferably at least 500 g/L. For example, glycine and proline have solubilities in_ deionized water at 25 C of approximately 250 g/L and 1620 g/L, respectively.
Other amino acids useful as promoieties are those containing basic amino side chains, such as lysine. For example, lysine has solubility in deionized water at 25 C
of approximately 700 g/L.
Among other amino acids useful as promoieties are those containing hydroxyl side chains, such as hydroxyproline, serine, and threonine. For example, threonine, hydroxyproline and serine have solubilities in deionized water at 25 C of approximately 100 g/L, 369 g/L and 420 g/L, respectively.

7 H:\work\1652\17690\SPEC\17690.spec without claimsil.doc Other preferred embodiments include those amino acids with relatively low solubility in aqueous media, for example, in deionized water at 25 C of at most 10 g/L, or for example, at most 2 g/L, or for example at most 0.6 g/L. For example, the solubility of tyrosine in deionized water at 25 C is approximately 0.5 g/L. Such prodrugs could be used to produce formulations with extended release characteristics, due to the limited solubility of the prodrugs.
Among other amino acids useful as promoieties are those containing carboxylic acid side chains, such as glutamic acid and aspartic acid. Other amino acids useful as promoieties are the non-essential amino acids, and the non-naturally occurring amino acids.
The following reaction schemes depict the reactions discussed hereinabove with respect to reaction of hydroxyl, carboxyl and amine containing drugs with various amino acids.
In the schemes below, R is the drug less the functional OH, COOH or NH2 group ¨ C ¨ R0 whichever is present, and R1 is wherein Ro is the side chain of the amino acid listed hereinbelow:
Reaction Scheme A: Where the hydroxyl group of the drug is reacted with the carboxyl group of an amino acid to from the ester prodrug R-OH + HOOC-R1- NH2 9 R-0-(C=0)-Ri- NH2 Drug Amino Acid Amino acid Ester Prodrug Reaction Scheme B: Where the carboxyl group of the drug is reacted with the hydroxyl group of a hydroxy amino acid wherein the hydroxy group is on the side chain to form the ester prodrug.

8 H:\work\1652\17690\SPEC\17690.spec without clairnsII.doc R-COOH + HO-R1-N112 4 R-(C=0)-0-R1-N/12 CLH COOH
Drug Hydroxy Amino Acid Amino Acid Ester Prodrug Reaction Scheme C: Where the amine group of the drug is reacted with the carboxyl group of the amino acid to from the amide prodrug R- NH2 + HOOC-Ri- NH2 --> R-NH(C=0)-Ri- NH2 Drug Amino Acid Amino Acid Amide Prodrug Reaction Scheme D: Where the carboxyl group of the drug is reacted with the carboxyl group of the amino acid to form the anhydride prodrug.
R-COOH + HOOC-R1- NH2 4 H-(C=0)-0-(C=0)-Hi- NH2 Drug Amino Acid Amino Acid Anhydride Prodrug Reaction Scheme E: Where the amine group of the drug is reacted with the amine group of the amino acid to form the azo prodrug derivative.
R- NH2 + NH2-121- COOH R-N=N-R1-COOH
Drug Amino Acid Amino Acid Azo Prodrug Reaction Scheme F: Where the carboxyl group of the drug is reacted with amine group of the amino acid to form the amide prodrug.
R-COOH + NH2-R1- COOH 3 R-(C=0)NH-Ri- COOH
Drug Amino Acid Amino Acid Amide Prodrug In the above schemes A-F, the preferred amino acids used are shown hereinbelow:

9 H:\work\1652\17690\SPEC\17690.spec without clairnsadoc _o 9 . P . 9 . pi . lp . 9 0-4T Nz.,'-' o*--i ti4.--;+
o--r.='-------- .t14-.;+ o'------ 4 ,..,..+ o--j-....---õ Liz+
glycine (gly) sarcosine (sar) GAM alanine (ala) vallne (val) isoleucine (ile) leucine (leu) . 9 . 9 9 - ...i tli + ..... + o--3 NZ+
o-) 4;
o----' . ' , 1 +
HO
. :
N'T: HO'"--------- " ---. 0 HO \ 0 --:.õ 0 HO
serine (ser) homoserine threonine (thr) carnitine choline aspartate (asp) glutamate (glu) 9 o 0---' 14.7 01-i kl,' o 9 o---J kl+i 97- 1 i +
/ +
O.-- N

N
o "--)4 --1( !. \ - N.
---k I + / I + 1 ...N 4' _ N N
omithine i µ lysine (lys) I = calanine / \ canavanine arginine (arg) 9 . P . 9 9 '+
+
o"-:-"=--N :,- (3.-J 4 .;
= , - N
ti I' - N N =-=-= N_.::- 0 1,1 N...1.,1 !I 0 praline (pro) asparagine (asn) glutamine (gin) histidine (hls) carnosine -+ o j . . = 1 +
: 1 + 1 + o-- N.: ry-' N.:- -. ;

o---' N.: 0-- NZ ...
00' N '.. ::-.N N OH
N =-phenylalanine (phe) tyrosine (tyr) tryptophan (trp) kyurenine kyurenio acid hypaphorine . 9 9 o . - P o . 9 ..1 .l. + o---; 4; : , +=:
---J --- 4.,.. ,-.-' r'z , :Tx 4 :f s' + -N' o 4; o -i HS / /
I
HS ---------Nc S S 0 = S

HO %
HS s cystine s 2 djenkolic acid /S
cysteine (cys) homowsteine cysteamIne :!: N , .. 0 methionine (met) taurine +l O +' ci As used herein the term "amino acid" refers to an organic compound having therein a carboxyl group (COOH) and an amino group (NH2) or salts thereof. In solution, these two terminal groups ionize to form a double ionized, through overall neutral entity identified as zwitterions. The amine donates an electron to the carboxyl group and the ionic ends are stabilized in aqueous solution by polar water molecules.
1-1:\work\1652\17690\SPEC\17690.spec without claimsIl.doc It is the side groups that distinguish the amino acids from each other. Some amino acids, such as lysine, have amino groups on the side chain; other amino acids have side chains containing hydroxy groups, such as threonine, serine, hydroxyproline, and tyrosine;
some amino acids have carboxy groups on the side chain, such as glutamic acid or aspartic acid. These functional groups on the side chain also can form a covalent bond with the drug, such as esters, amides, and the like. When these side groups become involved in these linkages, such as hydroxy group, the bond may be depicted as OAA, wherein AA is an amino acid residue having a side chain with a hydroxy group, but without the hydroxy group. Thus, AA by this definition, refers to the amino acid without the hydroxy side group since it took part in the reaction in forming the ester.
Moreover, when an ester is formed between the hydroxy group of the amino acid and the OH group of the drug, the hydroxy group on the carboxy group forms a byproduct with the hydrogen of the hydroxy group, thus, the resulting product does not have the OH
group on the carboxy group, but just the acyl moiety. When the bond is depicted as C(=0)-NHAA, this means that the amino acid forms as an amide bond between the carboxy group on the drug and the amino group of the amino acid. However, as written, since the NH from the amide bond comes from the amino acid, AA is the amino acid without the amino group.
The preferred amino acids are the naturally occurring amino acids. It is more preferred that the amino acids are the cc-amino acids. It is also preferred that the amino acids are in the L-configuration. The preferred amino acids include the twenty essential amino acids. The preferred amino acids are Lysine (Lys), Leucine (Leu), Isoleucine (Ile), Glycine (Gly), Aspartic Acid (Asp), Glutamic Acid (Glu), Methionine (Met), Alanine (Ala), Valine (Val), Proline (Pro), Histidine (His), Tyrosine (Tyr), Serine (Ser), Norleucine (Nor), Arginine (Arg), Phenylalanine (Phe), Tryptophan (Trp), Hydroxyproline (Hyp), Homoserine (Hsr), Carnitine (Car), Ornithine (Ort), Canavanine (Cav), Asparagine (Asn), Glutamine (Gln), Carnosine (Can), Taurine (Tau), djenkolic = Acid (Djk), 7-aminobutyric Acid (GABA), Cysteine (Cys) Cystine (Dcy), Sarcosine , 11 H: \work\1652 \17690 \SPEC \17690.spec without clahnsILdoc (Sar), Threonine (Thr) and the like. The even more preferred amino acids are the twenty essential amino acids, Lys, Leu, Ile, Gly, Asp, Glu, Met, Ala, Val, Pro, His, Tyr, Thr, Arg, Phe, Trp, Gln, Asn, Cys and Ser.
The prodrugs are prepared from a drug having a group thereon which can react with the amino acid.
The preferred drugs that are reacted with amino acids in accordance with various schemes are as follows:
Reaction Schemes Drugs A BCDE F
Cyclosporins YES
Lopinavir YES YES YES
Ritonavir YES YES YES
Cefdinir YES YES YES YES YES
Zileuton YES YES YES
Nelfinavir YES YES YES
Flavoxate YES YES YES
Candesarten YES YES YES YES YES
Propofol YES
Nisoldipine YES YES YES YES YES
Amlodipine YES YES YES YES YES
Ciprofloxacin YES YES YES YES
Ofloxacin YES YES YES YES
Fosinopril YES YES YES
Enalapril YES YES YES
Ramipril YES YES YES
Benazepril YES YES YES
Moexipril YES YES YES
Trandolapril YES YES YES

H:\work\1652\17690\SPEC\17690.spec without claimsll.doc Cromolyn YES YES YES YES
Amoxicillin YES YES YES YES YES YES
Cefuroxime YES YES YES YES YES YES
Ceftazimide YES YES YES YES YES YES
Cefpodoxime YES YES YES YES YES YES
Atovaquone YES
Gancyclovir YES YES YES
Pencielovir YES YES YES
Fameiclovir YES YES YES
Acyclovir YES YES YES
Niacin YES YES YES
Bexarotene YES YES YES
Propoxyphene YES
Salsalate YES YES YES YES
Acetaminophen YES
Ibuprofen YES YES YES
Lovastatin YES YES YES YES
Simavastatin YES YES YES YES
Atorvastatin YES YES YES YES
Pravastatin YES YES YES YES
Fluvastatin YES YES YES YES
Nadolol YES
Valsartan YES YES YES
Methylphenidate YES YES YES YES
Sulfa Drugs YES YES
Sulfasalazine YES
Methylprednisolone YES
Medroxyprogesterone YES
Estramustine YES
Miglitol YES

H:\work\1652\17690\SPEC\17690.spec without clairnsIl.doc Mefloquine YES YES
Capacitabine YES
Danazol YES
Eprosartan YES YES YES
Divalproex YES YES YES
Fenofibrate YES YES YES
Gabapentin* YES YES YES YES YES
Omeprazole YES
Lansoprazole YES
Megestrol YES
Metformin YES
Tazorotene YES YES YES
Sumitriptan YES
Naratriptan YES
Zolmitriptan YES
Aspirin YES YES YES
Olmesartan YES YES YES
Sirolimus YES
Tacrolimus YES
Clopidogyel YES YES YES
Amphotericin B YES YES YES YES
Tenofovir YES
Unoprostone YES YES YES
Fulvestrant YES
Cefditoren YES YES YES
Efavirenz YES
Eplerenone YES YES YES
Treprostinil YES YES YES YES
Adefovir YES

li:\work\1652\17690\SPEC\17690.spec without claims11.doc The prodrug of the present invention contains amino groups and as such are basic in nature. They are capable of forming a wide variety of pharmaceutically acceptable salts with various inorganic and organic acids. These acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitride, sulfate, bisulfate, phosphate, formate, acetate, citrate, tartate, lactate, and the like.
As indicated herein, in one embodiment, the present invention is directed to a prodrug wherein the prodrug comprises a drug, e.g., cyclosporine and an amino acid esterified to the MeBmt (x-y=CH=CH) or dihydro MeBmt moiety, (x-y=CH2CH2). The amino acid is attached to the cyclosporine and to the other other drugs by a covalent bond.
The compounds of the present invention are prepared by art recognized techniques. For examples, if the drug contains an OH group, said as cyclosporin, then an amino acid or an acylating derivatives thereof, such as the acid halide, e.g., amino acid fluoride, amino acid chloride, or an amino acid alkyl ester wherein alkyl group contains 1-6 carbon atoms is reacted with the carboxy group of the drug, e.g., cyclosporine under esterification condition. Preferably, the reaction is conducted in the presence of an acid, such as hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid and the like.
Alternatively, as described hereinabove, if the drug has an amino group thereon, then the amino acid may be reacted with the drug under amide forming conditions to form an amide as the covalent bond. Or if the drug has a carboxy group or acylating derivative thereon, it may be reacted with the amino group of the amino acid to form an amide under amide forming conditions to form an amide bond between the amino acid and the drug. Additionally if the drug has a carboxy group therein, the hydroxy group of the side chain of the amino acid may be reacted with the carboxy group or acylating derivative, therein under esteiification conditions to form the ester linkage between the amino acid and the drug, as described hereinabove.

1-1:\work\1652\17690\SPEC \17690.spec without clainisiLdoc If the amino acid has a group thereon which is reactive under the reaction conditions it is protected by a protecting group known in the art. After the completion of the reaction, the protecting group is removed. Examples of protecting groups that could be used are described in the book entitled, "Protective Group in Organic Synthesis" by Theodora W.
Greene, John Wiley & Sons, 19g1.
For example, if amino acids with carboxylic groups in their side chains, for example, aspartic acid and glutamic acid, are used in the aforementioned synthesis, these will generally require protection of the side chain carboxylic acid. Suitable protecting groups can be esters, such as cyclohexyl esters, t-butyl esters, benzyl esters, allyl esters, 9-fluorophenyl-methyl groups or adamantyl groups, such as 1-or 2-adamantyl which can be protected after the esterfication reaction is completed using techniques known to one of ordinary skill in the art.
If amino acids with hydroxyl groups in their side chains, for example, serine, threonine, hydroxyproline, and the like and amino acids with phenolic groups in their side chains, for example, tyrosine, and the like are used in the aforementioned esterification, reaction, they will desirably require protection of the chain hydroxyl or phenolic group.
Suitable for protecting groups for the hydroxyl side chain groups can be ethers, such as benzyl ether or t-butyl ether. Removal of the benzyl ether can be effected by liquid hydrogen fluoride, while the t-butyl ether can be removed by treatment with trifluoroacetic acid. Suitable protecting groups for phenolic side chain groups can be ethers, as above, including benzyl or t-butyl ether or 2,6-dichlorobenzyl, 2-bromobenzyloxycarbonyl, 2,4-dintrophenyl and the like.
Moreover, the products can be purified to be made substantially pure by techniques known to one of ordinary skill in the art, such as by chromatography, e.g., HPLC, crystallization and the like. By substantially "pure" it is meant that the product contains no more than about 10% impurity therein.

The prodrugs can be made into pharmaceutical compositions including prodrugs of, or pharmaceutical acceptable salts, pharmaceutical acceptable solvates, esters, enantiomers, diastereomers, N-Oxides, polymorphs, thereof, as described herein, along with a pharmaceutical acceptable carrier, and optionally but desirably pharmaceutically acceptable excipients using techniques known to one of ordinary skill in the art.
The prodrugs utilized in the present method are used in therapeutically effective amounts.
The physician will determine the dosage of the prodrugs of the present invention which will be most suitable and it will vary with the form of administration and the particular compound chosen, and furthermore, it will vary depending upon various factors, including but not limited to the patient under treatment and the age of the patient, the severity of the condition being treated and the like and the identify of the prodrug administered. He will generally wish to initiate treatment with small dosages substantially less than the optimum dose of the compound and increase the dosage by small increments until the optimum effect under the circumstances is reached.
It will generally be found that when the composition is administered orally, larger quantities of the active agent will be required to produce the same effect as a smaller quantity given parenterally. The compounds are useful in the same manner as the corresponding drug in the non-prolong form and the dosage level is of the same order of magnitude as is generally employed with these other therapeutic agents. When given parenterally, the compounds are administered generally in dosages of, for example, about 0.001 to about

10,000 mg/kg/day, also depending upon the host and the severity of the condition being treated and the compound utilized.
In a preferred embodiment, the compounds utilized are orally administered in amounts ranging from about 0.01 mg to about 1000 mg per kilogram of body weight per day, depending upon the particular mammalian host or the disease to be treated, more preferably from about 0.1 to about 500 mg/kg body weight per day. This dosage

11:\work\1652\17690\SPEC\17690.spec without claimsII.doc regimen may be adjusted by the physician to provide the optimum therapeutic response.
For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
The prodrug may be administered in any convenient manner, such as by oral, intravenous, intramuscular or subcutaneous routes.
The prodrug may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly into the food of the diet. For oral therapeutic administration, the prodrug may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% of the prodrug. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of the prodrug used in such therapeutic compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention contain between about 200 mg and about 4000 mg of prodrug. The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier.
Various other materials may be present as coatings or otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such H:\work\1652\17690\SPEC\17690.spec without claimsli.doc as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations. For example, sustained release dosage forms are contemplated wherein the active ingredient is bound to an ion exchange resin which, optionally, can be coated with a diffusion barrier coating to modify the release properties of the resin or wherein the prodrug of the present invention is associated with a sustained release polymer known in the art, such as hydroxypropylmethylcellulose and the like.
The prodrug may also be administered parenterally or intraperitoneally. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, e.g., PEG 100, PEG 200, PEG 300, PEG 400, and the like, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form is usually sterile and must be fluid to the extent that syringability exists. It must be stable under the conditions of manufacture and storage and usually must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and one or more liquid polyethylene glycol, e.g. as disclosed herein and the like), suitable mixtures thereof, and vegetable oils.
The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to FlAwork\1652\17690\SPEC\17690.spec without claimsll.doc include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the prodrug in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders, the above solutions are vacuum dried or freeze-dried, as necessary.
The prodrug can also be applied topically, as e.g., through a patch using techniques known to one of ordinary skill in the art. The prodrug can be administered buccally by preparing a suitable formulation of the prodrug of the present invention and utilizing procedures well known to those skilled in the art. These formulations are prepared with suitable non-toxic pharmaceutically acceptable ingredients. These ingredients are known to those skilled in the preparation of buccal dosage forms. Some of these ingredients can be found in Remington's Pharmaceutical Sciences, 17th edition, 1985, a standard reference in the field. The choice of suitable carriers is highly dependent upon the exact nature of the buccal dosage form desired, e.g., tablets, lozenges, gels, patches and the like. All of these buccal dosage forms are contemplated to be within the scope of the present invention and they are formulated in a conventional manner.
The formulation of the pharmaceutical compositions may be prepared using conventional methods using one or more physiologically and/or pharmaceutically acceptable carriers or excipients. Thus, the compounds and their pharmaceutically acceptable salts and solvates may be formulated for administration by inhalation or insuffiation (either through the mouth or the nose) or oral, buccal, parenteral, or rectal administration. For oral administration, the pharmaceutical compositions may take the H:\work\1652\17690\SPEC\17690.spec without claimsII.doc form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example, pregelatinized maize starch, polyvinylpyrrolidone, or hydroxypropylmethyl cellulose);
fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate);
lubricants (for example, magnesium stearate, talc, or silica); disintegrants (for example, potato starch, or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulfate). The tablets may be coated by methods well known in the art.
Liquid preparations for oral administration may take the form of, for example, solutions, syrups, or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicles before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives, such as suspending agents (for example, sorbitol syrup, corn syrup, cellulose derivatives or hydrogenated edible oils and fats); emulsifying agents (for example, lecithin or acacia);
non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example, methyl or propyl p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release of the active prodrug.
The prodrug of the present invention may be formulated for parenteral administration by injection, for example, by bolus injection or continuous infusion.
Formulations for injection may be presented in unit dosage form, for example, in ampoules, or in multi-dose containers, with an added preservative. The compositions may take such forms as suspension, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
Alternatively, the prodrug may be in the powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.

H:\work\1652\17690\SPEC\17690.spec without claimadoc The prodrugs of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, for example, containing conventional suppository bases such as cocoa butter or other glycerides.
In addition to the formulations described previously, the prodrug of the present invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the prodrugs may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
The pharmaceutical compositions containing the prodrugs of the present invention may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredients. The pack may for example comprise metal or plastic foil, such as blister pack. The pack or dispenser device may be accompanied by instructions for administration.
In tablet form, it is desirable to include a lubricant which facilitates the process of manufacturing the dosage units; lubricants may also optimize erosion rate and drug flux.
If a lubricant is present, it will be present on the order of 0.01 wt. % to about 2 wt. %, preferably about 0.01 wt. % to 0.5 wt, %, of the dosage unit. Suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, sodium stearylfumarate, talc, hydrogenated vegetable oils and polyethylene glycol. As will be appreciated by those skilled in the art, however, modulating the particle size of the components in the dosage unit and/or the density of the unit can provide a similar effect--i.e., improved manufacturability and optimization of erosion rate and drug flux--without addition of a lubricant.

H:\work\1652 \17690 \SPEC \I7690.spec without claimsII.doc Other components may also optionally be incorporated into the dosage unit.
Such additional optional components include, for example, one or more disintegrants, diluents, binders, enhancers, or the like. Examples of disintegrants that may be used include, but are not limited to, crosslinked polyvinylpyrrolidones, such as crospovidone (e.g., Polyplasdone XL, which may be obtained from GAF), cross-linked carboxylic methylcelluloses, such as croscanrnelose (e.g., Ac-di-sol , which may be obtained from FMC), alginic acid, and sodium carboxymethyl starches (e.g., Explotab , which may be obtained from Edward Medell Co., Inc.), agar bentonite and alginic acid.
Suitable diluents are those which are generally useful in pharmaceutical formulations prepared using compression techniques, e.g., dicalcium phosphate dihydrate (e.g., Di-Tab , which may be obtained from Stauffer), sugars that have been processed by crystallization with dextrin (e.g., co-crystallized sucrose and dextrin such as Di-Pak , which may be obtained from Amstar), calcium phosphate, cellulose, kaolin, mannitol, sodium chloride, dry starch, powdered sugar and the like. Binders, if used, are those that enhance adhesion. Examples of such binders include, but are not limited to, starch, gelatin and sugars such as sucrose, dextrose, molasses, and lactose.
Permeation enhancers may also be present in the novel dosage units in order to increase the rate at which the active agents pass through the buccal mucosa. Examples of permeation enhancers include, but are not limited to, dimethylsulfoxide ("DMSO"), dimethyl formamide ("DMF"), N,N-dimethylacetamide ("DMA"), decylmethylsulfoxide ("CioMSO"), polyethylene glycol monolaurate ("PEGML"), glycerol monolaurate, lecithin, the 1-substituted azacycloheptan-2-ones, particularly 1-n-dodecylcyclazacycloheptan-2-one (available under the trademark Azone® from Nelson Research & Development Co., Irvine, Calif.), lower alkanols (e.g., ethanol), SEPA (available from Macrochem Co., Lexington, Mass.), cholic acid, taurocholic acid, bile salt type enhancers, and surfactants such as Tergitol , Nonoxyno1-9 and TWEEN-800.
Flavorings may be optionally included in the various pharmaceutical formulations. Any suitable flavoring may be used, e.g., mannitol, lactose or artificial sweeteners such as H:\work\1652\17690\SPEC\17690.spec without claimsII.doc aspartame. Coloring agents may be added, although again, such agents are not required.
Examples of coloring agents include any of the water soluble FD&C dyes, mixtures of the same, or their corresponding lakes.
In addition, if desired, the present dosage units may be formulated with one or more preservatives or bacteriostatic agents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride, or the like.
As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents for pharmaceutical active substances well known in the art.
Except insofar as any conventional media or agent is incompatible with the prodrug, their use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of prodrug calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
The prodrug is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore described. A unit dosage, for example, contains the principal active compound in amounts ranging from about 10 mg e.g. in humans, or as low as 1 mg (for small animals) to about 2000 mg. If placed in solution, the concentration of the prodrug preferably ranges from about 10 mg/mL to about 250 mg/mL. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and mariner of administration of the said ingredients. In the case of buccal administration, the prodrugs are preferably in the buccal unit dosage = form present in an amount ranging from about 10 to about 50 mg.

H:\wor1\1652\17690\SPEC\17690.spec without clairnsEdoc The prodrugs of the present invention are effective in treating disease or conditions in which the corresponding drug (without the amino acid prodrug of the present invention) normally are used.
As used herein the term "treating" refers to reversing, alleviating or inhibiting the progress of a disease, disorder or condition, or one or more symptoms of such disease, disorder or condition, to which such term applies. As used herein, "treating"
may also refer to decreasing the probability or incidence of the occurrence of a disease, disorder or condition in a mammal as compared to an untreated control population, or as compared to the same mammal prior to treatment. For example, as used herein, "treating"
may refer to preventing a disease, disorder or condition, and may include delaying or preventing the onset of a disease, disorder or condition, or delaying or preventing the symptoms associated with a disease, disorder or condition. As used herein, "treating"
may also refer to reducing the severity of a disease, disorder or condition or symptoms associated with such disease, disorder or condition prior to a mammal's affliction with the disease, disorder or condition. Such prevention or reduction of the severity of a disease, disorder or condition prior to affliction relates to the administration of the composition of the present invention, as described herein, to a subject that is not at the time of administration afflicted with the disease, disorder or condition. As used herein "treating" may also refer to preventing the recurrence of a disease, disorder or condition or of one or more symptoms associated with such disease, disorder or condition. The terms "treatment" and "therapeutically," as used herein, refer to the act of treating, as "treating" is defined above.
As used herein the term "patient" or "subject" refers to a warm blooded animal, and preferably mammals, such as, for example, cats, dogs, horses, cows, pigs, mice, rats and primates, including humans. The preferred patient is humans.
H:\work\1652\17690\SPEC\17690.speo without clainasILdoc The prodrugs of the present invention exhibit the same utility as the corresponding drug without the amino acid linkage. The prodrug exhibits an enhanced therapeutic quality.
That is, they exhibit at least one and more preferably at least two enhanced therapeutic qualities relative to the drug which has not been transformed to the prodrug of the present invention prior to administration. These include, but are not limited to a. Improved taste, smell b. Desired octanol/water partition coefficient (i.e., solubility in water/fat) The various amino acids have different solubility in aqueous solutions. By selecting a particular amino acid, the octanol water partition coefficient can be affected. For example, many drugs in the following list are highly hydrophobic. The amino acids are highly hydrophilic. For example, assume propofol is the drug and lysine is the amino acid. Propofol is completely insoluble in water, while lysine is soluble to the extent of 700 mg/ml. When these two diverse molecules are esterified via an ester bond, the resulting lysine ester of propfol has a solubility in water in excess of 250 mg/ml.
On the other hand, cromolyn sodium is highly water soluble. For all practical purpose, it is not absorbed when administered orally. By affecting its water solubility one could improve absorption. In this case, one would look for conditions opposite to that of propofol, i.e., the goal is to decrease water solubility. By choosing apporoprieate low water soluble amino acids, such as tyrosine, one can achieve proper hydrophilic/lipophilic balance.
c. Improved stability in-vitro and in-vivo d. Enhanced penetration of blood-brain barrier e. Elimination of first-pass effect in liver, i.e., the drug not metabolized in liver and therefore more drug in system circulation f. Reduction of entero-hepatic recirculation (this improves bio-availability) g. Painless injections with parenteral formulations h. Improved bio-availability i. Improved changes in the rate of absorption (increase vs lack thereof) H:\work\1652\17690\SPEC\17690.spec without claimsll.doc j. Reduced side effects k. Dose proportionality A dose proportionality claim requires that when the drug is administered in escalating doses, proportionally escalating amounts of active drug is delivered into the blood stream. This is measured by determining the area under the plasma concentration vs.
time curve obtained after administering a drug via any route other than IV
route and measuring the same in plasma/blood. A simple mathematical procedure is as follows:
For example, a drug is administered at e.g., 3 different doses, 10, 100 and 1000 mg, orally to a patient, the area under the plasma concentration time curve (AUC) is measured. Then each total AUC is divided by the dose, and the result should be the same for all three doses. If it is the case, then there is dose proportionality.
Lack of dose proportionality indicates any one or more of the pharmacokinetic/pharmacological mechanisms are saturable, including absorption, metabolism or the number of receptor sites available for pharmacological response.
For example in the above study, assume the AUC values of 100, 1000 and 10,000 are obtained, in this case the dose proportionality is inappropriate. When there is lack of dose proportionality, there is either more or less amount of drug in the plasma, depending upon which mechanism is saturable. The following are the possibilities:
Saturable Absorption. If this is the case, as the dose is increased, proportionally less and less of the drug is absorbed, hence overall AUC will decrease as the dose is increased.
Saturable metabolism of elimination. If thus is the case, then more and more of the drug will be circulating in the blood, and the AUC will increase with increasing dose.
Saturable pharmacological receptor sites: In this case, since all the receptor sites will eventually be occupied by the drug, any additional drug will not increase the response.
Thus, increasing dose will not result in increasing response.

H:\work\ 1652 \I7690 \SPEC\17690.spec without claimsII.doc Dose proportionality is an excellent response profile, since one can predict accurately the pharmacological response and curative power at all doses. Thus dose proportionality is a desirable quality for any drug. Furthermore, achievement of dose proportionality is also dependent upon the formulation, and fed/fasted differences.
1. Selective hydrolysis of the prodrug at site of action m. Controlled release properties n. Targeted drug delivery o. Reduction in toxicity, hence, improved therapeutic ratio p. Reduced dose q. Alteration of metabolic pathway to deliver more drug at the site of action r. Increased solubility in aqueous solution s. Enhanced efficacy Thus, various dosage forms available with amino acid pro-drugs and they are prepared by conventional methods:
i. Oral liquid dosage (Controlled release and immediate release liquids containing sugar and sugar free, dye and dye free, alcohol and alcohol free formulations, including chewable tablets) ii. Oral solid dosage (Controlled release and immediate release tablets, capsules and caplets Intravenous (Injections, both ready to use and lyophilized powders) iv. Intramuscular (Injections, both ready to use and lyophilized powders) v. Subcutaneous (Injections, both ready to use and lyophilized powders) vi. Transdermal (Mainly patches) vii. Nasal (Sprays, formulations for nebulizer treatments) viii. Topical (Creams, ointments) ix. Rectal (Creams, ointments and suppositories) x. Vaginal (Creams, ointments and pessaries) xi. Ocular (Drops and ointments) FlAwork\ 1652 \ 17690 \SPEC\ 17690.spec without claiinsILdoc xii. Buccal (Chewable and now chewable tables) Many drugs discussed herein, especially in the table hereinbelow are characteristically highly hydrophobic and readily precipitate in the presence of even very minor amounts of water, e.g., on contact with the body (e.g., stomach fluids). It is accordingly extremely difficult to provide e.g., oral formulations which are acceptable to the patient in terms of form and taste, which are stable on storage and which can be administered on a regular basis to provide suitable and controlling patient dosing.
Proposed liquid formulations, e.g., for oral administration of a number of drugs shown herein in the table have heretofore been based primarily on the use of ethanol and oils or similar excipient as carrier media. Thus, the commercially available drink-solutions of a number of drugs employ ethanol and olive oil or corn oil as carrier medium in conjunction with solvent systems comprising e.g., ethanol and LABRIFIL and equivalent excipient as carrier media. For example, the commercially available Cyclosporin drink solution employs ethanol and olive oil or corn oil as carrier medium in conjunctions with a Labroid as a surfactant. See e.g., U.S. Patent NO.
4,388,307. Use of the drink solution and similar composition as proposed in the art is however accompanied by a variety of difficulties.
Further, the palatability of the known oil based system has proved problematic. The taste of the known drink-solution of several drugs is, in particular, unpleasant.
Admixture with an appropriate flavored drink, for example, chocolate drink preparation, at high dilution immediately prior to ingestion has generally been practiced in order to make regular therapy at all acceptable. Adoption of oil-based systems has also required the use of high ethanol concentrations which is itself inherently undesirable, in particular where administration to children is foreseen. In addition, evaporation of the ethanol, e.g., from capsules (adopted in large part, to meet problems of palatability, as discussed or other forms (e.g., when opened)) results in the development of a drug precipitate.
Where such compositions are presented in, for example, soft gelatin encapsulated form, HAwork\1652\176901SPEC\17690.spec without claiinsII.doc this particular difficulty necessitates packaging of the encapsulated product in an air-tight component, for example, an air-tight blister or aluminum-foil blister package. This in turn renders the product both bulky and more expensive to produce. The storage characteristics of the aforesaid formulations are, in addition, far from ideal.
Bioavailability levels achieved using existing oral dosage system for a number of drugs described herein are also low and exhibit wide variation between individuals, individual patient types and even for single individuals at different times during the course of therapy. Reports in the literature indicates that currently available therapy employing the commercially available drug drink solution provides an average absolute bioavailability of approximately 10-30% only, with the marked variation between individual groups, e.g., between liver (relatively low bioavailability) and bone-marrow (relatively high bioavailability) transplant recipients. Reported variation in bioavailability between subjects has varied from one or a few percent for some patients, to as much as 90% or more for others. And as already noted, marked change in bioavailability for individuals with time is frequently observed. Thus, there is a need for a more uniform and high bioavailability of a number drugs shown herein in patients.
Use of such dosage forms is also characterized by extreme variation in required patient dosing. To achieve effective therapy, drug blood or blood serum levels have to be maintained within a specified range. This required range can in turn, vary, depending on the particular condition being treated, e.g., whether therapy is to prevent one or more pharmacological actions of a specific drug and when alternative therapy is employed concomitantly with principal therapy. Because of the wide variations in bioavailability levels achieved with conventional dosage forms, daily dosages needed to achieve required blood serum levels will also vary considerably from individual to individual and even for a single individual. For this reason it may be necessary to monitor blood/blood-serum levels of patients receiving drug therapy at regular and frequent intervals. Monitoring of blood/blood-serum levels has to be carried out on a regular H:\work\1652\17690\SPEC\17690.spec without claimsIl.doe basis. This is inevitably time consuming and inconvenient and adds substantially to the overall cost of therapy.
It is also the case that blood/blood serum levels of a number of drugs described herein achieved using available dosage systems exhibit extreme variation between peak and trough levels. That is for each patient, effective drug levels in the blood vary widely between administrations of individual dosages.
There is also a need for providing a number of drugs described herein, especially the beta-lactum antibiotics, Cyclosporin, cephalosporins, steroids, quinolone antibiotics and Cyclosporin, in a water-soluble form for injection. It is well known that Cremaphore LID
(CreL) used in current formulations of a number of drugs described hereinbelow is a polyoxyethylated derivative of castor oil and is a toxic vehicle. There have been a number of incidences of anaphylaxis due to the castor oil component. At present there is no formulation that would allow many of these drugs to be in aqueous solution at the concentrations needed due to poor water solubility of the drag.
Beyond all these very evident practical difficulties lies the occurrence of undesirable side reactions already alluded to, observed employing available oral dosage forms.
Several proposals to meet these various problems have been suggested in the art, including both solid and liquid oral dosage forms. An overriding difficulty which has however remained is the inherent insolubility of the several of the drugs shown in the table hereinbelow in aqueous media, hence preventing the use of a dosage form which can contain the drugs in sufficiently high concentration to permit convenient use and yet meet the required criteria in terms of bioavailability, e.g. enabling effective absorption from the stomach or gut lumen and achievement of consistent and appropriately high blood/blood-serum levels.

H:\wor1\I652\l7690\SPEC\17690.spec without claimsadoc The particular difficulties encountered in relation to oral dosing with these drags have inevitably led to restrictions in the use of specific drug therapy for the treatment of relatively less severe or endangering disease conditions. For example, taking Cyclosporin as a test drug, a particular area of difficulty in this respect has been the adoption of Cyclosporin therapy in the treatment of autoimmune diseases and other conditions affecting the skin, for example for the treatment of atopic dermatitis and psoriasis and, as also widely proposed in the art, for hair growth stimulation, e.g. in the treatment of alopecia due to ageing or disease.
Thus while oral Cyclosporin therapy has shown that the drug is of considerable potential benefit to patients suffering e.g. from psoriasis, the risk of side-reaction following oral therapy has prevented common use. Various proposals have been made in the art for application of Cyclosporins, e.g. Cyclosporin, in topical form and a number of topical delivery systems have been described. Attempts at topical application have however failed to provide any demonstrably effective therapy.
However, the present invention overcomes the problems described hereinabove.
More specifically, the prodrug of the present invention significantly enhances its solubility in aqueous solutions relative to the non-prodrug form of the pharmaceutical, thereby avoiding the need to utilize a carrier, such as ethanol or castor oil when administered as a solution. Moreover, the prodrugs of these drugs, in accordance with the present invention, do not exhibit the side effects of the prior art formulations.
Further, it has been found that when many of the drugs in the table hereinbelow is administered in its prodrug form in accordance with the present invention, there is enhanced oral absorption, thereby enhancing significantly its bioavailability and its efficacy.
The preferred drugs used in combination with the amino acids are forming prodrugs are listed hereinbelow in the following table and the benefits found are as listed in the penultimate column of the table. In the table, the key is as follows:
a) Improved taste smell EI:\work\1652\17690\SPEC\17690.spec without claimsII.doc b) Desired Octanol/water partition coefficient (i.e. solubility in water) c) Improved stability in vitro and in vivo d) Penetration of blood-brain barrier e) Elimination of first pass effect in liver f) Reduction of enterohepatic recirculation g) Painless injections with parenteral formulations h) Improved bioavailability i) Increased rate of absorption j) Reduced side effects k) Dose proportionability 1) Selective hydrolysis of the prodrug at site of actions m) Controlled release properties n) Targeted drug delivery o) Reduction in toxicity, hence improved therapeutic ratio p) Reduced dose q) Alteration of metabolic pathway to deliver more drug at site of action.
Moreover, the table indicates the utility of the prodrug. The utility of the prodrug is the same as the corresponding drug (without the amino acid moiety attached). The utiluity is described in the literature such as the Physicians Desk Reference, 2004 edition.

Amino Acid Applicable Preferred Most Amino Acids that can Preferred Most Improvem Utility Prodrugs of Dose Dose Preferred be reacted with the Amino Acids Preferred ents with Range Range Dose Range drug to form the Amino prodrugs 0 n.) ster/arnide/azo/anhydri AC-ids utility =
o de prodrugs immuno un . 6 .
c:
Cyclosporin All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Lys, Pro, b,e, f, g, h, prophylaxis of organ un Preferred Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, & Gly and k, 1, o, and rejection, e.g., kidney, un Forms 5-1000 mg 20-250 25-100 mg Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, dipeptides p liver and heart allogenic Oral Tab/Cap 1-25 mg 10 mg/ml Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, of Lys- transplants, treatment of Oral Liquid mg/ml 5-15 50 mg/5m1 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and Gly, Pro- rheumatoid arthritis and IV Injections 10-250 mg mg/ml Cav, Asn, Gln, Can, Ser, Hyp, Sar or Gly, Gly- psoriosis per 5 nil 25-100 Tau, Djk, GABA, Cys, dipeptides of Gly mg per 5 Dcy, Thr, and Sar or combination of any ml dipeptide of two amino acids n combination of any especially AA-Gly, two amino acids where Gly is a iv in especially AA-Gly, spacer attached to co a, where Gly is a spacer cyclosporin and u.) a, attached to AA is the above-N) cyclosporin and AA is cited amino acids.
iv the above-cited amino 0, acids.

H
Lopinavir All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Lys, Pro, b, h, j, k, treatment of u.) Preferred Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Gly, & and o infections, e.g., AIDS 0 Forms 0.1-1 g 200-800 400-500 mg Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, Ala Oral Tab/Cap m mg 400 mg/5m1 Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, Oral Liquid 0.1-1 gm/5 0.2-0.8 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and nil g/5 ml _ Cav, Asn, Gln, Can, Ser, Hyp, Sar Tau, Djk, GABA, Cys, Dcy, Thr, and Sar Iv n c 4 k . , =
=
. 6 .
7: -:- 5 k . , . 6 .

H:\work\1652\17690\SPEC\17690.speo without claiinsILdoc vD
1¨, Cefdinir All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Ser, a, b, e, f, h, antibiotic treatment of diseases caused.
Preferred Asp, Glu, Met, Ala, ______________________ Asp, Glu, Met, Ala, Hyp, i, o, and p by Haemophilus influenzae, includinP
Forms 0.1-1gm 0.2-0.5 200-400 mg Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, Tyr, & B-lactamase producing strains, e.g., in Oral Tab/Cap 0.1-1 gm 0.2- Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, Thr Haemophilus parainfluenzae (includid Oral Liquid gm/5m1 0.2- 0.4grn/.5m1 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and f3 - 1 ac t o s am a s e producing strains) and\ n.) o IV Infusions 0.01-1 0.5gm/5m 50-150 Cav, Asn, Gln, Can, Ser, Hyp, Sar moraxella catarihalis (including 13-un gm/100 1 mg/100 ml Tau, Djk, GABA, Cys, lactamase producing strains), and 01 t:
ml 20-500 Dcy, Thr, and Sar streptococcus pyogenes; such as mg/100 pneumonia, bronchitis and sinusitis, ml pharyngitis and tonsillitis -.., '-' ..,,.
B z =
Zileuton All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Gly, Lys, b, h, i, j, k, treatment of asthma ..----t-- I
Preferred Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Sar, Ala, o, p ,...-Forms Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, ________________ Pro ..----.:---:
Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, Oral Tab/Cap 200-1200 200-800 300-400 mg Hyp, Hsr, Car, Ort, Gln, Asn, Cys and F :
r=
n Oral Liquid nag mg 200400 Cav, Asn, Gin, Can, Ser, Hyp, Sar 200-1200 200-800 mg/5m1 Tau, Djk, GABA, Cys, iv mg/5ra1 mg/5m1 Dcy, Thr, and Sar in u.) a, Nelfutavir All Doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Gly, Lys, b, h, i, j, k, treatment of HIV, infected patients, u.) a, Preferred Asp, Glu, Met, Ala, ______________________ Asp, Glu, Met, Ala, Sar, Ala, o, p e.g., AIDS "
forms 0.05-1 gm 0.1-0.5 0.2-0.4 gm Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, Pro iv Oral Tab/Cap 10-250 gm 40-100 mg/gm Nor, Arg, Phe, Tip, Thr, Arg, Phe, Trp, 0 c7, Oral Powder mg/gm 20-200 40-100 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and 0 H
IV 10-250 mg/gm mg/100m1 Cav, Asn, Gln, Can, Ser, Hyp, Sar 1 u.) Formulation mg/100 20-200 Tau, Djk, GABA, Cys, ml mg/100m Dcy, Thr, and Sar oo n 1-i cp tµ.) o o .6.
k . , . 6 .
, . z =

.
HAwork\1652\17690\SPEC\17690.spec without claimsli.doc Flavoxate All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Ser, Tyr, b, h, i, j, k, treatment of urinary spasms Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Thr 1, o,& p Oral Tab/Cap 10-1000 mg 20-500 mg 50-250 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, 73 Oral Liquid 10-1000 20-500 50-250 Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Tip, 4 ''' o mg/5m1 mg/5m1 mg/5m1 Car, Ort, Cav, Asn, Gin, Asn, Cys and . o Gln, Can, Tau, Djk, Ser, Hyp, Sar .,.
GABA, Cys, Dcy, Thr, C t:
and Sar Lil c3;
Candesarten All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Ser, Tyr, b, c, e, f, treatment of hypertension Preferred Forms Glu, Met, Ala, Val, Pro, Asp, GM, Met, Ala, & Thr h, I, .i, k, I, -r-Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, o, p, q -.
1-100 mg 2-75 mg 4-50 ., , Oral Liquid Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Tip, ...-¨
mg/5m1 mg/5m1 mg/5m1 Car, Ort, Cav, Asn, Gln, Asn, Cys and Gln, Can, Tau, Djk, Ser, Hyp, Sar ...
,.
GABA, Cys, Dcy, Thr, ......i_z .--._ _ , ..
and Sar ....-...
n Propofol All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Gly, Lys, Sar, b, c, d, g, provides central nervous i ---' Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Pro, Ala, & h, j, k, 1, system anethesia o iv IV Infusions 5-15 raginil His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, Val m, n, o, p, in 1-25 mg/ml 2.0-20 u.) mg/
Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, q u.) Car, Ort, Cav, Asn, Gln, Asn, Cys and a, iv Gln, Can, Tau, Djk, Ser, Hyp, Sar iv GABA, Cys, Dcy, Thr, c7, and Sar - -- - o Nisoldipine All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Gly, Lys, Ser, b, e, h, i, j, calcium channel blocker, H
I
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Hyp o treatment of hypertension u.) o Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, Oral Liquid 2-100 mg 2.5-75 mg 5-50 mg Phe, Tip, Hyp, Hsr, Thr, Arg, Phe, Tip, 2-100 2.5-75 5-50 Car, Ort, Cav, Asn, Gln, Asn, Cys and mg/5m1 mg/5m1 mg/5m1 Gln, Can, Tau, Djk, Ser, Hyp, Sar GABA, Cys, Dcy, Thr, and Sar .o n ,-i cp t., =
=
.6.
-a-, t., .6.
=

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc ¨
Amlodipine All Doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Gly, Lys, Ser, b, e, h, i, j, calcium channel blocker, Preferred forms IV Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, & Hyp o treatment of hypertensiodr, Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, Oral Tab/Cap 0.1 ¨ 20 mg 1-10 mg 2.5-5 mg Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, o Oral Liquid 0.1-20 1-10 2.5-5 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and n.) o mg/5m1 mg/5m1 mg/5m1 Cav, Asn, Gln, Can, Ser, Hyp, Sar un Tau, Djk, GABA, Cys, Dcy, Thr, and Sar c:
.....¨...
un Ciprofloxacin All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Hyp, Ser, a, b, c, g, Antibiotic; inhibits variou un Preferred Forms Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Thr, Gly, & h, i, j, k, o, bacteria, e.g., pseudomonds, Oral Tab/Cap 0.1-1.5 gm 0.1-1.0 g 0.2-0.8 gm Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, LysP aeruginosa, staphy1ococcu5 i l Oral Liquid 0.05- m 0.12-1 g/5m1 Nor, Arg, Phe, Tip, Thr, Arg, Phe, Trp,., aureus or proteus mirabilisr IV Bulk (Sterile) igm/5nil 0.08-1 5-15 mg/m1 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and treatment of comeal ulcersi,, 2-25 mg/m1 gm/5m1 Cav, Asn, Gln, Can, Ser, Hyp, Sar conjunctivitis, acute otitis 3-20 mg/ml Tau, Djk, GABA, Cys, extema, Dcy, Thr, and Sar !-----?-n_ Ramipril All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Hyp, Ser, j, o treatment of hypertension Preferred Forms Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Thr, Gly, & 0 iv Oral Tab/Cap Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, ______________ Lys in 0.1-20 mg 0.5-12 mg 1-10 mg u., Oral Liquid Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, u.) 0.1-20 0.5-12 1-10 mg/5m1 a, mg/5m1 mg/5m1 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and I.) Cav, Asn, Gln, Can, Ser, Hyp, Sar I.) Tau, Djk, GABA, Cys, c7, Dcy, Thr, and Sar H
Trandolapril All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Ser, Hyp, j, o treatment of hypertension 1 u.) Preferred Forms Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Thr, Gly & 0 Oral Tab/Cap Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, ______________ Lys 0.1-10 mg 0.5-7.5 mg 1-4 mg 0.1-10 0.5-7.5 1-4 mg/5m1 Oral Liquid Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, Hyp, Hsr, Car, Ort, Gln, Asn, Cys and mg/5m1 mg/5m1 Cav, Asn, Gln, Can, Ser, Hyp, Sar Tau, Djk, GABA, Cys, Dcy, Thr, and Sar 1 Iv n c 4 k . , =
=
. 6 .
k . , . 6 .

o o HAwork\1652\17690\SPEC\17690.spec without claimsII.doo 1¨, Fosinopril All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Ser, Hyp, j, o treatment of hypertension Preferred Forms Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Thr, Gly, & ,..,...
Oral Tab/Cap 1-100 mg 2-75 mg 5_50 mg Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, Lys ri Oral Liquid 1-100 2-75 mg/5m1 5-50 Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, o mg/5m1 mg/5m1 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and o Cav, Asn, Gln, Can, Ser, Hyp, Sar un Tau, Djk, GABA, Cys, Dcy, Thr, and Sar o ::---, un Enalapril All Doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Ser, Hyp, j, o treatment of hypertension-Q. --4 un Preferred forms 0.5-100 mg 1-50 mg 2-25 mg Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Thr, Gly & .--' Oral Tab/Cap 0.5-100 1-50 mg/5m1 2-25 Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, Lys .., Oral Liquid mg/5m1 monil Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, ...,..,...
Hyp, Hsr, Car, Ort, Gln, Asn, Cys and Cav, Asn, Gln, Can, Ser, Hyp, Sar Tau, Djk, Djk, GABA, Cys, -a......5 Dcy, Thr, and Sar F: :
.---,----Benazepril All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Hyp, Ser, j, o treatment of hypertension n Preferred Forms Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Thr, Gly, & 0 Oral Tab/Cap 1-100 mg 2-75 mg 2.5-50 Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, Lys iv in Oral Liquid 1-100 2-75 mg/5m1 mg Nor, Arg, Phe, Trp, Ur, Arg, Phe, Trp, u.) a, u.) mg/5m1 2.5-50 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and a, iv ing/5mi, Cav, Asn, Gln, Can, Ser, Hyp, Sar iv Tau, Djk, GABA, Cys, Dcy, Thr, and Sar c7, Perindopril All doses expressed as drug base Lys, Leu, Ile, Gly, Lys, Leu, Ile, Gly, Hyp, Ser, j, o treatment of hypertension 0 H
Preferred Forms Asp, Glu, Met, Ala, Asp, Glu, Met, Ala, Thr, Gly, & 1 u.) Oral Tab/Cap Val, Pro, His, Tyr, Ser, Val, Pro, His, Tyr, ______________ Lys 0.1-20 mg 0.5-15 mg 1-10 mg Oral Liquid Nor, Arg, Phe, Trp, Thr, Arg, Phe, Trp, 0.1-20 0.5-15 mg/5m1 1-10 mg/5m1 mg/5m1 Hyp, Hsr, Car, Ort, Gln, Asn, Cys and Cav, Asn, Gln, Can, Ser, Hyp, Sar Tau, Djk, GABA, Cys, Dcy, Thr, and Sar .0 n ,-i cp t.., =
=
.6.
t.., .6.

=
HAwork\1652\17690\SPEC\17690.spec without claimsII.doc 1¨, Moexipril All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, j, o treatment of hypertension Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly & Lys 1:f Oral Tab/Cap His Tyr Ser, Nor Arg Val, Pro, His, Tyr, ________________________________________________________ n 1-30 mg 2-20 mg 5-15 mg ' " "
= f Oral Liquid Phe Tr Hyp Hsr, , p, , , Thr, Arg, Phe, Trp, 0 E
1-30 mg/5m1 2-20 mg/5m1 5-15 ', mg/5m1 Car, Ort, Cav, Asn, Gln, Asn, Cys and %
Gln, Can, Tau, Djk, Ser, Hyp, Sar un -:-..
GABA, Cys, Dcy, Thr, ,....: :,. .6.
and Sar o Cromolyn All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, & b, c, h, i, j, inhibits release of histiffane --4 un Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Pro k, 1, n, o, and leukotrienes fromPT-a. st Oral Tab/Cap 10-200 mg 20-100 mg 20-50 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, I), q, cell; treatment of --- Ai Oral Liquid 10-200 20-100 20-50 Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, mastocytosis, asthma w mg/5m1 mg/5m1 mg/5m1 Car, Ort, Cav, Asn, Gln, Asn, Cys and .---.
,.-_-,..
Gln, Can, Tau, Djk, Ser, Hyp, Sar ,-..
GABA, Cys, Dcy, Thr, f't .-...., and Sar n Amoxicillin All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, a, b, c, h, antibiotic effective against Preferred forms ________________________ Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly & Lys i, j, k, 1, o, 13-lactamase negative strains 0 Oral Tab/Cap* 0.1-1.5 gm 0.2-1.2 0.25-1 gm His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, p causing infections of ear, N) in Oral Liquid 0.1-1.5 gm 0.25-1 Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, nose, throat, e.g., u.) a, gm/5m1 0.2-1.2 gm/5m1 Car, Ort, Cav, Asn, Gln, Asn, Cys and streptococcus, u.) a, Oral Powder 0.1-0.75 gm gm/5m1 0.125-0.5 Gln, Can, Tau, Djk, Ser, Hyp, Sar staphylococcus or H iv (*also chewable) 0.1-0.6 gm GABA, Cys, Dcy, Thr, influenzae;treatment of iv gm and Sar infections of genitourinary c7, tact due to E. coil, P.

H

mirabilis, E. faecalis, u.) infections of skin due to streptococcus, staphylococcus or E. coli, infections of lower respiratory tract due to streptoccus, staphyloccus.
H. influenzae, and Iv n gonorrhea Cefuroxime All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Ser, Thr, b, c, e, f, antibiotic; treatment of cp Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Lys h, i, j, k, o, pharyngitis/tonsillitis caused n.) o =
.6.
7:-:-.., t., .6.

=
H:\work\1652\17690\SPEC\17690.spec without claimsII.doc 1¨, Oral Tab/Cap 10-1000 mg 50-750 100-600 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, p by streptococcus, acuto7, Oral Liquid 10-1000 mg mg Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, bacterialotitis media cats' ed mg/5m1 50-750 100-600 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and by streptococcus, H J.
mg/5m1 mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar influenzae, moraxella 0 Dcy, Thr, and Sar catarihalis or streptocabus, urinary tract infectionsC
caused by E coli or ILI
Klebsiella pneumonia, uri gonorrhea, skin infection3 cause by staphylococcukor straptococcuso o o T

HAworld1652\17690 \SPEC\17690.spec without claimsTI.doc Ceftazidime All doses expressed as drug base Lys, L,eu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Ser, Thr, a, b, c, g, antibiotic, treatmtent Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Lys h, i, j, k, 1, lower respiratory tractn Powder for IV His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, o, p, q infections, including 0.1-5 gm 0.25-4 gm 0.5-2 gm Oral Tab/Cap Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, pneumonia caused by 0.1-1 gm 0.25-1 gm 0.5-1 gm t=.) Oral Liquid 0.1-2.5 0.25-2 0.5-1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and pseudomonas, H.
Tau, Djk, GABA, Cys, Ser, Hyp, Sar influenzae, Klebsiella, gm/5m1 gm/5m1 gm/5m1 -:-Dcy, Thr, and Sar Enterbacter, E. coli, proteus mirabilis, streptococcu staphylococcus; skin anT1 skin structure infectionAl caused by peudomonue, =
aeruginosa, coli, Proteus enterbact&-',' staphylococcus, streptococcus, urinary it-act infections casued by pseudomonas aeruginosa, enterbacter, proteus, Klebsiella, E. coli; bone and joint infections caused by pseudomonas, eruginosa, Klebsiella, Enterbacter, or staphylococcus;

gynecologic infections including endometritis, pelvic cellulits and infections of the female genital tract caused by E.
coli, intra-abdominal infections and central nervous system infections, including meningitis tµ.) -:-HAwork\1652\17690\SPEC\17690.spec without clafinsII.doc Cefpodoxime All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, a, b, c, g, h, i, antibiotic especial%
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly & Lys j, k, 1, o, p, q against streptococcils, Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, H. influenzae, s 10-500 mg 25-350 mg 50-250 Oral Liquid 10-500 25-350 mg Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, moraxella catarrhalig; 0 mg/5m1 mg/5m1 50-250 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and treatment of acutelaiis n.) o mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar media, pharyngitii7 un 1.17, -:-..
Dcy, Thr, and Sar tonsillitis, pneumcma, .6.
bronchitis, gonorrtid, o un r-and rectal infectioin un in women '---.
Atovaquone All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Sar, a, b, h, i, j, k, treatment of malarrej A
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Ala, Pro & Ser o, p caused by plasmodPmli Oral Tab/Cap 50-1000 mg 100-500 200-300 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, parasite ¨
¨ .
E-_-:
Oral Liquid above/5 ml mg mg Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, ri For Pediatric Use 10-150 above/5 ml above/5 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and P
mg/5m1 25-100 ml Tau, Djk, GABA, Cys, Ser, Hyp, Sar n mg/5m1 50-75 Dcy, Thr, and Sar mg/5m1 iv _ Acyclovir All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Sar, Hyp b, c, h, i, j, k, treatment of human in u.) Preferred forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Pro & Ser o, p cytomegalovirus a, u.) Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, (HCMV) a, iv Oral Liquid 50-1000 mg 100-750 ml 150-500 Phe, Tip, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, iv 50-1000 100-750 mg Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and 0 mg/5m1 mg/5m1 150-500 Tau, Djk, GABA, Cys, Ser, Hyp, Sar c7, mg/5m1 Dcy, Thr, and Sar H
I
CA

IV
n ,-i cp t., =
=
.6.
7:-:-.., t., .6.

o o 11:\work\1652\17690\SPEC\17690.spec without claimsII.doc 1¨, Gancyclovir All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Ser, Thr, b, c, e, f, h, i, j, treatment of human ' Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Lys k, o, pcytomegat , . :,-...
o virus V' Oral Tab/Cap 0.1-1 gm 0.2-0.8 gm 0.2-0.6 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, (HCMV) 0 Oral Liquid 0.1-1gm/5m1 0.2- gm Phe, Tip, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, ..J
E
IV Infusions 10-200 mg/ml 0.8mg/5m1 0.2- Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and \ O
tµ.) 25-100 0.6mg/5 Tau, Djk, GABA, Cys, Ser, Hyp, Sar C =
o mg/ml ml Dcy, Tin, and Sar fit u.
=

o mg/ml 'f-- -4 Penciclovir All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leta, Ile, Gly, Hyp, Ser, Thr, , b, c, e, f, h, i, j, treatment of humair Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Lys k, o, p.
cytomegaloviru' s si.
Powder for IV His, Tyr, Ser, Nor, Arg, ___________________ Val, Pro, His, Tyr, (HCMV) ...¨..-10-1000mg/m1 25-750 50-500 _=
Topical Cream 0.1_5% mg/m1 mg/ml Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, ¨
Oral Cap/Tab Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and 10-500 mg 0.25-3% 0.5-2.5%
20-300 mg 25-250 Tau, Djk, GABA, Cys, Ser, Hyp, Sar 0 Dcy, Thr, and Sar 1 :
IF--mg .
.
Niacin ER All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Tin, a, b, h, i, j, 1, lipid management n Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Tyr, Gly &
Lys m, n, o, p, q 0 iv Oral Tab/Cap His Tyr Ser, Nor, Arg, ______________________ Val, Pro, His, Tyr, in 0.2-2 gm 0.25-1.5 0.5-1 gm ' " u.) Oral Liquid Phe Trp,, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, a, 0.2-2 gm/5m1 gm 0.5-1u.) Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and a, 0.25-1 grn/5m1 iv Tau, Djk, GABA, Cys, Ser, Hyp, Sar gm/5m1iv Dcy, Thr, and Sar _ _ c7, Bexarotene - All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Re, Gly, Ser, Hyp, Thr, b, c, h, i, j, k, 1, treatment of skin 0 Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Lys o, p conditions, especially H

u.) Oral Tab/Cap 10-500 mg 25-250 mg 50-100 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, those requiring 0 Oral Liquid above/5m1 above/5m mg Phe, Tip, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, activation of retinoid Topical Gel 0.1-5% 0.25-2.5%1 above/5 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and X receptors ml Tau, Djk, GABA, Cys, Ser, Hyp, Sar 0.5- Dcy, Thr, and Sar 1.5%

.0 n ,-i cp .
t., =
=
.6.

=
,., .6.
HAwork\1652\17690\SPEC\17690.spec without claimadoc g -Propoxyphene All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, a, b, c, h, i, j, treatment of pain Preferred forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Lys k, 1, o, 0 p Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, _ In o Oral Liquid 20-400 mg 25-250 mg 30-150 Phe, Tip, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, n.) 20-400 25-250 mg Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and 7 =
o mg/5m1 mg/5m1 30-150 Tau, Djk, GABA, Cys, Ser, Hyp, Sar -...
=
un 7:-:-.., mg/51n1 Dcy, Thr, and Sar Salsalate All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Ser, Thr, Gly, b, c, h, i, j, treatment of un Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Lys . k, o, p inflammatory 7.----, ...----Oral Tab/Cap 0.2-2 gm 0.25-1.5 gm 0.3-1 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, conditions ..., Oral Liquid 0.2-2 gin/5m1 0.25-1.5 gm Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, ' gm/5m1 0.3-1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and ,--gmi5mi Tau, Djk, GABA, Cys, Ser, Hyp, Sar -,-----Dcy, Thr, and Sar 4,fi _ ._ Acetaminophen All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Ser, Sar, Gly, a, b, c, e, h, treatment of pain=eir Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Lys i, j, k, o, p fever r- n Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, 0 20-1000 mg 50-800 mg 100-600 iv Oral Liquid Phe T
, rp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, in 20-1000 50-800 mg u.) , ln, , Gln, Asn, Cys and a, mg/5m1 mg/5m1 100-600 Ort, Cav, Asn G
Can u.) mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar a, N) Dcy, Thr, and Sar iv _ _ _ Ibuprofen All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Tyr, a, b, h, i, j, 1, treatment of pain, fever c7, I
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly & Lys m, n, o, p, q or inflammation H
Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, 1 20-1000 mg 50-800 mg 100-600 u.) Oral Liquid 20-1000 50-800 mg Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, 0 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and mg/5m1 mg/5m1 100-600 Tau, Djk, GABA, Cys, Ser, Hyp, Sar mg/5m1 Dcy, Thr, and Sar , _______________________________________________________________________________ ____________________________________ -n ,-i c, ,., =
=
.6.
,., . .6.
,., 44 =
11:\work\1652\17690\SPEC\17690.spec without claimsII.doe Lovastatin A11 doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Gly, b, c, e, f, lowers choloesterol Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Lys h, i, j, k, concentration; II
Oral Tab/Cap 1-100 mg 2-80 mg 5-50 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, 1, o, p inhibits HMG-CoAn Oral Liquid 1-100 mg/5m1 2-80 5-50 Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, reductase....-4 ,.: 0 mg/5m1 mg/5m1 Car, Ort, Cav, Asn, Gln, Asn, Cys and -...
, n.) =
Gln, Can, Tau, Djk, Ser, Hyp, Sar un GABA, Cys, Dcy, Thr, .6.
and Sar .= - .., un Simavastatin All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Gly, b, c, e, f, lowers choloesterol7-, --Preferred forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Lys h, i, j, k, concentration;
Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, 1, o, p inhibits HMG-CoA
.._...
Oral Liquid 1-200 mg 2-150 mg 2.5-100 mg Phe, T¨, Hyp, Hsr, Thr, Arg, Phe, Trp, reductase -, 1-200 mg/5m1 2-150 2.5-100 Car, Ort, Cav, Asn, Gln, Asn, Cys and ..--.----mg/5m1 mg/5m1 Gln, Can, Tau, Djk, Ser, Hyp, Sar .:.-....:._:-.
GABA, Cys, Dcy, Thr, and Sar _ n Atorvastatin All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Gly, b, c, e, f, lowers choloesterol Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Lys h, i, j, k, concentration; 0 iv Oral Tab/Cap 1-250 mg 2-125 mg 5-100 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, 1, o, p inhibits HMG-CoA in u.) Oral Liquid 1-250 mg/5m1 2-125 5-100 Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, reductase a, u.) mg/5m1 mg/51n1 Car, Ort, Cav, Asn, Gln, Asn, Cys and a, iv Gln, Can, Tau, Djk, Ser, Hyp, Sar iv GABA, Cys, Dcy, Thr, c7, and Sar Pravastatin All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Gly, b, c, e, f, lowers choloesterol H
I
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Lys h, i, j, k, concentration; u.) Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, 1, o, p inhibits HMG-CoA
1-250 mg 2-125 mg 5-75 mg Oral Liquid Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, reductase 1-250 mg/5m1 2-125 5-75 Car, Ort, Cav, Asn, Gln, Asn, Cys and mg/5m1 mg/5m1 Gln, Can, Tau, Djk, Ser, Hyp, Sar GABA, Cys, Dcy, Thr, and Sar .0 n ,-i c 4 t., =
=
.6.
t., .6.
=
H:\work\1652\17690\SPEC\17690.spec without claimsII.doc 1¨, Fluvastatin All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Tyr, b, c, e, f, lowers choloesterol Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly & Lys h, i, j, k, concentration; 'Irt Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, 1, o, p inhibits HMG-CoAn 1-250 mg 2-125 mg 5-75 mg O
Oral Liquid 1-250 mg/5m1 2-125 Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, reductase _k:

' -'1 t=.) mg/Sml mg/5m1 Car, Ort, Cav, Asn, Gln, Asn, Cys and %, o Gln, Can, Tau, Djk, Ser, Hyp, Sar f"'W u.
7:-:-.., GABA, Cys, Dcy, Thr, rw.-..
and Sar un _ :7-'=--: ---1 Nadolol All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Sar, Ser, b, h, i, j, treatment of angina' un Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Pro k, 1, o, p pectoris and ..----,---...
Oral Tab/Cap 1-250 mg 5-225 mg 10-200 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, hypertension; p- ".--- 4.
Oral Liquid 1-250 mg/5m1 5-225 mg Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, adrenergic receptorri li mg/5m1 10-200 Car, Ort, Cav, Asn, Gln, Asn, Cys and antagonist -:.,--..---momi Gln, Can, Tau, Djk, Ser, Hyp, Sar .,_...
GABA, Cys, Dcy, Thr, .----, and Sar n Valsartan All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Ser, Thr, Lys, b, f, i, j, treating hypertension, Preferred forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly & Sar k, 1, o, p angiotension II 0 iv Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, antagonist in u.) Oral Liquid 10-500 mg 25-250 mg 50-200 Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Tip, a, u.) 10-500 25-250 mg Car, Ort, Cav, Asn, Gln, Asn, Cys and a, iv mg/5m1 mg/5m1 50-200 Gln, Can, Tau, Djk, Ser, Hyp, Sar iv mg/5m1 GABA, Cys, Dcy, Thr, c7, d Sanar _ Methyl All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Hyp, Sar, a, b, c, h, treatment of attention H

phenidate Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, & Ser j, k, 1, o, deficit disorders and u.) Preferred Forms His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, P narcolepsy Oral Tab/Cap 1_50 mg 2-40 mg 2.5-25 mg Phe, Trp, Hyp, Hsr, Thr, Arg, Phe, Trp, Oral Liquid 1-50 mg/5m1 2-40 2.5-25 mg/5m1 Car, Ort, Cav, Asn, Gln, Asn, Cys and mg/5m1 Gln, Can, Tau, Djk, Ser, Hyp, Sar GABA, Cys, Dcy, Thr, and Sar 4 , n ,-i cp t., =
=
.6.
t., .6.

o o HAwork\1652\17690\SPEC\17690.spec without claimsll.doc 1¨, Trovafloxacin All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Ser, Pro, a, b, e, h, j, antibiotic; inhib0 Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Hyp & Thr k, o, p bacteria such as E.
Oral Tab/Cap His, Tyr, Ser, Nor, Arg, ____________________ Val, Pro, His, Tyr, coli, pseudomorfal 10-500 mg 50-300 80-250 mg ' Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, aeruginosa, H.
Oral Liquid ==1 10-500 mg 80-250 mg/5m1 50-300 mg/5ml Ort, Cav, Asia, Gln, Can, Gln, Asn, Cys and influenzae, Tau, Pik, GABA, Cys, Ser, Hyp, Sar streptococous, a: 0 mg/inl S
n.) Dcy, Thr, and Sar Klebsiella, Li fl o o staphylococcus,in u, Ci5 mycoplasma c:
pneu.moniae, ,..7...
un --.1 peptostreptococcA, un prevotella; treatiiiint of pneumonia, t a postsurgical infections;

graecolgic and pelvic infections, infections, such as n endomyometritis, parametritis, septic iv abortions,and post-in u.) partum infections;
a, u.) skin infections, e.g., a, iv diabetic foot iv infections 5-AS* All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Glu, Gly, Tyr & Lys b, c, i, j, 1, treatment of c7, Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, m, n, o, p, tuberculosis H

Oral Tab/Cap His, Tyr, Ser, Nor, Arg, ____________________ Val, Pro, His, Tyr, q u.) 1-200 mg 5-150 10-125 mg ar, Phe, Trp, Hyp, Hsr, C, Thr, Arg, Phe, Trp, Oral Liquid 1-200 mg/5m1 mg 10-125 (*5-Arnino- Ort, Cav, Asti, Gln, Can, Gln, Asn, Cys and 5-150 mg/Sinl Salicylic acid) Tau, Djk, GABA, Cys, Ser, Hyp, Sar mg/5m1 Dcy, Thr, and Sar _______________________________________________________________________________ __________________________________ I
IV
n ,-i cp ,., =
=
.6.

t.., .6.
HAwork\1652 \I7690 \SPEC \I7690.spec without claimsII.doc g Methyl All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Pro, b, c, g, j, 1, treatment of 177 prednisolone Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Sar & Ser m, n, o, p, inflammation ,r3 Preferred Forms His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, q especially from ---4 o IM Injection 2-200 mg/ml 5-150 10-100 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, infections, tissud-,õ n.) o mg/ml mg/ml Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and damage, allergyptd a .--Topical Cream 0.001-5% Tau, Djk, GABA, Cys, Ser, Hyp, Sar auto-immune 7:-:-.., 0.01- 0.1-2% Dcy, Thr, and Sar disease .
un ,-,¨; --4 2.5%,....-_-õ
un _ ¨
._ Medroxy All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Pro, b, c, g, j, 1, providing , Progesterone Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Sar & Ser m, n, o, p, contraception Preferred forms ________________________ His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, q ¨ A
IM Injections Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, 4- Ill 1 mg ¨ 4 10 mg ¨ 40 rag ¨ 1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and gm/ml 2 gm/m1 gm/ml Tau, Djk, GABA, Cys, Ser, Hyp, Sar , Dcy, Thr, and Sar ILL
_ n Estramustine All doses expressed as drug base Lys, Lau, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Gly, Lys, Pro, Ala, b, c, h, i, j, treatment of cancer Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Sar & Val k, 1, o, p especially treatment 0 iv Oral Tab/Cap 10-500 mg 25-250 50-200 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, of metastatic or in u.) Oral Liquid 10-500 mg 50-200 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, progressive a, u.) mg/5ral 25-250 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and carcinoma of a, iv rug/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar prostate iv Dcy, Thr, and Sar0 ' Miglitol All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Sar, Pro, & b, c, i, j, n, treatment of type II 0 Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Ser q diabetes H

Oral Tab/Cap 1-250 mg 2-150 _______ 10-125 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, u.) Oral Liquid Phe, Tip, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, 1-250 mg/5m1 mg 10-125 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and 2-150 mg/Sral mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar Dcy, 'Thr, and Sar , _______________________________________________________________________________ ___________________________________ Iv n ,-i t., =
=
.6.
7:-:-.., t., .6.

o H:\work\1652\17690\SPEC\17690.spec without clairnsadoc Mefloquine All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Sar, Pro, a, b, c, h, i, treatment of malgia Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Val, Ala .i, 1c 1, 0, I), qj Oral Tab/Cap His, Tyr, Ser, Nor, Arg, ____________________ Val, Pro, His, Tyr, n 10-500 mg 100-400 150-300 mg q , o Oral Liquid Phe Tr p, Hsr, C
, p, Hyp, , Car, , g, , p, ..--,..E
10-500 mg 150-300 Thr, Arg, Phe, Tip, mg/5m1 , , , , , , , y mg/5m1 25-400 mg/5m1 Ort Cav, Asn Gln Can Gln Asn Cs and un Tau, Djk, GABA, Cys, Ser, Hyp, Sar ..----- , mg/5m1 m..-.. o Dcy, Thr, and Sar Danazol All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Hyp, Pro, Ala, Val, a, b, c, e, f, treatment of -_-.
Preferred forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Ser & Thr g, h, i, j, k, endometriosis atitt-Oral Tab/Cap His, Tyr, Ser, Nor, Arg, ____________________ Val, Pro, His, Tyr, 1, n, o, p, q flbrostatic breast\
Oral Liquid 2-500 mg 10-350 mg 25-250 mg Phe, Tip, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, disease .---i :-........4 2-500 10-350 25-250 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and mg/5m1 mg/5m1 mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar ..-4-,-Dcy, Thr, and Sar Eprosartan All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Mr, Lys, b, c, h, i, j, ACE inhibitors,p_, n Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly & Val k, 1, o, p treatment of Oral Tab/Cap 0.1-1 gm 200-800 300-750 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, hypertension o iv Oral Liquid 0.1-1 mg 300-750 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, in co gm/5m1 200-800 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and a, u.) a, mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar iv Dcy, Thr, and Sar iv _______________________________________________________________________________ _________________________________________ o Divalproex Na All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Lys, a, b, c, f, h, treatment of epilepsy 0 c7, Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Val i, j, k, 1, o, ' Oral Tab/Cap His, Tyr, Ser, Nor, Arg, ____________________ Val, Pro, His, Tyr, p H

50-800 mg 75-750 mg 100-600 mg u.) Oral Liquid 50-800 75-750 100-60 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, 0 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and mg/5m1 mg/5m1 mg/Sml Tau, Djk, GABA, Cys, Ser, Hyp, Sar Dcy, Thr, and Sar Iv n c 4 k . , =
=
. 6 .
-a 5 k . , . 6 .
49 ,. z =
HAwork\1652\17690\SPEC\17690.spec without claimsII.doe 1-"

Fenotibrate All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Lys, b, c, h, i, j, treatment of Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Ala k, 1, o, p, q hypercholestemii Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, i.--10-800 mg 20-750 mg 100-600 mg o Oral Liquid Phe Tr H Hsr, Car, , p, Hyp, , , Thr, Arg, Phe, Trp, i =

Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and , mg/5m1 mg/5m1 mg/5m1 7. =
un Tau, Djk, GABA, Cys, Ser, Hyp, Sar r..
Dcy, Thr, and Sar .,..-...
c:
un Gabapentin All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Cyclic Deriv. & Tyr b, c, d, e, f, treatment of un Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, h, i, j, k, 1, convulsions Oral Tab/Cap 10_800 mg 25-750 mg 50-500 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, n, 0, 13, p Oral Liquid 10-800 25-750 50-500 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, mg/5m1 mg/5m1 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and Tau, Djk, GABA, Cys, Ser, Hyp, Sar Dcy, Thr, and Sar , Lansoprazole All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Gly, Lys, Pro, Sar, b, e, f, h, i, suppression of daitric n Preferred forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Ser & Val j, k, 1, o, p acid secretion by 0 Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, inhibition of (H+, K+) iv Oral Liquid 1-60 mg 2-50 mg 10-40 mg Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, ATP-ase enzyme in co 1-6- 2-50 mg/5m1 1040 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and system at the secretory a, u.) a, mg/5m1 mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar surface of the gastric K) Dcy, Thr, and Sar parietal cell; treatment "

of gastric hyperacidity c7, _ Omeprazole All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Val, Pro & b, e, f, h, i, suppression of gastric 0 H
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Sar j, k, 1, o, p acid secretion by 1 u.) Oral Tab/Cap 1-200 mg 2-100 mg 5-60 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, inhibition of (H+, K+) 0 Oral Liquid 1-200 2-100 5-60 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, ATP-ase enzyme mg/5m1 mg/5m1 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and system at the secretory Tau, Djk, GABA, Cys, Ser, Hyp, Sar surface of the gastric . Dcy, Thr, and Sar parietal cell, treatment of gastric hyperacidity Iv n c 4 k . , =
=
. 6 .
k . , . 6 .
o ,-, H:\work\1652 \17690 \SPEC \17690.spec without claimsil.doc Megestrol All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Gly, Lys, Sar, Pro, b, c, h, i, j, treatment of anorexia;
,....-.
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Ser & Ala k, 1, n, o, p improving appetite in Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, .
2-100 mg 4-80 mg 20-60 mg anorexic and pents a't'r Oral Liquid 2-100 4-80 mg/5m1 20-60 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, suffering from ADS O
mg/5m1 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and o Tau, Djk, GABA, Cys, Ser, Hyp, Sar C =
un Dcy, Thr, and Sar c:
Metformin All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Asp, Glu, Lys &
Azo o, p4 .7.
treatment of Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, dimer hyperglycemia; Qs un Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, insulin to improirre.
0.2 ¨ 3 gm 0.25-1.5 gm 0.5-1 gm Oral Liquid 0.2-1 0,25-1.5 0.5-1 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, transport of gluaie, 1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and into cells ,--_ gm/5m1 mg/5m1 gm/5m1 1=
Tau, Djk, GABA, Cys, Ser, Hyp, Sar pri Dcy, Thr, and Sar ----, . .
,-..---:
Tazarotene All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Lys, & B, c, h, I, j, treatment of psoliasis n Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly k, 1, o, p and acne especially Topical Gel 0.01-0.3% 0.02-0.25% 0.025-His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, those caused by 0 iv 0.125% Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, pathogenic in u.) Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and microorganisms, allergy a, u.) Tau, Djk, GABA, Cys, Ser, Hyp, Sar and inflammation a, iv Dcy, Thr, and Sar iv Sumatriptan All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Ala, Pro, b, c, d, g, h, 5 HT subtype receptor 0 c7, Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Sar & Val i, j, k, 1, n, agonist, treatment of 1 Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, o, p, q migraine headaches H

Oral Liquid 5-250 mg 10-200 mg 20-125 mg Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, u.) 5-250 10-200 20-125 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and IM Injections mg/5m1 mg/5m1 mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar 1-36 mg/ml 2-24 mg/ml 4-20 Dcy, Thr, and Sar mg/ml Iv n c 4 k . , =
=
. 6 .
k . , .6.
H:\work\1652\17690\SPEC\17690.spec without clainasII.doc o 1¨, ,--Naratriptan All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly Lys, Gly, Sar, Val, b, h, i, j, k, 5 HT subtype _ Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Alf,, Ala, & Pro 1, o, p receptor agonise Oral Tab/Cap 0.1-10 mg 0.25-5 mg 0.5-4 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, treatment of i 4 Oral Liquid 0.1-10 0.25-5 0.5-4 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, migraine headades 0 n.) mg/5m1 mg/5m1 me5mi Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and o -:-Tau, Djk, GABA, Cys, Ser, Hyp, Sar C un 7: 5 - Dcy, Thr, and Sar _ _ _ Zolmitriptan All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Sar, Val, b, h, i, j, k, 5 HT subtype ri un .....,:. -4 Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Ala, & Pro 1, o, p receptor .----un ---....-z-4 Oral Tab/Cap His, Tyr, Ser, Nor, Arg, ____________________ Val, Pro, His, Tyr, agortist;treatmerikof 0.1-12 mg 0.5-10 mg 1-7.5 mg Oral Liquid Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, migraine headaclie's 4 1-12 0.5-10 1-7.5 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and m1 mg/5m1 mg/5m1 mg/5 .
Tau, Djk, GABA, Cys, Ser, Hyp, Sar .".:¨...
Dcy, Thr, and Sar .-...., El Aspirin All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Lys, a, b, c, e, f, antipyretic, antilu.
n Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Ala g, h, j, k, I, inflammatory, Oral Tab/Cap His, Tyr, Ser, Nor, Arg, ____________________ Val, Pro, His, Tyr, m, n, o, p, q analgesic, 0 10-1000 20-800 mg 25-600 iv Oral Liquid Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, thrombolytic; in mg 20-800 mg u.) Ort, Cav, Asn, G C Gn, Cys and treatment of a, 10-1000 mg/ml 25-600 ln, an, ln, As u.) . Tau, Djk, GABA, Cys, Ser, Hyp, Sar hyperthermia, a, mg/ml mg/ml "
Dcy, Thr, and Sar myocardial iv infarction and thrombolysis c7, _ .

Olmesartan All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Lys, b, h, i, j,k, 1, ACE inhibitor, 0 H
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, GIu, Met, Ala, Gly, & Ala o, p treatment of 1 u.) Oral Tab/Cap 1-100 mg 2-80 mg 4-50 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, hypertension Oral Liquid 1-100 2-80 4-50 mg/5m1 Pile, Tip, Hyp, Hsr, Car, Thr, Arg, Phe, Tip, mg/5m1 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and Tau, Djk, GABA, Cys, Ser, Hyp, Sar Dcy, Thr, and Sar Iv n k . , =
=
. 6 .
7: -:- 5 k . , . 6 .
52 o o H:\work\1652\17690\SPEC\17690.spec without claimsII.doc 1¨, Sirolimns All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Lys, b, h, i, j,k, 1, immunosuppregant Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly, & Ala o, p in surgical hump Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, patients with õ.4.
Oral Liquid 0.1-20 mg 0.5-10 mg 1-8 mg Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, transplants;
0.1-20 0.5-10 1-8 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and antibiotic; treating n.) IM Injections mg/51111 mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar -,,-,..
vitiligo psoriassit-E
o un 7: -:- 5 Dcy, Thr, and Sar acne c:
Tacrolimus All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Ala, Thr, b, c, g, h, i, immunosuppresRint un ,. un Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Sar & Pro j, k, 1, o, p in surgical human¨

Oral Tab/Cap 0.1-20 mg 0.2-15 mg 0.25-10 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, patients with ...".-";
Oral Liquid above/5m1 above/5m1 above/5m1 Phe, Tip, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, transplants; l'-..
¨ A
IV Infusions 1-20 mg/ml 2-15 2.5-8 mg/ml Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and antibiotic; treating, 13 mg/ml Tau, Djk, GABA, Cys, Ser, Hyp, Sar vitiligo psoriass Dcy, Thr, and Sar acne ...f9 õ:,..i, Pimeerolimus All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Ala, Thr, = b, c, g, h, i, immunosuppre4int Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Sar & Pro j, k, 1, o, p in surgical human n Oral Tab/Cap 0.1-20 mg 0.2-15 mg 0.25-10 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, patients with 0 Oral Liquid above/5m1 above/5m1 above/5m1 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, transplants; "
in Ointment Cream 0.01 ¨ 10% 0.1-5% 0.5-2% Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and antibiotic treating u.) a, Tau, Djk, GABA, Cys, Ser, Hyp, Sar vitiligo psoriass, u.) a, Dcy, Thr, and Sar acne "
_ Clopidogrel All doses expressed as drug base 20-125 mg 25-100 mg Ser, Hyp, Thr, Lys, b, c, h, i, j, treatment of "

Preferred Forms 20-125 mg/5m1 25-100 mg/5m1 Ala, & Gly k, 1, m, o, p, myocardial 0 c7, Oral Tab/Cap q infections 0 10-250 mg 20-125 25-100 mg H
Oral Liquid (Ai 10-250 mg 25-100 mg/5m1 20-125 mg/5m1 mg/5m1 , Iv n c 4 k . , =
=
. 6 .
7: -:- 5 k . , . 6 .

o o HAwork\1652\17690\SPEC\17690.spec without claimsILdoc 1¨, Aruphoteriein All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Lys, b, c, g, i, j, treatment of futtps, B Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Ala, & Gly 1, m, n, o, p, expecially those=:.
Preferred Forms His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, q acting on cell ir,k 0.5-20 1-15 2-10 IV Infusion mg/kg/day mg/kg/day mg/kg/day Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, membrane claangim Ort, Cav, Asn, Gin, Can, Gba, Asn, Cys and its permeability '''-i.
0.01-10% 0.1-5% 0.5-2%
n.) Topical Cream Tau, Djk, GABA, Cys, Ser, Hyp, Sar d.---.
o Dcy, Thr, and Sar ---.
o _ .
_ Tenofovir All doses expressed as drug base - Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Ala, Pro, b, c, h, i, j, inhibitor of HP
e.n Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Ser & Sar k, 1, o, p virus, treatment,*
---.) cm Oral Tab/Cap 10-900 mg 50-750 100-500 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, AIDS infections.::,,:
Oral Liquid 10-900 mg 100-500 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp,f..ig 4 , mg/5m1 50-750 mg/5m1 Ort, Cav, Asn, Gin, Can, Gin, Asn, Cys and r -a-mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar 4 Dcy, Tim-, and Sar n -. -Unoprostone All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, lie, Gly, Ser, Hyp, Thr, Tyr, b, c, h, i, j, treatment of '' Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Pro, & Lys k, 1, n, o, p, glaucoma, n Ocular Drops - His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, q especially caused by 0.01-1% 0.05-0.5% 0.01-0.25% Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, age; lowers 0 iv Ort, Cav, Asn, Gin, Can, Gln, Asn, Cys and intraocular pressure (.71 w Tau, Djk, GABA, Cys, Ser, Hyp, Sar A.
w Dcy, Thr, and Sar A.
n) _ _ _ Fulvestrant All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Gly, Lys, Pro, Ala, B, c, g, j, 1, treating cancer, iv Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Val & Sar o,p especially breast o 0, IM Injection 2-1250 10-1000 ' 20-500 His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, cancer 1 mg/5m1 mg/5m1 mg/5m1 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, '-Ort, Cav, Asn, Gin, Can, Gin, Asn, Cys and w Tau, Djk, GABA, Cys, Ser, Hyp, Sar Dcy, Thr, and Sar _ 1-e n 1 7..3.
c A
w c , 4-.
---, t.., 4-.
HAwork\ 1652 \17690\SPEC117690.spec without claims11.cloc vz 1¨k Cefditoren All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Gly, b, c, h, i, j, antibiotics, Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Lys & Ala k, 1, o, p especially inhibTig Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, H. influenzae;
20-500 mg 100-400 150-300 mg n Oral Liquid Phe Trp H
, , Hyp, Hsr, Car, Thr, Arg, , , 20-500 mg 150-300 Phe Trp Haemophilus pas-mg/5m1 100-400 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and influenzae, n.) mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar streptococcus, o Dcy, Thr, and Sar Maraxella . 6 .
catarrhalis;
un treatment of 2 , un bronchitis, ,,,,, pharyngitis, tonsillitis, skin infections _ Efavirenz All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Gly, Lys, Pro, Ala, b, c, h, i, j, inhibitor of HIVa Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Sar, & Val k, 1, o, p specific, non- r-g Oral Tab/Cap His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, nucleoside, reveXse 0.2-1.2 gm 300-800 400-750 Oral Liquid Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, transcirptase; n 0.2-1.2 mg mg gm/5m1 300-800 400-750 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and treatment of AIDS

nag/5m1 mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar infections iv in Dcy, Thr, and Sar u.) a, Eplerenone All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Ser, Hyp, Thr, Lys, b, c, h, i, j, treatment of a, iv Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Gly & Val k, 1, o, p hypertension, blocks iv Oral Tab/Cap 10-250 mg 15-200 ¨20-150 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, binding of 0 Oral Liquid 10-250 mg 20-150 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, aldosterone to c7, mg/5m1 15-200 mg/5m1 Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and mineralo-corticoid 0 H

mg/5m1 Tau, Djk, GABA, Cys, Ser, Hyp, Sar receptors u.) Dcy, Thr, and Sar _ Iv n _ c 4 =
=
. 6 .
7: -:- 5 t.., .6.
HAwork\1652\17690\SPEC\17690.spec without clahnsII.doo o 1¨, Treprostinil All Doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Gly, Lys, Val, Hyp, b, c, g, h, i, Inhibits platelet,..
Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Thr & Ser j, k, 1, o, p aggregation and:
SC infusion His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, vasodilation of 0.1-100 0.2-50 0.5-20 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, systemic and 7'9 C) Oral Tab/Cap mg/ml mg/ml mg/ml Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and pulmonary vasCillar 10-1000 mg 20-800 mg 25-500 mg Tau, Djk, GABA, Cys, Ser, Hyp, Sar bed, treatment aZ

Dcy, Thr, and Sar cardiovascular M
related conditioe Adefovir All doses expressed as drug base Lys, Leu, Ile, Gly, Asp, Lys, Leu, Ile, Gly, Lys, Gly, Val, Ser, b, c, h, i, j, HIV reverse Preferred Forms Glu, Met, Ala, Val, Pro, Asp, Glu, Met, Ala, Hyp, & Pro k, 1, 0, P. transcriptase Oral Tab/Cap 1-100 mg 2-50 mg 5-20 mg His, Tyr, Ser, Nor, Arg, Val, Pro, His, Tyr, inhibitors; treatment.
.
-Oral Liquid 1-100 2-50 5-20 Phe, Trp, Hyp, Hsr, Car, Thr, Arg, Phe, Trp, of HIV mfection, mg/5m1 mg/5m1 moini Ort, Cav, Asn, Gln, Can, Gln, Asn, Cys and and AIDS
Tau, Djk, GABA, Cys, Ser, Hyp, Sar Dcy, Thr, and Saro .1õ,ff=-=
o o c7, o o 11:\work\1652\17690\SPEC\17690.spec without clairnsli.doc The following non-limiting examples further illustrate the invention:
Synthesis of Various Amino Acid Derivatives of Selected Drugs I. Propofol Derivatives Propofol (2,6-diisopropylphenol) is a low molecular weight phenol which widely used as a central nervous system anesthetic, and posses sedative and hypnotic activities. It is administered intravenously in the induction and maintenance of anesthesia and/or sedation in mammals. The major advantages of Propofol are that it can induce anesthesia rapidly, minimal side effects and upon withdrawal, the patient recovers quickly without prolonged sedation.
PROPOFOL
01-13. OH CH3 CHIA
Propofol has been shown to have a large number of therapeutic applications, which are quite varying and somewhat surprising. For example, it has been shown to be an effective antioxidant, anti-emetic, anti-pruritic, anti-epileptic, anti-inflammatory, and even seems to possess anti-cancer properties.
Mechanism of Action:
The mechanism of action of Propofol has been extensively studied. Its central nervous system anesthetic activity has been shown to be related its high affinity for a specific subclass of GABA receptors (Collins G.G.S., 1988, Br. J. Pharmacology. 542, 225-232).
However, there are a number of different receptors in the brain which are substrates for propofol, hence its varied activities.

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc Propofol also has significant biological effect as an antioxidant. Because of this generalized activity of propofol, it is theoretically useful in the treatment of a number of inflammatory processes where oxidation is an important factor. For example, cyclooxygenase mediated prostaglandin synthesis results in inflammation. By inhibiting oxidation in the respiratory tract, one could use propofol in the treatment of acid aspiration, adult/infant respiratory distress syndrome, airway obstructive diseases, asthma, cancer and a number of other similar pathological conditions.
Since oxidative tissue damage is a very common occurrence, it has been suggested that propofol could be useful in the treatment of Parkinson's disease, Alzheimer disease, Friedrich's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, spinal chord injuries, and various other neurodegenerative diseases.
Propofol is currently available in the US market as an intravenous emulsion marketed by Astra Zenaca under the brand name Diprivane. It is one the most widely used short acting central nervous system anesthetics in the market. The concentration of propofol is 10 mg/mL in non-pyrogenic sterile emulsion and the formula contains soybean oil, glycerol, egg lecithin, disodium edetate and sodium hydroxide.
A significant disadvantage of Propofol is that it is completely insoluble in water. Even at very low concentrations of 10 mg/mL, the drug precipitates out of an aqueous solution in room temperature. Therefore, manufacturers of this formulation use heroic methods to emulsify this product in water using extraordinarily complex and toxic emulsifying agents. For example, manufacturers of the IV formulations use egg lecithin, Cremaphor Le, castor oil, and other similar emulsifiers.
However, use of such emulsifiers is associated with number of problems. It is well now that various types of Cremaphor Le emulsifiers can precipitate allergic reactions. Egg lecithin and castor oil have been shown to produce anaphylactic shock in some patients.
Furthermore, maintenance of stability of propofol in these emulsions is short lived and 11:\work\1652\17690\SPEC\17690.spec without claimsII.doc more expensive. Moreover, the presence of egg lecithin and castor oil make the emulsion prone to microbial growth. It may be possible to dissolve propofol in water by complexing it with cyclodextrin, but cyclodextrin has not been approved by the FDA for use in intravenous therapy.
Heretofore, no one has made a safe prodrug of propofol. The British patents 1,102,011, and 1,160,468 and US Patent 3,389,138 describe the various phenol esters of amino acids, wherein the propofol is attached to a number of side chains which when released in the body produce toxic effects.
US Patent 6,451,854 describe a number of substituted alpha amino acetic acid esters of propofol, wherein propofol and the side chain were substituted with a number of different chemical groups. All the N,N-disubstituted glycine esters of propofol have not shown to be non-toxic and there many of the compounds described are derivative of propofol. Thus when released in the body after the cleavage of ester by the enzymes, many of the active drugs released are not propofol, and hence they do not possesses any toxicity data and are entirely new molecules with unknown therapeutic efficacy in man.
In yet another published paper on the water soluble salts of amino acid esters of anesthetic agent propofol, (Int. J. Pharmaceutics, 175[4 195-204, 1998) authors have synthesized a number of water soluble derivatives of propofol. However, when these prodrugs are cleaved by esterase enzymes, substituted non-natural amino acids with unknown toxicity profile are released in the body.
Until now there has been no pharmaceutical preparation has been available in the market that can deliver propofol without harmful side effects. The present invention however, has produced a number of water soluble, non-toxic derivatives of propofol which are suitable for delivering propofol in the body without any harmful side effects and without the needs for toxic and expensive additives, solubilizers and emulsifiers.

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc Accordingly, in one aspect, the present invention is directed to a class of prodrugs of Propofol. The prodrug consists of the carboxyl group of an amino acid esterified to the free hydroxyl group present on the propofol molecules.
=
More specifically, one aspect of the present invention is directed to, the compounds of the formulae AA PROPOFOL

or pharmaceutically acceptable salts thereof; wherein AA is an amino acid, in which the carboxyl group of AA is reacted with the hydroxyl group of the Propofol.
In antoher aspect, the present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of the various Propofol prodrugs above and a pharmaceutical carrier therefor.
In another embodiment, the present invention is directed to a method of treating a patient in need of propofol therapy, which method comprises administering to said patient an effective amount of the Propofol.
In a further embodiment, the present invention is directed to a method of enhancing the solubility of propofol in an aqueous solution comprising reacting the hydroxyl functionality of the Propofol and isolating the products thereof.
In a still further embodiment, the present invention is directed to a method of substantially and in a therapeutically efficacious manner, reducing or eliminating the potential toxic side effects of current formulations containing toxic exepients when HAwork\1652\17690\SPEC\17690.spec without claimsII.doc administered to a patient which comprises reacting the hydroxyl functionality of the propofol molecule with carboxyl function of selected amino acids to form an ester covalent bond respectively and isolating the product thereof and administering said product to the patient.
The current invention shows that when unsubstituted naturally occurring amino acids are esterified to propofol, the resulting prodrugs are highly water soluble, (>200 mg/L in water), release non-toxic amino acids upon cleavage in the body and require none of the toxic emulsifier, additives and other exepients.
Furthermore, it has been shown that the current invention also produced drugs, while they are prodrugs of propofol of the present invention are highly effective central nervous system anesthetics. Thus the current amino acid prodrugs are effective central nervous system anesthetics, with or without releasing the active parent drug.
The amino acid esters of the present invention are at least 10 times more soluble that propofol in water in room temperature. Especially the glycine, proline and lysine esters of propofol are soluble at the range of more than 100 mg/ml, and in case of lysine it is greater than 250 mg/mL.
While the prodrugs of the present invention are not expected to possess any antioxidant activity due to blockage of the phenolic group responsible for such; however the present inventor has found that the prodrugs of propofol are effective anesthetics with or without releasing propofol. The propofol prodrugs described release the propofol when administered in vivo and the resulting drug maintains its pharmacological and anti-oxidant properties.
The prodrug of propofol of the present invention clearly provides a number of advantages over propofol, for example, all of the side chains cleaved from these prodrugs are naturally occurring essential amino acids and hence are non-toxic. This 11:\work\ 1652 \ 17690 \ SPEC\ 17690.spec without claimsn.doc results in high therapeutic index. Secondly all the prodrugs are readily cleaved in the body to release propofol. Furthermore, due their high water solubility, they can be easily administered by either forming an in-situ solution just before IV
administration using lyophilized sterile powder or providing the drug in solution in prefilled syringe or bottles for infusion. The aminoacid esters are more stable than propofol since OH
group in propofol is blocked to oxidation. Thus the propofol prodrugs of the present invention are more effective then propofol itself without the toxicity and other pharmaceutical problems associated with current marketed formulations.
The prodrugs of propofol of the present invention possess anti-inflammatory, anti-oxidant, anti-cancer, anti-convulsive, anti-emetic and anti-pruritic properties.
These prodrugs of propofol of the present invention are effective in treating diseases or conditions in which Propofol normally are used. The prodrugs disclosed herein are transformed within the body to release the active compound and enhances the therapeutic benefits of the Propofol by reducing or eliminating biopharmaceutical and pharmacokenetic barriers associated with each of them. However it should be noted that these prodrugs themselves will have sufficient activity without releasing any active drug in the mammals. Since the prodrugs are more soluble in water then Propofol, it does not need to be associated with a carrier vehicle, such as alcohol or castor oil which may be toxic or produce unwanted side reactions. Moreover, oral formulations containing the prodrugs of Propofol are absorbed into the blood and are quite effective.
Thus, the prodrug of the present invention enhances the therapeutic benefits by removing biopharmaceutical and pharmacokenetic barriers of existing drugs.
Furthermore, the prodrugs are easily synthesized in high yields using reagents which are readily and commercially available.

H:\work\1652\17690\SPEC\17690.speo without clainisIl.doc Overview:
The procedure for the synthesis of the glycine, L-proline, and L-lysine esters of Propofol is depicted hereinbelow. However, these are exemplary and any amino acid produrugs thereof can be prepared using the following methodology. The complete procedure and analytical data is given in the Experimental Section. In general, as shown in the following scheme Propofol (10 g) was coupled with the N-Boc protected amino acid (1 equivalent) with 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC) in the presence of a catalytic amount of 4-(N,N-dimethyamino)-pyridine (DMAP).
The EDC was removed by extraction with water. After drying over sodium sulfate, filtration, and concentration the crude protected amino acid ester of Propofol was purified by flash chromatography to generate the protected esters in 50-60% yield. The protecting groups were then removed by stirring the protected esters in diethyl ether saturated with hydrochloric acid (gas) at room temperature. Yields for the deprotection step were generally 60-95%. After filtration and drying the hydrochloride salts of the glycine and L-proline esters of Propofol did not require additional purification. The hydrochloride salt of the L-lysine-Propofol ester was crystallized once from ethanol to remove a trace of mono-protected L-lysine-Propofol ester.
Synthetic Sequence:

HAwork\1652\17690\SPEC\17690.spec without claimsEdoc 1. SPI0010 Cl-=OH + HO 0 a) y b) 0 y o)-LN+1-1 Propofol Boc-glycine SPI0010 2. SPI0011 O O
\\P-8 CI¨

b) t-0 a) 0 OH
0101 YL612.-H
HO))1 sõN o =

Propofol Boc-L-proline 3. SPI0013 0 a)40 0 01,\"---0 b) o CI-OH 0 õ1\1744 HONI-1 9 ( 0,1L(NH 0 H
/---\ A ><
ANOci-Propofol Boc-L-lysine H HH
SCHEME
Synthesis of the glycine, L-proline, and L-lysine esters of Propofol: a) EDC, DMAP, CH2C12; b) HC1 (g), Et20.
Experimental Section:
The synthesis of SPI0010, SPI0011 and SPI0013 were conducted in batches.
Generally a small-scale experiment was performed first followed by a larger batch.
Reagents mentioned in the experimental section were purchased at the highest obtainable purity from Aldrich, Acros, or Bachem, except for solvents, which were purchased from either Fisher Scientific or Mallinlcrodt.

H:\work\1652\17690\SPEC\17690.spec without clafinsILdoc 1) SPI0010 Propofol (9.98 g, 55.97 mmole) was dissolved in dichloromethane (200 mL) at room temperature, under an argon atmosphere. N-t-Butyloxocarbonyl-glycine (11.2 g, 63.91 mmole) was added along with 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 11.1g, 57.9 mmole) and 4-(N,N-dimethylamino)-pyridine (DMAP, 1.5 g, 12.27 mmole). After stirring for 21 hours under an argon atmosphere at room temperature, water (200 mL) was added and the layers were separated. The dichloromethane layer was washed again with water (200 mL) and dried for 1 hour over sodium sulfate (5 g). After filtration and concentration under reduced pressure, the remaining oil was purified by flash chromatography on silica gel (250 g), eluting with hexanes/ethyl acetate (10:1). The procedure generated the protected N-BOC
protected glycine ester of Propofol as a white solid (11.34g, 60% yield).
tert-Butoxycarbonylamino-acetic acid 2,6-diisopropylphenyl ester:
111 NMR (300 MHz, CDC13): 6 = 7.25-7.13 (m, 3H), 5.18 (br s, 1H), 4.22 (d, 2H, J= 5.7 Hz), 2.89 (m, 2H), 1.46 (s, 9H), 1.18 (d, 12H, Jr= 6.9 Hz).
13C NMR (75 MHz, CDC13): = 169.35, 155.75, 145.22, 140.35, 126.90, 124.14, 80.32, 42.66, 28.54, 27.79, 23.57.
The Propofol-Boc-gycine ester (11.28 g, 33.6 mmole) was dissolved in anhydrous diethyl ether (200 mL) at room temperature. Hydrochloric acid (gas) was passed through the solution for 45 minutes while stirring. The mixture was allowed to stir at rooin temperature for 48 hours under an argon atmosphere. After 48 hours hexanes (200 mL) were added and the precipitate was filtered. The white solid was dried under high FlAwork\1652\17690\SPEC\17690.spec without clahnsil.doc vacuum for 5 hours at 88 C. The experiment produced SPI0010 (8.73 g, 95%
yield, purity 99.9% by HPLC) as a white solid.
CI
H
\N H

Amino-acetic acid 2,6-diisopropyl-phenyl ester, hydrochloride:
1HNMR (300 MHz, CDC13): 6 = 8.77 (br s, 3H), 7.20-7.08 (m, 3H), 4.14 (m, 2H), 2.87 (m, 2H), 1.11 (d, 12H, J= 7 Hz).
13C NMR (75 MHz, CDC13): 6 =166.42, 144.84, 140.42, 127.10, 124.06, 40.47, 27.61, 23.55.
CHN analysis:
cafe.: C 61.87, H 8.16, N 5.15; found: C 61.14, H 8.20, N 5.14.
2) SPI0011 Propofol (10.03 g, 56.23 mmole) was dissolved in dichloromethane (100 mL) at room temperature, under an argon atmosphere. N-t-Butyloxocarbonyl-L-proline (14.04 g, 65.22 mmole) was added along with 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 11.95 g, 62.33 mmole) and 4-(N,N-dimethylamino)-pyridine (DMAP, 1.1 g, 9.0 mmole). After stirring for 3 hours under an argon atmosphere at room temperature, water (100 mL) was added and the layers were separated. The dichloromethane layer was washed again with water (100 mL) and dried for 1 hour over sodium sulfate (5 g). After filtration and concentration under reduced pressure, the remaining oil was purified by flash chromatography on silica gel (250 g), eluting with hexanes/ethyl acetate (10:1). The procedure generated the protected N-BOC
protected HAwork\1652\17690\SPEC\17690.spec without clairnadoc L-proline ester of Propofol as a clear oil (11.34g, 66% yield) that solidified on standing in the freezer.

0 ==
Pynolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-(2,6-diisopropyl-phenyl) ester:
NMR (300 MHz, CDC13): 8 = 7.31-7.20 (m, 3H), 4.73 (m, 1H), 3.70-3.50 (m, 2H), 3.20-2.94 (m, 2H), 2.46-2.20 (m, 2H), 2.20-2.0 (m, 2H), 1.55 (m, 9H), 1.25 (m, 12H).
13C NMR (75 MHz, CDC13): ö = 171.87, 171.01, 154.34, 153.93, 145.35 145.23, 140.06, 140.21, 126.69, 126.53, 123.95, 80.28, 79.89, 59.14, 46.67, 46.42, 31.10, 30.17, 28.61, 28.56, 28.56, 27.44, 27.18, 23.47.
The Propofol-Boc-L-proline ester (13.95 g, 37.14 mmole) was dissolved in anhydrous diethyl ether (100 mL) at room temperature. Hydrochloric acid (gas) was passed through the solution for 60 minutes while stirring. The mixture was allowed to stir at room temperature for 22 hours under an argon atmosphere. After 22 hours hexanes (50 mL) were added and the precipitate was filtered. The white solid was dried under high vacuum for 5 hours at 88 C. The experiment produced SPI0011 (9.1 g, 81%
yield, purity 99.1% by HPLC) as a white solid.
CI-oç

Pyrrolidine-2(S)-carboxylic acid 2,6-diisopropyl-phenyl ester, hydrochloride:

11:\work\1652\17690\SPEC\17690.spec without clahnsadoc 11-INMR (300 MHz, CDC13): 5 = 10.15 (br s, 2H), 7.27-7.14 (m, 3H), 4.78 (t, 1H, J= 7.8 Hz), 3.56 (m, 2H), 2.85 (m, 2H), 2.64 (m, 1H), 2.40 (m, 1H), 2.20 (m, 1H), 2.05 (m, 1H), 1.18 (m, 12H).
13C NMR (75 MHz, CDC13): 5 = 168.30, 144.23, 139.74, 126.98, 123.96, 51.58, 38.21, 29.32, 26.64, 26.18, 23.71, 23.02, 21.67.
CHN analysis:
calc.: C 65.48, H 8.40, N 4.49; found: C 65.50, H 8.43, N 4.50.
3) SPI0013 The dicyclohexylamine salt of di-N-boc-L-lysine (23.62 g, 0.0447 mole) was added to diethyl ether (200 mL) and potassium hydrogen sulfate (9.14 g) in water (200 mL) that was cooled in an ice/water bath. After strining for 20 minutes, the layers were separated. The ether layer was extracted three times with cold water (100 mL).
The ether layer was then dried over sodium sulfate (15 g) for one hour, filtered, and concentrated under reduced pressure. The procedure generated the free acid of N,N'- di-boc-L-lysine (15.5 g, 100% recovery).
Propofol (8.0 g, 45 mmole) was dissolved in dichloromethane (100 mL) at room temperature, under an argon atmosphere. N, N'-di-t-Butyloxocarbonyl-L-lysine (15.5 g, 44.7 mmole) was added along with 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 8.62 g, 45 mmole) and 4-(N,N-dimethylamino)-pyridine (DMAP, 0.55 g, 4.5 mmole). After stirring for 3 hours under an argon atmosphere at room temperature, water (100 mL) was added and the layers were separated. The dichloromethane layer was washed again with water (100 mL) and dried for 1 hour over sodium sulfate (5 g). After filtration and concentration under reduced pressure, the remaining oil was purified by flash chromatography on silica gel (250 g), eluting with hexanes/ethyl acetate (9:1). The procedure generated the protected N-BOC
protected L-lysine ester of Propofol as a white foam (12.42 g, 55% yield).

FlAwork\1652\17690\SPEC\17690.spec without claimsadoc J 1;i O
o r'NÄ(X
2(S),6-Bis-t-butoxycarbonylarnino-hexanoic acid 2,6-diisopropyl-phenyl ester:
NMR (300 MHz, CDC13): S = 7.28-7.15 (m, 3H), 5.22 (d, 1H, J= 8.4 Hz), 4.70 (m, 1H), 4.59 (m, 1H), 3.17 (m, 211), 2.93 (m, 2H), 2.09 (m, 1H), 1.86 (m, 1H), 1.67-1.54 (m, 411), 1.48 (s, 9H), 1.46 (s, 9H), 1.20 (m, 12H).
13C NMR (75 MHz, CDC13): 5 = 171.82, 156.10, 155.65, 145.25, 140.30, 126.80, 124.03, 80.14, 79.28, 53.76, 40.29, 32.09, 28.66, 28.54, 27.48, 23.91, 23.10.
The Propofol-di-Boc-L-lysine ester (12.34 g, 24.37 mmole) was dissolved in anhydrous diethyl ether (250 mL) at room temperature. Hydrochloric acid (gas) was passed through the solution for 60 minutes while stirring and cooling in an ice/water bath. The mixture was allowed to stir at room temperature for 48 hours under an argon atmosphere. After 48 hours the precipitate was filtered and crystallized from ethanol (100 mL). The white solid was dried under high vacuum for 4 hours at 90 C.
The experiment produced SPI0013 (5.5 g, 60% yield, purity 98.6% by HPLC) as a white solid.
H CI
0)0 \ H
sµr\L¨H
\--_\ CI¨

,N¨H
H I
2(S),6-Diamino-hexanoic acid 2,6-diisopropyl-phenyl ester, dihydrochloride:

\work\1652 \17690 \SPEC \17690.spec without claimsll.doc IIINMR (300 MHz, CDC13): = 9.05 (br s, 3H), 8.35 (br s, 3H), 7.26-7.13 (m, 3H), 4.43 (t, 1H, .1= 6 Hz), 3.0-2.6 (m, 4H), 2.09 (m, 2H), 1.80-1.50 (m, 4H), 1.10 (d, 12H, J=
7 Hz).
13C NMR (75 MHz, CDC13): 8 = 168.30, 144.23, 139.74, 126.98, 123.96, 51.58, 38.21, 29.32, 26.64, 23.71, 23.02, 21.67.
CHN analysis:
calc.: C 56.99, H 8.50, N 7.38; found: C 56.48, H 8.56, N 7.30.
II. PRO DRUGS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
(NSAIDs) The NSAIDs comprise a class of structurally distinctive, carboxylic acid moiety attached to a planar aromatic functionality, Examples include: acetyl salicyclic acid, salicyclic acid, diflunisal, ibuprofen, fenoprofen, carprofen, flurbiprofen, ketoprofen, naproxen, sulindac, indomethacin, etodolac, tolmetin, ketorolac, diclofenac, and meclofenamate.
The NSADIs posess anti-inflammatory, analgesic, antipyretic and anti-clotting activity.
Examples of the chemical structures of this uniques class of compounds showing wide variety of pharmacological activities are shown below.
HAwor1\1652\17690\SPEC\17690.spec without claimsII.doc 0 all: F
cH3 0 0OH 00 101 . , 411, OH OH
OH ,CH3 Salicylic Acid 8 011 cil3 c., Ibuprofen Acetylsalicylic Acid Diflunisal P
Oli 01 ,11 _ 011 OH *a = 1.11 illin Fenoprofen Carprofen Flurbiprofen o ca 3 o CH3 0 0 i illt \
oso OH OS OH "Ilki N 0 is .
c . . c.,.Ø
Ketoprofen Naproxen Etodolac ct o 0 o F Cal 01.1 ato OH
OH
0111111 40 \- =OH
_CHs /
ofe0 Cfil....
0 CH.3 Sulindac Indomethacin Tolmetin Ketorolac NSAIDs are widely used for the treatment of acute and chronic pain, management of edema, tissue damage resulting from inflammatory joint diseases and also, effective anti-clotting agents in the treatment of myocardial infraction. A number of the agents also possess antipyretic activity in addition to analgesic and anti-inflammatory action, thus useful in reducing fever.
Some drugs in the above group have also been prescribed for Rheumatoid Arthritis, Osteoarthritis, acute gout, ankolysing spondylitis, and dysmenorrhea.

H: \ work\1652 \ 17690 \ SPEC \ 17690.spe,c without clainisll.doc Mechanism of Action:
The major mechanism by which the NSAIDs produce their therapeutic effect is via inhibition of prostaglandin synthesis. Specifically NSAIDs inhibit cyclooxygenases, such as COX-1 and COX-2 enzymes, where these two enzymes are responsible for synthesis of prostaglandins. While COX-1 enzyme is important for the regulation of platelet aggregation, regulation of blood flow in kidney and stomach, and regulation of gastric acid secretion, COX-2 enzyme plays an important role in the pain and inflammatory processes. NSAIDs significantly increase clotting time and can be used for prophylaxis of thromboembolism and myocardial infarction.
All NSAlDs are relatively medium to strong organic acids with pKa's in the 3-6 range.
Most of them are carboxylic acid derivatives. Acidic group is essential for COX
inhibitory activity and in physiological pH, all the NSAIDs are ionized. All of them have quite varying hydrophilic lipophilic balance, and these are functions of their aryl, aromatic and aliphatic side chains and other heterocyclic variations in their structures.
Most of the NSAIDs are highly bound to plasma proteins and often competitively replace other drugs which have similar affinity for plasma proteins. Hence concomitant administration of NSAIDs with other therapeutic class must be carefully evaluated to prevent drug interactions. Most of the drugs, due to acidic carboxyl group are metabolized by the manunals via conjugation. The major pathway of metabolic clearance of a number of NSAIDs is glucuronidation followed by renal elimination.
Use of acetylsalicylic acid (aspirin) in the prophylaxis of coronary heart diseases is now well known, and this drug has proved to be a lifesaver for a number of patients with myocardial infarction. Several additional uses have already been documents for aspirin, for example, it was recently reported in the medical journal Lancet (Vol 349, p 1641) that aspirin reduces the risk of stroke in patients with early warning signs of transient ischemic heart attacks. Pre-eclampsia and fetal growth retardation, both caused by blockages of the blood vessels of the placenta, are two of the commonest complications of pregnancy ¨ there are millions of cases of pre-eclampsia in the world each year. In a FlAwork\1652\17690\SPEC\17690.spec without claims11.doc trial involving more than 9000 women in 16 countries, a daily dose of 60mg aspirin reduced the risk of pre-eclampsia by 13 per cent. (Aspirin Foundation website). Aspirin has also been shown to be effective in some studies to prevent colon cancer, lung cancer and pancreatic cancer in post-menopausal women. Since aspirin can improve blood flow, its usefulness in the treatment of diabetes certain forms of dementia such as Alzheimer's disease are becoming increasingly clear.
Because of their unique pharmaceutical potential, the NSAIDs have attracted considerable attention in the press. The primary area of clinical investigation for above drugs has been as non-steroidal anti-inflammatory agents, in particular in relation to their application to patients suffering from pain, arthritis, (Rheumatoid and Osteo) other inflammatory reactions, fever and for the prophylaxis of coronary heart diseases. These drugs are also used in the treatment of migraine headache, menstrual syndromes, back pain and gout.
Despite the very major contribution which NSAIDs have made, difficulties have been encountered in providing more effective and convenient means of administration (e.g., galenic formulations, for example, oral dosage form, which are both convenient and for the patient as well as providing appropriate bioavailability and allowing dosaging at an appropriate and controlled dosage rate) as well as the reported occurrence of undesirable side reactions; in particular severe gastric and duodenal ulcers, mucosal erythema, and edema, erosions, perforations, blood in stool, ulcerative colitis have been obvious serious impediments to their wider use or application. The dual injury theory involves NSAID-mediated direct damage, followed by a systemic effect in which prostaglandin synthesis is inhibited. Topical injury may also occur as a result of the biliary excretion of active hepatic metabolites and subsequent duodenogastric reflux. (Arthritis and Rheumatism 1995; 38(1):5-18) The effects are additive; either topical or systemic mechanisms alone are sufficient to produce gastro duodenal mucosal damage.

H:\work\1652 \17690 \SPEC \17690.spec without claimsadoc Moreover, the above mentioned NSAIDs are characteristically highly hydrophobic and readily precipitate in the presence of even very minor amounts of water, e.g., on contact with the body (e.g., stomach fluids). It is accordingly extremely difficult to provide e.g., oral formulations which are acceptable to the patient in terms of form and taste, which are stable on storage and which can be administered on a regular basis to provide suitable and controlling patient dosaging.
Proposed liquid formulations, e.g., for oral administration of NSAIDs, have heretofore been based primarily on the use of natural gums, like Xanthan, cellulose, citric acid, and lime flavor etc. See e.g., U.S. Patent NO. 5,780,046. Commercially available NSAIDs drink-solution employs incompatible orange color and berry flavor, citric acid, Xanthan Gum, polysorbate 80, pregelatinized starch, glycerin, sodium benzoate, and additional artificial colors and flavors. Use of the drink solution and similar composition as proposed in the art is however accompanied by a variety of difficulties.
Further, the palatability of the known oil based system has proved problematic. The taste of the known drink-solution is, in particular, unpleasant. Admixture with an appropriate flavored drink, for example, chocolate drink preparation, at high dilution immediately prior to ingestion has generally been practiced in order to make regular therapy at all acceptable. Adoption of oil based systems has also required the use of high ethanol concentrations to itself inherently undesirable, in particular where administration to children is forseen. In addition, evaporation of the ethanol, e.g., from capsules (adopted in large part, to meet problems of palatability, as discussed or other forms (e.g., when opened) results in the development of a NSAID precipitate.
Where such compositions are presented in, for example, soft gelatin encapsulated form; this particular difficulty necessitates packaging of the encapsulated product in an air-tight component, for example, an air-tight blister or aluminum-foil blister package.
This in turn renders the product both bulky and more expensive to produce. The storage characteristics of the aforesaid formulations are, in addition, far from ideal.

flAwork\1652\17690\SPEC\17690.spec without claimsII.doc Gastric irritability of the NSAIDs has been a topic of great concern to the practicing physicians and as well as patients. Acute uses of aspirin, fenoprofen, flurbiprofen, indomethacin, ketorolac, meclofenamate, mefanamic acid, and piroxicam produce serious GI side effects. Even Ibuprofen is shown to cause severe gastric lesions upon long term use. Gastrointestinal toxicity is the most frequently encountered side effect associated with NSAIDs and presents considerable concern. Approximately one half of all hospital admissions for a bleeding ulcer are attributed to the use of NSAIDs, aspirin, or the two taken in combination during the week prior to admission. (Faulkner G, Prichard P, Somerville K, et al. Aspirin and bleeding peptic ulcers in the elderly. Br Med J. 1988; 297:1311-1313). A survey of Tennessee Medicaid patients who were hospitalized with GI complications showed that patients who used NSAIDs had approximately a fourfold greater risk for developing GI hemorrhage or peptic ulcer disease than patients not taking NSAIDs. (Griffin MR, Piper JM, Daugherty JR, et al.
Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991; 114:257-263). Serious GI events, according to the FDA, occur in as many as 2% to 4% of patients per year who are taking continuous NSAID therapy for rheumatoid arthritis. The relative risk of gastric ulcer (4.725), duodenal ulcer (1.1 to 1.6), bleeding (3.8), perforation, and death are all increased by NSAID use when such patients are compared to those who do not take these products. In 1989, patients with rheumatoid arthritis had approximately 20,000 hospitalizations per year with an estimated cost of $10,000 per stay. (Fries JF, Miller SR, Spitz PW, et al.
Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. J Gastroenterology. 1989; 96:647-655).
There is also a need for providing some of the NSAIDs in a water soluble form for injection. It is well known that high concentrations of alcohol and tromethamine used to form a salt in the current formulations of Ketorolac are toxic. At present there is no formulation that would allow the NSAIDs to be in aqueous solution at the concentrations needed due to poor water solubility of the drug.
flAwork\1652\17690\SPEC\17690.spec without clahnsII.doc Beyond all these very evident practical difficulties lies the occurrence of undesirable side reactions already alluded to, observed employing available oral dosage forms.
Several proposals to meet these various problems have been suggested in the art, including both solid and liquid oral dosage forms. An overriding difficulty which has however remained is the inherent insolubility of the NSAIDs in aqueous media, hence preventing the use of a dosage form which can contain NSAIDs in sufficiently high concentration to permit convenient use and yet meet the required criteria in ten-ns of bioavailability, e.g. enabling effective resorption from the stomach or gut lumen and achievement of consistent and appropriately high blood/blood-serum levels.
The present prodrugs of NSAIDs overcome the problems described hereinabove.
More specifically, an embodiment of the present invention is directed to a prodrug of NSAID
which significantly enhances its solubility in aqueous solutions, thereby avoiding the need to utilize a carrier, such as ethanol or castor oil when administered as a solution.
Moreover, the prodrugs of NSAID, in accordance with the present invention, do not exhibit the side effects of the prior art formulations. Further, the prodrugs of the present invention are almost completely devoid of gastric irritability upon oral administration, thereby enhancing significantly the therapeutic index of the prodrugs tested and their efficacy.
Accordingly, in one aspect, the present invention is directed to a prodrug of NSAIDs.
The preferred prodrugs of the NSAIDs have the formula II: \work\ 1652\17690 \SPEC\ 17690.spec without claimsII.doc a Y 41 Y Mr 0 cE3 0 CH3 * i OH
Salicylic Acid 6 - OH cH3 Ibuprofen Acetylsalicylic Acid Diflunisal cs3 0 a CH3 0 CH3 0 Y /Y P ailh Olt Fenoprofen Carprofen Flurbiprofen 0 cH3. 0 CE3 0 0 i \
40 . Y 40* Y IS N
I o c s H Y

CHICH:f Ketoprofen Naproxen Etodolac 0 o o o F Y .0130 0* alit, Y cal 1,11 \ Y -- ii-c213 ccril% Y
I
,c2)iir0 N

Cr23,, 4, Cl 0 Cfis Sulindac Indomethacin Tolmetin Ketorolac or pharmaceutically acceptable salts thereof; wherein Y is either NH-AA or 0-AA and AA is an amino acid, in which either an amine group or the hydroxyl group of AA is reacted with the carboxylic acid group of the NSAIDs.
The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of the various NSAIDs above and a pharmaceutical carrier therefor.

11:\work\1652\17690\SPEC\17690.spec without clainisILdoc In another embodiment, the present invention is directed to a method of treating a patient in need of NSAID therapy, which method comprises administering to said patient an effective amount of the NSAIDs.
In a further embodiment, the present invention is directed to a method of enhancing the solubility of NSAID in an aqueous solution comprising reacting the carboxyl functionality of each of the NSAIDs and isolating the products thereof.
In a still further embodiment, the present invention is directed to a method of substantially and in a therapeutically efficacious manner, reducing or eliminating the gastric mucosal damage of NSAIDs when administered to a patient which comprises reacting the carboxyl functionality of each of the NSAID molecule with either amine or hydroxyl function of selected amino acids to form either an amide or ester covalent bond respectively and isolating the product thereof and administering said product to the patient.
A. Synthesis of Ibuprofen Amino Acid Derivaties Overview:
The procedure for the synthesis of the L-serine, L-threonine, and L-hydroxyproline esters of Ibuprofen is outlined in Synthetic Sequence section. The complete procedure and analytical data is given in the Experimental Section. Again, these synthetic schemes are exemplary. The scheme is applicable for other amino acids in the preparation of the NSAID prodrugs of the present invention. In general, ( )-Ibuprofen (4-10 g, in batches) was coupled with the N-benzyloxy/benzyl ester protected amino acids (1 equivalent) with 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 1 equivalent) in the presence of a catalytic amount of 4-(N,N-dimethyamino)-pyridine (DMAP). Once the reactions were complete, any excess EDC
was removed by extraction with water, DMAP was removed by extraction with dilute acid, and Ibuprofen was removed by extraction with sodium bicarbonate. After drying over sodium sulfate, filtration, and concentration the crude protected amino acid esters 1-1:\work\1652\17690\SPEC\17690.spec without claiinsIl.doc of ( )-Ibuprofen were either used directly or purified by flash chromatography on silica gel to generate the protected esters in good yield (85-95%). The column chrornatogaphy was generally not necessary if a slight excess of Ibuprofen and coupling agent were used, and a thorough extraction procedure was conducted. The protecting graups were removed by hydrogenation (25-35 psi H2) in the presence of 10% palladium on carbon and hydrochloric acid. Yields for the deprotection step ranged from 70-90%.
After filtration and drying the hydrochloride salts of the serine and threonine esters of ( )-Ibuprofen were purified by crystallization. The hydrochloride salt of the L-hydroxyproline-lbuprofen ester was a gel that would not solidify/crystallize.
In this case the hydrogenation was repeated without the use of acid and the neutral compound was purified.
Because the Ibuprofen started as a mixture of enantiomers, the final products were delivered as a mixture of diastereomers except for the threonine ester. In the case of the threonine ester of Ibuprofen, washing with water, acetone or acetonitrile could readily separate the final diastereomeric salts. The insoluble isomer (SPI0016A) was determined to be the active isomer by comparison with an authentic standard prepared from S-(+)-Ibuprofen. The serine and hydroxyproline esters of ( )-Ibuproferi could not be readily separated in this fashion.

HAwork\1652\17690\SPEC\17690.spec without claimsIl.doc Synthetic Sequence:
1. SPI0015 0 o a) 0 b) 1101 OH õ..---rkObz ----*" = 0 401 0:
il HO
+ HAls-cbz \¨clObz OH
H,N1,--cbz -I-I
( )-Ibuprofen Z-Ser-OBz SPI001501 SPI0015 2. SPI0016A and SPI0016B
0 o 0 o %

0õ.\ ____________________________________________ CILObz 0.3---(ILOH
a) , b) 110 OH :3--rit'Obz ---÷. ,..N-- =. ,N, H cuz H I H
HO
* li H
,NI-.. b H c z CI-( )-Ibuprofen Z-Thr-OBz SPI001601 SPI0016 c)/
o 0 0 ..)..._11 OH OH

0 ,N H I H
Ark H. +
I H H
VW H
CI-Cl 41 SPI0016A SPI0016B
3. SPI0017 o 0 0 OH HO,,,,Cf 0 'Obz --""a) o d) =410 0 04,0)...0bz +
`cbz `cbz H
( )-Ibuprofen Z-Hyp-OBz SPI001701 Synthesis of the L-serine, L-threonine, and L-hydroxyproline esters of ( )-Ibuprofen: a) EDC, DMAP, CH2C12; b) HC1, 10% Pd/C, Et0H c) acetone, d) 10% Pd/C, Et0H.
flAwork\1652\17690\SPEC\17690.spec without claiinsIl.doc Experimental Section:
The synthesis of SPI0015, SPI0016 and SPI0017 were conducted in two or three batches. Reagents mentioned in the experimental section were purchased at the highest obtainable purity from Sigma-Aldrich, Acros, or Bachem, except for solvents, which were purchased from either Fisher Scientific or Mallinkrodt.
1) Preparation of ( )-Ibuprofen-L-serine ester, hydrochloride (SPI0015).
( )-Ibuprofen (5.04 g, 24.4 mmole), N-carbobenzyloxy-L-serine benzyl ester (8.11 g, 24.6 mmole), 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 4.87g, 25.4 mmole), and 4-(N,N-dimethylamino)-pyridine (DMAP, 0.40 g, 3.27 mmole) were dissolved in dichloromethane (150 mL) at room temperature, under an argon atmosphere. After stirring for 22 hours under an argon atmosphere at room temperature, water (100 mL) was added and the layers were separated. The dichloromethane layer was washed again with water (100 mL) and dried for 1 hour over sodium sulfate (5 g). After filtration and concentration under reduced pressure, the remaining oil was purified by flash chromatography on silica gel (250 g), eluting with hexanes/ethyl acetate (3:1). The procedure generated the protected L-serine-( )-Ibuprofen ester (SPI001501) as a colorless solid (11.4 g, 90% yield).
= o Obz HNCbZ

2(S)-Benzyloxycarbonylamino-342(R,S)-(4-isobutyl-pheny1)-propionyloxy]-propionic acid benzyl ester:
1H NMR (300 MHz, CDC13): 5 = 7.40-7.20 (m, 10H), 7.14-7.01 (m, 4H), 5.50 (d, V2H, J= 8.4 Hz), 5.29 (d, V2H, J= 8.4 Hz), 5.11-5.02 (m, 2.5H), 4.90 (d, 1/2H, ,T=

12 Hz), 4.62 HAwor1\1652\17690\SPEC\17690.speo without clainasII.doc , (m, 1H), 4.49-4.43 (m, 1H), 4.36-4.32 (m, 1H), 3.59 (m, 1H), 2.39-2.35 (m, 2H), 1.78 (m, 1H), 1.42-1.39 (m, 3H), 0.85 (d, 6H, J= 6.6 Hz).
=
13C NMR (75 MHz, CDC13): 8 = 174.05, 169.19, 169.07, 155.68, 140.73, 137.20, 136.12, 135.05, 134.91, 129.44, 128.67, 128.65, 128.60, 128.41, 128.33, 128.30, 128.19, 127.19, 127.16, 67.75, 67.32, 64.51, 64.32, 53.71, 45.16, 45.02, 30.35, 22.60, 18.27.
The protected Ibuprofen-L-serine ester (22.50 g, 43.4 mmole) was dissolved in ethanol (200 mL) at room temperature and added to a Parr bottle that contained 10%
palladium on carbon (3.86 g, 50% wet) under a nitrogen atmosphere. Hydrochloric acid (10 mL
37% HC1 in 30 mL water) was added and the nitrogen atmosphere was replaced with hydrogen gas (25 psi). After 4 hours of shaking, the palladium catalyst was removed by filtration through celite. The ethanol/water was removed under reduced pressure. The remaining white solids were washed with water (25 mL), acetone (20 mL) and dried under high vacuum (4 hours at 88 C). The experiment produced ( )-Ibuprofen-L-sarine ester, hydrochloride SPI0015 (11.3 g, 80% yield) as a colorless solid.
O
\¨rit0H
H H ¨
H CI

2(S)-Amino-342(R,S)-(4-isobutylpheny1)-propionyloxy)-propionic acid, hydrochloride;
((R,S)-Ibuprofen-L-Serine ester, hydrochloride):
NMR (300 MHz, DMS0): 8 = 8.92 (br s, 3H), 7.22 (t, 2H, J= 7.5 Hz), 7.10 (d, 2H, J= 7.5 Hz), 4.56 (in, 1H), 4.37-4.20 (m, 211), 3.83 (q, 1H, J= 6.9 Hz), 2.41 (d, 2H, J= 6.9 Hz), 1.80 (m, 1H), 1.41 (d, 3H, J= 6.9 Hz), 0.85 (d, 611, J= 6.9 Hz).
*Trade-mark 13C NMR (75 MHz, DMS0): 6 = 173.36, 173.32, 168.08, 168.04, 139.70, 128.96, 129.92, 127.20, 127.05, 62.47, 51.59, 51.49, 44.28, 44.00, 43.90, 29.68, 22.28, 18.70, 18.42.
HPLC analysis:
99.13% purity; rt = 3.133 min; Luna C18 5u column (sn 167917-13); 4.6x250 mm;

nm; 50% ACN/50% TFA buffer (0.1%); 35 C; 20 ul inj.; lml/min; 1 mg/mL sample size; sample dissolved in mobile phase.
CHN analysis:
cale.: C 58.27, H 7.33, N 4.25; found: C 58.44, H 7.46, N 4.25.
Melting point: 169.5 - 170.5 C
2a) Preparation and Separation of ( )-Ibuprofen-L-threonine ester, hydrochloride (SPI0016A and SPI0016B).
( )-Ibuprofen (4.15 g, 20.11 mmole), N-carbobenzyloxy-L-threonine benzyl ester (6.90 g, 20.11 mmole), 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 3.95 g, 20.6 mmole), and 4-(N,N-dimethylamino)-pyridine (DMAP, 0.25 g, 2.0 mmole) were dissolved in dichloromethane (50 mL) at room temperature, under an argon atmosphere. After stirring for 19 hours, the dichloromethane layer was washed with water (50 mL), 5% hydrochloric acid (2x25 mL), water (25 mL), saturated sodium bicarbonate (2x25 mL), and water (50 mL). After drying for one hour over sodium sulfate (5 g), filtration, and concentration under reduced pressure, the remaining oil was used without further purification. The procedure generated the protected L-threonine-( )-Ibuprofen ester (SPI001601) as a light yellow oil (10.2 g, 95.3% yield), which solidified on standing.

H:\work\1652\17690\SPEC\17690.spec without clahnsII.doc H
N
SPI001601 lp 2(S)-Benzyloxycarbonylamino-342(R,S)-(4-isobutyl-pheny1)-propionyloxykbutyric acid benzyl ester:
1IINMR (300 MHz, CDC13): = 7.40-7.15 (m, 10H), 7.14-7.01 (m, 4H), 5.48-5.25 (m, 2H), 5.11-5.01 (m, 3H), 4.90 (d, 1/2H, J= 12 Hz), 4.68 (d, 1/2H, J= 12 Hz), 4.48 (m, 1H), 3.60-3.48 (m, 1H), 2.39(m,.2H), 1.79 (m, 1H), 1.42-1.35 (m, 3H), 1.27 (d, 1.5 H, J= 6.6 Hz), 1.17 (d, 1.5 H, J= 6.6 Hz), 0.85 (m, 6 H).
13C NMR (75 MHz, CDC13): 8 = 173.32, 169.70, 169.30, 156.55, 140.75, 137.38, 137.22, 136.14, 135.07, 134.99, 129.45, 129.41, 128.65, 128.39, 128.22, 127.21, 127.14, 70.97, 70.70, 67.81, 67.66, 67.53, 57.83, 45.19, 30.39, 22.61, 18.57, 18.30, 17.18, 16.87.
The protected Ibuprofen-L-threonine ester (10.15 g, 19.0 mmole) was dissolved in warm ethanol (150 mL) and added to a Parr bottle that contained 10% palladium on carbon (3.4 g, 50% wet) under a nitrogen atmosphere. Hydrochloric acid (6 mL 37% HC1 in 20 mL water) was added and the nitrogen atmosphere was replaced with hydrogen gas (30 psi). After 3 hours of shaking, the palladium catalyst was removed by filtration through celite (30 g). The ethanol/water was removed under reduced pressure. The experiment produced ( )-Ibuprofen-L-threonine ester, hydrochloride (SPI0016A and SPI0016B, 6.4 g, 97% crude yield) as a colorless solid. The crude mixture of diastereomers was stirred in acetone (200 mL) for 2 hours at room temperature under an argon atmosphere.
After 2 hours the solids (2.84 g, SPI0016A) were filtered. The filtrate (SPI0016B, 3.0 g) was concentrated under reduced pressure.

HAwork\1652\17690\SPEC\17690.spec without claimsII.doc 1.) Purification of SPI0016A (active isomer):
After 3 batches of the S-Ibuprofen-L-threonine ester (SPI0016A) had been completed, the batches were combined (8.78 g total) and crystallized three times from DIUF water (100 mL). Each time a small amount of zwitterion was generated. In order to regenerate the salt, the solid generated (from each crystallization) was dissolved in 1%
hydrochloric acid in ethanol (3 mL 37% hydrochloric acid in 100 mL ethanol). The ethanol solution was then concentrated under reduced pressure at room temperature. After the third crystallization and regeneration procedure, the salt (5.6 g) was stirred in acetonitrile (100 mL) for 44 hours at room temperature, under an argon atmosphere. The salt was then filtered and dried under high vacuum at 50-55 until the weight was constant (5.5 g).

N, OH
HI H
Cl-2(S)-Amino-3(R)42(S)-(4-isobutyl-phenyl)-propionyloxy]-butyric acid;
(S-Ibuprofen-L-threonine ester, hydrochloride, active isomer):
1H NMR (300 MHz, DMS0): 8 = 8.76 (br s, 3H), 7.19 (d, 211, J= 8.1 Hz), 7.11 (d, 2H, J= 8.1 Hz), 5.28 (dq, 1H, J= 6.3, 3.6 Hz), 4.14 (q, 1H, J= 3.6 Hz), 3.80 (q, 1H, J= 7.2 Hz), 2.41 (d, 2H, J= 7.2 Hz), 1.80 (m, 1H), 1.37 (d, 3H, J= 7.2 Hz), 1.21 (d, 3H, J= 6.3 Hz), 0.85 (d, 6H, J= 6.6 Hz).
13C NMR (75 MHz, DMS0): 8 = 172.66, 168.24, 139.68, 137.24, 128.95, 126.97, 67.98, 55.35, 44.23, 43.83, 29.66, 22.24, 18.52, 16.47.
CHN analysis:
calc.: C 59.38, H 7.62, N 4.07; found: C 59.17, H 7.63, N 4.04.
FlAwork\1652 \I7690 \SPEC \17690,spec without claimsII.doc HPLC analysis:
98.28% purity; r.t.= 6.951 min.; 60% TFA (0.1%)/40% acetonitaile; 1 mL/min;
37.5 C;
Luna C18, 3u column (SN 167917-13), 4.6x250 mm; 22 ul injection.
Optical rotation: + 24.5 Melting Point: 189-190 C
2) Purification of SPI0016B (inactive isomer):
After 3 batches of the R-Ibuprofen-L-threonine ester (SPI0016B) had been completed, the batches were combined (9.02 g total) and crystallized from DIUF water (50 mL). A
small amount of zwitterion was generated during the crystallization. In order to regenerate the salt, the solid generated was dissolved in 1% hydrochloric acid in ethanol (3 mL 37% hydrochloric acid in 100 mL ethanol). The ethanol solution was then concentrated under reduced pressure at room temperature. The remaining salt (5.93 g) was crystallized three times from hot toluene (100 mL) with the addition of a small amount on acetone (1 mL). The salt was then filtered and dried under high vacuum at room temperature until the weight was constant (5.1 g).

110 OH:10 N+N, OH
"
CI

2(S)-Amino-3(R)42(R)-(4-isobutyl-phenyl)-propionyloxyl-butyric acid;
(R-Ibuprofen-L-threonine ester, hydrochloride, inactive isomer):

FlAwork\1652\17690\SPEC\17690.spec without claimsII.doc 1H NMR (300 MHz, DMS0): 8 = 8.82 (br s, 3H), 7.23 (d, 2H, J= 7.8 Hz), 7.10 (d, 2H, J= 7.8 Hz), 5.27 (m, 1H), 4.18 (m, 1H), 3.80 (q, 1H, J= 7.2 Hz), 2.41 (d, 2H, J= 7.2 Hz), 1.81 (m, 1H), 1.41 (d, 3H, J= 6.9 Hz), 1.34 (d, 3H, J= 6.3 Hz), 0.85 (d, 6H, J= 6.3 Hz).
13C NMR (75 MHz, DMS0): 6 = 72.56, 168.08, 139.64, 136.98, 128.84, 127.14, 68.8, 55.29, 44.28, 29.69, 22.28, 18.24, 16.41.
CHN analysis:
calc.: C 59.38, H 7.62, N 4.07; found: C 59.30, H 7.60, N 4.05.
HPLC analysis:
98.43% purity; r.t.= 6.19 min.; 60% TFA (0.1%)/40% acetonitrile; 1 mL/min;
37.5 C;
Luna C18, 3u column (SN 167917-13), 4.6x250 mm; 22 ul injection.
Optical Rotation: + 10.4 Melting Point: 176-177 C
2b) Preparation of the S-(+)-Ibuprofen-L-threonine ester, hydrochloride standard (SPI0016S).
S-(+)-Ibuprofen (2.0 g, 9.69 mmole), N-carbobenzyloxy-L-threonine benzyl ester (3.25 g, 9.91 mmole), 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 1.90 g, 9.91 mmole), and 4-(N,N-dimethylamino)-pyridine (DMAP, 0.12 g, 1.0 mmole) were dissolved in dichloromethane (25 mL) at room temperature, under an argon atmosphere. After stirring for 4 hours, the dichloromethane layer was washed with water (25 mL), 5% hydrochloric acid (25 mL), saturated sodium bicarbonate (2x25 mL), and water (25 mL). After drying for one hour over sodium sulfate (5 g), filtration, and concentration under reduced pressure, the remaining oil was used without further purification. The procedure generated the protected S-(+)-Ibuprofen-L-threonine ester (SPI001601S) as a light yellow oil (5.01 g, 98 % yield), which solidified on standing.

H:\work\1652\17690\SPEC\17690.spec without claimadoc 1.s HD¨e d--C) 2(S)-Benzyloxycarbonylamino-342(R,S)-(4-isobutyl-pheny1)-propionyloxy]-butyric acid benzyl ester:
1H NMR (300 MHz, CDC13): 6 = 7.35-7.23 (m, 10H), 7.10 (d, 2H, J= 7.8 Hz), 7.05 (d, 2H, J= 7.8 Hz), 5.48-5.25 (m, 2H), 5.17-5.01 (m, 4H), 4.50 (dd, 1H, J= 9.6, 1.8 Hz), 3.50 (q,11-1, J= 7.2 Hz), 2.40 (d, 2H, J= 7.2 Hz), 1.80 (m, 1H), 1.37 (d, 3H, J= 7.2 Hz), 1.17 (d, 3 H, J= 6.3 Hz), 0.86 (d, 6 H, J= 6.6 Hz).
13C NMR (75 MHz, CDC13): 8 = 173.29, 169.69, 156.51, 140.68, 137.21, 136.08, 135.06, 129.40, 128.70, 128.66, 128.57, 128.38, 128.24, 127.14, 70.70, 67.80, 67.53, 57.87, 45.19, 45.11, 30.39, 22.61, 18.57, 16.87.
The protected S-(+)-Ibuprofen-L-threonine ester (5.0 g, 9.40 mmole) was dissolved in warm ethanol (100 mL) and added to a Parr bottle that contained 10% palladium on carbon (1.0 g, 50% wet) under a nitrogen atmosphere. Hydrochloric acid (1 mL
37%
HC1 in 10 mL water) was added and the nitrogen atmosphere was replaced with hydrogen gas (32 psi). After 2 hours of shaking, the palladium catalyst was removed by filtration through celite (30 g). The ethanol/water was removed under reduced pressure.
The experiment produced S-(+)-Ibuprofen-L-threonine ester, hydrochloride (SPI0016S, 2.8 g, 85% crude yield) as a colorless solid. The salt was stirred in acetone (50 mL) for 3 hours at room temperature under an argon atmosphere. After 3 hours the solids (2.24 g, 69% yield) were filtered and dried under high vacuum at room temperature, until the weight was constant.

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc s 0 = H, 1\1, OH
H , H
CI

2(S)-Amino-3(R)42(S)-(4-isobutyl-phenyl)-propionyloxy]-butyric acid;
(S-Ibuprofen-L-threonine ester, hydrochloride, active isomer):
1H NMR (300 MHz, DMS0): 6 = 8.76 (br s, 3H), 7.19 (d, 2H, J= 8.1 Hz), 7.11 (d, 2H, J= 8.1 Hz), 5.28 (dq, 1H, J= 6.3, 3.6 Hz), 4.14 (q, 1H, J= 3.6 Hz), 3.80 (q, 1H, J= 7.2 Hz), 2.41 (d, 211, J= 7.2 Hz), 1.80 (m, 111), 1.37 (d, 3H, J= 7.2 Hz), 1.21 (d, 3H, J= 6.3 Hz), 0.85 (d, 6H, J= 6.6 Hz).
13C NMR (75 MHz, DMS0): 8 = 172.66, 168.24, 139.68, 137.24, 128.95, 126.97, 67.98, 55.35, 44.23, 43.83, 29.66, 22.24, 18.52, 16.47.
HPLC analysis:
98.28% purity; r.t.= 6.951 min.; 60% TFA (0.1%)/40% acetonitrile; 1 mL/min;
37.5 C;
Luna C18, 3u column (SN 167917-13), 4.6x250 mm; 22 ul injection.
Optical rotation: + 26.5 Melting Point: 189-190 C
3) Preparation of the ( )-Ibuprofen-L-hydroxyproline ester (SPI0017).
( )-Ibuprofen (5.10 g, 24.7 mmole), N-carbobenzyloxy-L-hydroxyproline benzyl ester (8.80 g, 24.7 mmole), 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 5.10g, 26.0 mmole), and 4-(N,N-dimethylamino)-pyridine (DMAP, 0.30 g, 2.40 mmole) were dissolved in dichloromethane (100 mL) at room temperature, under an H:\work\1652\17690\SPEC\17690.spec without clairnadoc argon atmosphere. After stirring for 24 hours under an argon atmosphere at room temperature, water (100 mL) was added and the layers were separated. The dichloromethane layer was washed again with water (100 mL), 5% sodium bicarbonate (2x50 mL) and dried for 1 hour over sodium sulfate (5 g). After filtration and concentration under reduced pressure, the remaining oil was used without further purification. The procedure generated the protected ( )-Ibuprofen-L-hydroxyproline ester (SPI001701) as a light yellow oil (11.5 g, 85% yield).

o 4(R)42-(4-Isobutyl-pheny1)-propionyloxyl-pyrrolidine-2(S)-carboxylic acid;
((R,S)-Ibuprofen-L-hydroxyproline ester):
1H NMR (300 MHz, CDC13): 5 = 7.33-7.02 (m, 14H), 5.25-4.95 (m, 5H), 4.51-4.19 (m, 1H), 3.75-3.50 (m, 3H), 2.40 (d, 2H, J= 6.9 Hz), 2.15 (m, 1H), 1.81 (m, 1H), 1.44 (d, 3H, J= 7.0 Hz), 0.87 (d, 6H, J= 6.6 Hz).
13C NMR (75 MHz, CDC13): 5 = 173.99, 171.93, 171.72, 154.68, 154.15, 140.70, 137.23, 137.04, 136.23, 135.44, 135.23, 129.41, 128.59, 128.47, 128.35, 128.19, 128.08, 127.89, 127.02, 72.86, 72.16, 67.40, 67.18, 67.09, 58.12, 57.83, 52.66, 52.49, 52.13, 45.15, 36.63, 35.67, 32.07, 30.33, 29.23, 22.90, 22.58, 18.36.
The protected Ibuprofen-L-hydroxyproline ester (11.40 g, 43.4 mmole) was dissolved in ethanol (150 mL) at room temperature and added to a Parr bottle that contained 10%
palladium on carbon (2.73 g, 50% wet) under a nitrogen atmosphere. The nitrogen atmosphere was replaced with hydrogen gas (34 psi). After 5 hours of shaking, the = palladium catalyst was removed by filtration through celite. The ethanol was removed H:\work\1652\17690\SPEC\17690.spec without claimsII.doc under reduced pressure. The remaining white solids (6.60 g) were washed with DIUF
water (50 mL), diethyl ether (50 mL) and dried under high vacuum until the weight was constant. The experiment produced ( )-Ibuprofen-L-hydroxyproline ester SPI0017 (5.64 g, 84% yield) as a colorless solid.
o 4(R)42-(4-Isobutyl-pheny1)-propionyloxy]-pyrrolidine-2(S)-carboxylic acid;
((R,S)-Ibuprofen-L-hydroxyproline ester):
IHNMR (300 MHz, CDC13): 5 = 7.22 (d, 2H, J= 7.2 Hz), 7.09 (d, 2H, J= 7.2 Hz), 5.27 (m, 1H), 4.40 (t, 0.5H, J= 7 Hz), 4.24 (t, 0.5 H, J= 9 Hz), 3.75 (m, 1H), 3.61(m, 1H), 3.28 (d, 0.5H, J= 13 Hz), 3.15 (d, 0.5H, J= 13 Hz), 2.42-2.10 (m, 4H), 1.78 (m, 1H), 1.40 (br t, 3H, J= 6 Hz), 0.82 (d, 6H, J= 6 Hz). (mixture of diastereomers) 13C NMR (75 MHz, CDC13): 5 = 173.28, 173.23, 168.98, 139.88, 137.33, 137.23, 129.12, 127.26, 127.17, 72.58, 57.60, 57.50, 50.24, 50.12, 44.34, 44.15, 34.31, 34.16, 29.77, 22.34, 18.43, 18.23. (mixture of diastereomers) HPLC analysis:
100% purity; r.t.= 5.35, 5.22 min.; 55% TFA (0.1%), 45% ACN; 1 mL/min; 32.3 C, Luna C18, serial # 188255-37; 20 ul inj..
CHN analysis:
calc.: C 67.69, H 7.89, N 4.39; found: C 67.47, H 7.87, N 4.30.
Melting Point: 198-199 C

11:\work\1652\17690\SPEC\17690.spec without claimsII.doc Efficacy (anti nociceptive potential) of Synthesis of the L-serine, L-threonine, and L-hydroxyproline esters of ( )-Ibuprofen by employing acetylcholine induced abdominal constriction method in male albino mice:
The present study was conducted to evaluate the efficacy of L-serine, L-threonine, and L-hydroxyproline esters of ( )-Ibuprofen taking into account the antagonizing property on acetylcholine induced writhe as an index in albino mice. Ibuprofen (racemic mixture) and ibuprofen (S)-(+) served as reference controls.
Different new formulations of ibuprofen and reference controls viz., ibuprofen (racemic mixture) and ibuprofen (S)-(+) were administered by gavage to male albino mice (Swiss strain), using 5% (v/v) Tween 80 in milli Q water as the vehicle. The study was conducted at two dose levels viz. 50mg and 100mg/kg body weight along with a vehicle control group. At each dose level 10 animals were used. All the doses were expressed as ibuprofen molar equivalents. The doses used as well as the molar equivalents are presented below.

1-1:\work\1652\17690\SPEC\17690.spec without claim.sII.doc Table 2: Formulation: Molar Equivalent:
Formulation Molar equivalent 0.833 units are equivalent to 1 unit of S-(+)-Ibuprofen-L-threonine ester Ibuprofen 1.6 units are equivalent to 1 unit of ( )-Ibuprofen-L-serine ester Ibuprofen 1.55 units are equivalent to 1 unit of ( )-Ibuprofen-L-hydroxproline ester Ibuprofen Table 3: Test Item: Group: Dose(mg/kg): Equivalent wt. Of the test item:
Equivalent Dose (mg per kg) weight of the Test Item Group [in terms of Test item Ibuprofen]
[mg/kg]
Vehicle control 0.0 Vehicle Group S-(+)-Ibuprofen-L- Test Group 1 50.0 41.65 threonine ester Test Group 2 100.0 83.30 ( )-Ibuprofen-L- Test Group 3 50.0 80.0 serine ester Test Group 4 100.0 160.0 (Ibuprofen S) ( )-Ibuprofen-L- Test Group 5 50.0 77.5 hydroxyproline ester Test Group 6 100.0 155.0 Ibuprofen (racemic Test Group 7 50.0 50.0 mixture) Test Group 8 100.0 100.0 Ibuprofen +
Test Group 9 50.0 25.0 S
Test Group 10 100.0 50.0 The efficacy in terms of antagonizing effect on acetylcholine induced single writhe at two dose levels ¨ 50.0 and 100.0 mg/kg for the three formulations and reference controls are presented below.

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc Table 4: Test Item: Group: Dose (mg/kg): Number of animals showing absence of single writhe (out of 10) Number of animals showing absence of single Dose (mg writhe (number of animals per kg) Test Item Group per dose = 10) [in terms of One hour Three hours Ibuprofen]
after after dosing dosing Vehicle Vehicle control 0.0 0 0 S-(+)-Low dose 50.0 1 0 Ibuprofen-L-threonine High dose 100.0 3 0 ester Low dose 50.0 4 2 ( )-Ibuprofen-L-High dose 100.0 6 4 serine ester Low dose 50.0 5 4 ( )-Ibuprofen-L-hydroxyprolin High dose 100.0 7 7 e ester Low dose 50.0 4 2 Ibuprofen (racemic High dose 100.0 6 6 mixture) Low dose 50.0 5 1 Ibuprofen S +
High dose 100.0 6 6 Statistical analysis employing Chi ¨ square test procedure did not show any statistically significant difference among the formulations in comparison to reference control, while comparing the number of animals not showing writhe in each groups, as the respective "p" was found to be greater than 0.05, the level of significance.
From clinical observation based on the number of animals not showing writhes due to administration of acetylcholine, ( )-Ibuprofen-L-hydroxyproline ester was found to be H:\work\1652\17690\SPEC\17690.spec without claimsII.doc more effective in antagonizing the acetylcholine induced writhe when compared to other formulations and Ibuprofen (racemic) and Ibuprofen (S)-(+).
Table 5: Summary of Efficacy of L-serine, L-threonine, and L-hydroxyproline esters of ( )-Ibuprofen, Ibuprofen (racemic mixture) and Ibuprofen (S)-(+) -Based on Antagonizing Property of Acetylcholine Induced Writhe in Albino Mice Number of animals showing Dose absence of single writhe (number (mg/kg) Test Item of animals per dose = 10) [in terms of One hour after Three hours Ibuprofen] dosing after dosing Vehicle control 0 0 S-(+)-Ibuprofen-L-threonine ester ( )-Ibuprofen-L-serine ester 50mg/kg ( )-Ibuprofen-L-hydroxyproline 5 4 ' ester Ibuprofen (racemic mixture) Ibuprofen (S)-(+) 5 1 Table 6:
Vehicle control 0 0 S-(+)-Ibuprofen-L-threonine ester ( )-Ibuprofen-L-seine ester 100mg/kg ( )-Ibuprofen-L-hydroxyproline 7 7 ester Ibuprofen (racemic mixture) Ibuprofen (S)-(+) 6 6 H:\work\1652\17690\SPEC\17690.spec without claimsII.doc The data were subjected to statistical analysis employing Chi ¨ square test procedure for evaluating the efficacy of the new formulations in comparison to the reference controls.
The test did not show any statistically significant difference among the formulations in comparison to reference control, while comparing the number of animals not showing writhe in each groups, as the respective "p" was found to be greater than 0.05, the level of significance.
The data is also summarized in FIGS. 1 and 2. From clinical observations and bar diagram for comparative efficacy (FIGS. 1 and 2) based on the number of animals not showing writhes due to administration of acetylcholine, ( )-Ibuprofen-L-hydroxyproline ester was found to be more effective in antagonizing the acetylcholine induced writhe when compared to other formulations and Ibuprofen (racemic) and Ibuprofen (S)-(+).
CONCLUSION
The present study was conducted to evaluate the relative efficacy of new formulations of ibuprofen. For this the antagonizing property of new formulations on acetylcholine writhes was taken as an index to determine the relative efficacy of the formulations.
Ibuprofen (racemic mixture and ibuprofen (S)-(+) served as reference controls.
The study was conducted at two dose levels (50.0 and 100.0 mg/kg) along with a vehicle control group.
The efficacy in terms of antagonizing effect of acetylcholine induced single writhe at two dose levels ¨ 50.0 and 100.0 mg/kg for the three formulations and reference controls are presented below.

Mwork\1652\17690\SPEC\17690.spec without claimsadoc Table 7: Test Item: Group: Dose (mg/kg): No. of animals showing absence of single writhe (out of 10) Number of animals showing absence of single writhe Dose (mg per (number of animals per dose =
kg) Test Item Group 10) [in terms of Three hours Ibuprofen] One hour after after dosing dosing Vehicle Vehicle 0.0 0 0 control S-(+)-Ibuprofen- Low dose 50.0 1 0 L-threonine ester High dose 100.0 3 0 Low dose 50.0 4 2 ( )-Ibuprofen-L-serine ester High dose 100.0 6 4 Low dose 50.0 5 4 ( )-Ibuprofen-L-hydroxyproline High dose 100.0 7 7 ester Low dose 50.0 4 Ibuprofen (racemic High dose 100.0 6 6 mixture) Low dose 50.0 5 1 Ibuprofen (S)-(-0 High dose 100.0 6 6 Statistical analysis employing Chi ¨ square test procedure did not show any statistically significant difference among the formulations in comparison to reference control, while comparing the number of animals not showing writhe in each groups, as the respective "p" was found to be greater than 0.05, the level of significance.
However from clinical observation based on the number of animals not showing writhes due to administration of acetylcholine ( )-Ibuprofen-L-hydroxyproline ester was found H:\work\1652 \17690 \SPEC\17690.spec without claimsII.doc to be more effective in antagonizing the acetylcholine induced writhe when compared to other formulations and Ibuprofen (racemic) and Ibuprofen (S)-(+).
Gastric mucosal irritation potential of L-serine, L-threonine, and L-hydroxyproline esters of ( )-Ibuprofen in fasted male albino rats SUMMARY
The present study was conducted to determine the relative potential of new formulations of ibuprofen (L-serine, L-threonine, and L-hydroxyproline esters of ( )-Ibuprofen) to cause gastric mucosal irritation/lesions in fasted male albino rats. Ibuprofen (racemic mixture) and Ibuprofen(S)-(+) served as reference controls.
Different new formulations of ibuprofen and ibuprofen (racemic mixture) and ibuprofen(S)-(+) were administered by gavage to fasted male albino rats (Wistar strain), using 5% solution of Tween 80 in milli Q water as the vehicle. The study was conducted at two dose levels viz. 200mg and 300mg/kg body weight along with a vehicle control group. At each dose level 5 animals were used. All the doses were expressed as ibuprofen (racemic mixture) molar equivalents. The doses used as well as the molar equivalents were presented below.
Table 8: Formulation: Molar Equivalent Formulation Molar equivalent 0.833 units are equivalent to 1 unit of S-(+)-Ibuprofen-L-threonine ester Ibuprofen 1.60 units are equivalent to 1 unit of ( )-Ibuprofen-L-serine ester Ibuprofen 1.55 units are equivalent to 1 unit of ( )-Ibuprofen-L-hydroxyproline ester Ibuprofen H:\work\1652 \I7690 \SPEC \I7690.spec without claimsII.doc The various groups used are tabulated hereinbelow:
Table 9: Test item: group: Dose (mg/kg) Equivalent wt.
Equivalent Dose (mg per kg) weight of Test item Group [in terms of the Ibuprofen] Test item [mg/kg]
Vehicle control 0.0 Vehicle Group S-(+)-Ibuprofen-L- Test Group 1 200.0 0.0 threonine ester Test Group 2 300.0 166.6 ( )-Ibuprofen-L-serine Test Group 1 200.0 249.9 ester Test Group 2 300.0 320.0 ( )-Ibuprofen-L- Test Group 1 200.0 480.0 _ hydroxyproline ester Test Group 2 300.0 310.0 Ibuprofen (racemic Test Group 1 200.0 465.0 mixture) Test Group 2 300.0 300.0 _ Test Group 1 200.0 100.0 Ibuprofen (S)- (+) Test Group 2 300.0 150.0 The rats were fasted for a period of 18 to 22 hours before dosing. The test item was administered as a single dose by gavage. Three hours after drug administration, the animals were killed humanely by CO2 gas inhalation. The stomach was dissected out and observed for = the quantity of mucous exudate, = degree of hyperemia and thickening of stomach wall, = hemorrhagic spots (focal or diffuse), nature of hemorrhages (petechial or ecchymotic) along with the size and = perforations or any other lesions 11:\work\1652\17690\SPEC\17690.spec without claimsII.doc The observations on gastric mucosal irritation of animals of various groups were summarized below Table 10: Test item: Group: Dose (mg/kg): Observation Doe mg/kg Test Item Group ( as per Observation ibuprofen) None of the animals Vehicle control showed any evidence Vehicle control 0.0 Group of gastric mucosal irritation None of the dosed animals showed any Test Group 1 200.0 evidence of gastric S-(+)-Ibuprofen- mucosal irritation L-threonine ester None of the dosed animals showed any Test Group 2 300.0 evidence of gastric mucosal irritation.
None of the dosed animals showed any Test Group 1 200.0 evidence of gastric ( )-Ibuprofen-L- mucosal irritation.
setine ester None of the dosed animals showed any Test Group 2 300.0 evidence of gastric mucosal irritation None of the dosed animals showed any Test Group 1 200.0 evidence of gastric ( )-Ibuprofen-L-mucosal irritation hydroxyproline None of the dosed ester animals showed any Test Group 2 300.0 evidence of gastric mucosal irritation Gastric mucosal irritation was Ibuprofen (racemic mixture) Test Group 1 200.0 observed in one animal out of 5 animals dosed.

H:\wor1\1652\17690\SPEC\17690.spec without claimsndoc Gastric mucosal irritation was Test Group 2 300.0 observed in two animals out of 5 animals dosed.
Gastric mucosal irritation was Test Group 1 200.0 observed in all the 5 animals dosed.
Ibuprofen (S) Gastric mucosal irritation was Test Group 2 300.0 observed in three animals out of 5 animals dosed.
The results of the present study showed that none of the formulations of ibuprofen had caused any evidence of irritation of gastric mucosa in fasted male albino rats of male sex at the two dose levels tested (200mg and 300mg/kg body weight). In contrast both ibuprofen (racemic mixture) and ibuprofen (S) ¨ (+) had caused irritation of gastric mucosa at the two dose levels tested. Further ibuprofen(S ) - (+) was found to be more gastric mucosal irritant than ibuprofen (racemic mixture).
Overview Ketoprofen S(+) Threonine Ester Synthesis:
The procedure for the synthesis of the L-threonine esters of Ketoprofen is outlined in Synthetic Sequence section. This synthesis is exemplary and is equally applicable for the other amino acids. The complete procedure and analytical data is given in the Experimental Section. In general, ( )-Ketoprofen (5 g) was coupled with N-boc-L-threonine t-butyl ester' (1 equivalent) with 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 1 equivalent) in the presence of a catalytic amount of 4-(N,N-dimethyamino)-pyridine (DMAP). Once the reaction was complete, any excess EDC was removed by extraction with water, DMAP was removed by extraction with dilute acid, and Ketoprofen was removed by extraction with sodium bicarbonate. After drying over sodium sulfate, filtration, and concentration the crude H:\work\1652\17690\SPEC\17690.spec without claimsiLdoc protected L-threonine-( )-Ketoprofen was purified by flash chromatography on silica gel to generate the protected L-threonine ester in good yield (98%). The protecting groups were removed by treatment with 2M hydrochloric acid in diethyl ether to cleave the boc group, followed by treatment with trifluoroacetic acid to remove the t-butyl ester. After drying, the mixture of L-threonine-R,S( )-Ketoprofen esters was separated by crystallization from acetonitrile. The hydrochloride salt of the L-threonine-S(+)-Ketoprofen ester preferentially precipitated from acetonitrile. A sample of an optically pure standard was prepared starting with S(+)-ketoprofen for comparison. After drying and analysis, a sample of L-threonine-S(+)-Ketoprofen ester, hydrochloride (1.75 g) was 1 0 separated from the mixture.
Synthetic Sequence:

O
o a) I. 0. 0 HO 1,1¨boc 10 0 /
õ0 H-14' %boo ( )-Ketoprofen Boc-Thr-O-tBu SPI001801 b) c) 4. = 10 0 /
10 110 0 0 d) Fri 0, 0, WI 0, H H H H
H H

1 5 Synthesis of the L-threonine esters of ( )-Ketoprofen: a) EDC, DMAP, CH2C12; b) FIC1 (2M); c) TFA; d) ACN (crystallization).
Experimental Section:
The synthesis of SPI0018A was conducted in a single batch. Reagents mentioned in the experimental section were purchased at the highest obtainable purity from Sigma-H:\work\1652\17690\SPEC\17690.spec without clahnsII.doc Aldrich, Acros, or Bachem, except for solvents, which were purchased from either Fisher Scientific or Mallinkrodt.
Preparation and Separation of S(+)-Ketoprofen-L-threonine ester, hydrochloride (SPI0018A).
( )-Ketoprofen (5.32 g, 20.92 mmol), N-t-butylcarbonyl-L-threonine t-butyl ester (Boc-Thr-OtBu, 5.17 g, 18.72 mmol, (prepared in accordance with the literature), 1-(3-dimethylaminopropy1)-3-ethylcarbodiimide, hydrochloride (EDC, 4.0 g, 20.9 mmol), and 4-(N,N-dimethylamino)-pyridine (DMAP, 0.22 g) were dissolved in dichloromethane (50 mL) at room temperature, under an argon atmosphere. After stirring for 5 hours, the dichloromethane layer was washed with water (50 mL), 5%
hydrochloric acid (2x25 mL), water (25 mL), saturated sodium bicarbonate (2x25 mL), and water (50 mL). After drying for one hour over sodium sulfate (5 g), filtration, and concentration under reduced pressure, the remaining oil (10.3 g) was purified by column chromatography on silica gel (150 g), eluting with hexanes/ethyl acetate (2:1). After combining the product containing fractions, concentration and drying under high vacuum, the procedure generated the protected L-threonine-( )-Ketoprofen ester (SPI001801) as a clear oil (9.42 g, 98% yield).
µboc 20 342(R,S)-(3-Benzoyl-pheny1)-propionyloxy]-2(S)-tert-butoxycarbonylamino-butyric acid tert-butyl ester: (mix of diastereomers) IFINMR (300 MHz, CDC13): 5 = 7.83-7.42 (m, 9H), 5.43 (dd, 1H, J= 13.2, 6.9 Hz), 5.10 (dd, 1H, Jr= 20.7, 9.3), 4.29 (t,11-1, J= 11.7 Hz), 3.75 (q, 1H, J= 7.2 Hz), 1.50-1.42 (m, 25 19.5H), 1.30-1.18 (m, 4.5H).

11:\wor1\1652\17690\SPEC\17690.spec without claimsII.doc 13C NMR (75 MHz, CDC13): 8 =. 196.18, 172.62, 172.55, 168.85, 168.58, 155.81, 140.33, 140.23, 137.86, 137.39, 132.46, 132.42, 131.54, 131.38, 130.00, 129.31, 129.13, 129.02, 128.54, 128.27, 82.50, 82.37, 80.05, 71.38, 71.22, 57.59, 57.52, 45.46, 45.31, 28.40, 27.98, 27.84, 18.54, 18.48, 17.19, 16.84.
The protected (R,S)-Ketoprofen-L-threonine ester (9.42 g, 18.41 mmol) was dissolved in dichloromethane (25 mL) under an argon atmosphere, at room temperature.
Anhydrous hydrochloric acid in diethyl ether (2M, 25 mL) was added to the solution and the mixture was allowed to stir for 17 hours at room temperature. The mixture was concentrated under reduced pressure. The remaining foam (8.2 g) was dissolved in a mixture of dichloromethane (10 mL) and trifluoroacetic acid (20 mL). After stirring at room temperature for 6.5 hours the solution was concentrated under reduced pressure.
Toluene (25 mL) was added to the remaining oil and the mixture was concentrated a second time. A mixture of ethanol (20 mL) and anhydrous hydrochloric acid in diethyl ether (2M, 20 mL) was added and the solution was concentrated a third time.
After drying under high vacuum for 2 hours at room temperature, the experiment produced ( )-Ketoprofen-L-threonine ester, hydrochloride (mix of diastereomers, 7.11 g, 98%
crude yield) as an off-white solid. The crude mixture of diastereomers (7.0 g) was crystallized 3 times from acetoniffile (200 mL). After the third crystallization, the remaining white solid was dried under high vacuum at 50 C until the weight was constant (4 hours). The experiment produced L-threonine-S(+)-Ketoprofen ester, hydrochloride SPI0018A (2.2 g, 30% yield from SPI001801).

o O \>/<
H_N+ _OH
H Cl SPI0018A
2(S)-Amino-3(R)-[2(S)-(3-benzoyl-phenyl)-propionyloxy]-butyric acid, hydrochloride (L-threonine-S(+)-Ketoprofen ester, hydrochloride):

H:\work\1652 \17690 \SPEC \17690.spec without claimsII.doc 1H NMR (300 MHz, DMS0): 8 = 14.08 (br s, 1H), 8.72 (br s, 3H), 7.74-7.51 (m, 9H), 5.29 (t, 1H, J= 4.5 Hz), 4.16 (m, 1H), 3.97 (q, 1H, J= 6.3 Hz), 1.42 (d, 3H, J= 6.9 Hz), 1.23 (d, 3H, J= 6.3 Hz).
13C NMR (75 MHz, DMS0): 6= 195.34, 172.26, 168.21, 140.42, 137.05, 136.74, 132.66, 131.66, 129.48, 128.73, 128.49, 128.30, 68.23, 55.31, 44.00, 18.44, 16.45.
CHN analysis:
calc.: C 61.30, ILI 5.66, N 3.57; found: C 61.02, H 5.58, N 3.58.
HPLC analysis:
98.28% purity; r.t.= 25.14min.; 55% DTUF water (0.1% TFA)/45% methanol; 1 mL/min;
36.4 C; Luna Cl 8, 5u column (serial # 211739-42), 4.6x250 mm; 20 ul injection.
Optical rotation: + 27.0 (20 C, 174.4 mg/10 mL ethanol, 589 nm); Melting Point:

Preparation of the S-(+)-Ketoprofen-L-threonine ester, hydrochloride standard.

(+)-Ketoprofen (1.87 g, 7.74 mmol), N-t-butylcarbonyl-L-threonine t-butyl ester (Boc-Thr-OtBu, 2.25 g, 8.14 mmol, prepared in accordance with the literature method), 1-(3-dimethylaminopropy1)-3-ethylcarbodihnide, hydrochloride (EDC, 1.65 g, 8.60 mmol), and 4-(N,N-dimethylamino)-pyridine (DMAP, 0.1 g) were dissolved in dichloromethane (25 mL) at room temperature, under an argon atmosphere. After stirring for 4 hours, the dichloromethane layer was washed with water (25 mL). After drying for one hour over sodium sulfate (5 g), filtration, and concentration under reduced pressure, the remaining oil was used without purification. The procedure generated the protected L-threonine-(+)-Ketoprofen ester as a clear oil (4.01 g, ¨100% yield).

1-Bwork\1652\17690\SPEC\17690.spec without clahnsIl.doc of Si 0 boc 1H NMR (300 MHz, CDC13): 8 = 7.81-7.42 (m, 9H), 5.43 (m, 1H), 5.10 (d, 1H, .1.= 9.3), 4.29 (d, 1H, J= 9.6 Hz), 3.75 (q, 1H, J= 7.2 Hz), 1.50-1.42 (m, 21H), 1.18 (d, 3H, .1.= 6.3 Hz).
13C NMR (75 MHz, CDC13): 8 = 196.4, 172.79, 168.99, 155.94, 140.44, 137.99, 137.51, 132.59, 131.50, 130.13, 129.31, 129.25, 129.15, 128.66, 128.40, 82.68, 80.24, 71.37, 57.71, 45.43, 28.53, 28.10, 18.99, 16.96.
The protected (S)-Ketoprofen-L-threonine ester (3.92 g, 7.66 mmol) was dissolved in anhydrous hydrochloric acid in diethyl ether (2M, 50 mL) and stirred for 17 hours at room temperature. The mixture was concentrated under reduced pressure. The remaining foam (3.4 g) was dissolved in a mixture of dichloromethane (20 mL) and trifluoroacetic acid (20 mL). After stirring at room temperature for 6.5 hours the solution was concentrated under reduced pressure. Toluene (25 mL) was added to the remaining oil and the mixture was concentrated a second time. A mixture of ethanol (20 mL) and anhydrous hydrochloric acid in diethyl ether (2M, 20 mL) was added and the solution was concentrated a third time. After drying under high vacuum for 2 hours at room temperature, the experiment produced S(+)-Ketoprofen-L-threonine ester, hydrochloride (3.05g crude) as an off-white solid. The crude material was stirred with acetone (50 mL) for 2 hours at room temperature under an argon atmosphere. The remaining white solid was filtered and dried under high vacuum at 50 C until the weight was constant (4 hours). The experiment produced L-threonine-S(+)-Ketoprofen ester, hydrochloride (2.04 g, 67 % yield).

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc NMR (300 MHz, DMS0): 5 = 14.08 (br s, 111), 8.72 (br s, 3H), 7.74-7.51 (m, 9H), 5.29 (t, 1H, J= 4.5 Hz), 4.16 (m, 1H), 3.97 (q, 1H, J= 6.3 Hz), 1.42 (d, 3H, J= 6.9 Hz), 1.23 (d, 3H, J= 6.3 Hz).
13C NMR (75 MHz, DMS0): 5 = 195.34, 172.26, 168.21, 140.42, 137.05, 136.74, 132.66, 131.66, 129.48, 128.73, 128.49, 128.30, 68.23, 55.31, 44.00, 18.44, 16.45.
HPLC analysis:
99.43% purity; r.t.= 25.14min.; 55% DIUF water (0.1% TFA)/45% methanol; 1 mL/min;
36.4 C; Luna C18, 5u column (serial # 211739-42), 4.6x250 mm; 20 ul injection.
Optical rotation: + 27.1 (20 C, 177.8 mg/10 mL ethanol, 589 nm); Melting Point:

C. Amino Acid Derivaties of Aspirin Overview:
The procedure for the synthesis of the L-serine, L-threonine, and L-hydroxyproline esters of acetylsalicylic acid is outlined in Synthetic Sequence section and is exemplary for other amino acids. The complete procedure and analytical data is given in the Experimental Section. In general, acetylsalicyloyl chloride (10 g-25 g, in batches) was coupled with the N-benzyloxy/benzyl ester protected amino acids in the presence of pyridine. Once the reactions were complete (24 to 48 hours at room temperature), the mixture was poured into ice-cold 2N hydrochloric acid. The dichloromethane fraction was then washed with sodium bicarbonate, water and brine. After drying over sodium sulfate, filtration, and concentration the crude protected amino acid esters of acetylsalicylic acid were purified by flash chromatography on silica gel. The procedure generated the protected amino acid esters of acetylsalicylic acid in yields ranging from 68% to 95%. The protecting groups were removed by hydrogenation (20 psi H2) in the presence of 10% palladium on carbon. The amino acid esters of acetylsalicylic acid were extracted away from the palladium catalyst with water, concentrated, and dried.

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc The final compounds were washed with solvent (water, dioxane, acetonitile, and/or dichloromethane) until pure and dried under high vacuum until a constant weight was achieved.
Synthetic Sequence:
1. SPIB00102 0 o o o o o a) 40 0,.)-µ
,...... OBzl H' b) 1 ____________________ cit. ¨i.- 0 0-)----OH
HO., OBzl H" H' CIDZ
0 N,H
0 + H __ N¨cbz 0 0\
Acetylsalicylic acid Z-Thr-OBzI SPIB0010201 SPIB00102 2. SPIB00101 O o o o o o 0 OH a) HO LOBz1 0 r.,,,¨(1L0Bz1 b) ('OH---- ---.-''' N¨ --0-H... cb z 0 00- ,N, O H H
bz H c 0\ --N¨= 0 0---ec Acetylsalicylic acid Z-Ser-OBzI SPIB0010101 SPIB00101 3. SPIB00103 O o o 40 OH + HOii., OBzi a) 04 b) 40 OBz1 0 ''''CrYLOH
'''CrL ----..

\ cbz 0 0 \ cbz o=
H
Acetylsalicylic acid Z-Hyp-OBzI SPIB0010301 SPIB00103 Synthesis of the L-serine, L-threonine, and L-hydroxyproline esters of acetylsalicylic acid: a) pyridine, CH2C12; b) 10% Pd/C, Et0H, Et0Ac.
Experimental Section:
The synthesis of SPIB00101, SPII300102 and SPIB00103 was conducted in one or two batches. Reagents mentioned in the experimental section were purchased at the highest 1-1:\work\1652\17690\SPEC\17690.spec without clairnslidoc obtainable purity from Lancaster, Sigma-Aldrich, Acros, or Bachem, except for solvents, which were purchased from either Fisher Scientific or Mallinkrodt.
1) SPIB00102: 2-0-Acetylsalicylic acid (2S, 3R)-(-)-threonine ester A mixture of N-carbobenzyloxy-L-threonine benzyl ester (Z-Thr-OBz1, 21.77 g, 63.40 mmole) and pyridine (25 mL) in anhydrous dichloromethane (500 mL) was cooled in an ice bath while under a nitrogen atmosphere. Acetylsalicyloyl chloride (17.63 g, 88.76 mmole) was added and the mixture was allowed to warm to room temperature and stir overnight. After 24 hours, the mixture was poured into ice-cold 2N
hydrochloric acid (400 mL). After mixing, the layers were separated and the dichloromethane fraction was washed with water (500 mL), saturated sodium bicarbonate solution (500 mL), water (500 mL), brine (500 mL) and dried over sodium sulfate (25 g). After filtration, concentration under reduced pressure, and drying under high vacuum, the remaining yellow oil (35. 43 g) was purified by flash chromatography on silica gel (300 g, 0.035-0.070 mm, 6 nn pore diameter), eluting with hexanes/ethyl acetate (3:1). After concentration of the product containing fractions under reduced pressure and drying under high vacuum until the weight was constant, the experiment produced the protected acetylsalicylic-L-threonine ester SPIB0010201 (28.1 g, 88% yield) as a colorless oil.

0 H \O
0\ 0 =

1H NMR (300 MHz, CDC13): 5 = 7.74 (1H, d, .1= 7.5 Hz), 7.51 (1H, dt, J= 7.5, 1.5 Hz), 7.34-7.17 (11H, m), 7.06 (1H, d, .1= 7.2 Hz), 5.62 (2H, m), 5.13 (4H, m), 4.65 (1H, dd, .1= 9.6, 2.4 Hz), 2.29 (3H, s), 1.38 (3H, d, J.= 6.6 Hz).

H: \work\ 1652 \ 17690 \SPEC\17690.spec without claimsII.doc 13C NMR (75 MHz, CDC13): 8 = 169.35, 169.22, 162.73, 156.26, 150.41, 135.79, 134.67, 133.77, 131.24, 128.35, 128.24, 128.08, 127.95, 125.78, 123.51, 122.61, 71.22, 67.72, 67.26, 57.64, 20.98, 16.88.
The protected acetylsalicylic-L-threonine ester SEIB0010201 (14.50 g, 28.68 mmole) was dissolved in ethanol (100 mL) and ethyl acetate (100 mL) at room temperature and added to a Parr bottle that contained 10% palladium on carbon (3.0 g, 50% wet) under a nitrogen atmosphere. The nitrogen atmosphere was replaced with hydrogen gas (20 psi).
After 20 hours of shaking, the palladium catalyst was removed by filtration through celite. The remaining solids (palladiurn/celite and product) were washed with water (600x4 mL) until the product was removed. The ethanol and water fractions were concentrated under reduced pressure at room temperature. The remaining solids were washed with water (20 mL) and dioxane (20 mL) for 48 hours. After filtration, the remaining white solid was dried at room temperature under high vacuum until the product weight was constant (16 hours). The experiment produced acetylsaficylic-L-threonine ester, SPIB00102 (4.40 g, 55% yield) as a white solid.

0) (C3''' -N, H H

0\

1H NMR (300 MHz, D20-DC1): = 8.00 (1H, dd, J= 7.8, 1.5 Hz), 7.74 (111, dt, J=
7.8, 1.5 Hz), 7.47 (1H, dt, J= 7.8, 1.5 Hz), 7.27 (1H, dd, J= 7.8, 1.5 Hz), 5.76 (1H, dq, J= 6.9, 3.0 Hz), 4.49 (1H, d, J= 3.0 Hz), 2.39 (3H, s), 1.55 (3H, d, J= 6.9 Hz).
13C NMR (75 MHz, D20-DC1): 8 = 173.03, 168.84, 163.97, 149.56, 135.32, 131.26, 126.85, 123.48, 121.49, 69.16, 56.36, 20.45, 15.86.

HAwork\1652 \17690 \SPEC \17690.spec without claints11.doc HPLC analysis:
98.7% purity; rt= 6.233 min; Luna C18 5u column (sn 167917-13); 4.6x250 mm;

nm; 35% Me0H/65% TFA (0.1%) pH= 1.95; 35 C; 20 ul inj.; lml/min; sample dissolved in mobile phase with 1 drop phosphoric acid.
CHN analysis:
calc.: C 55.51, H 5.38, N 4.98; found: C 55.37, H 5.40, N 5.03.
Melting point: 153.5 C (dec.) 2) SPIB00101: 2-0-Acetylsalicylic acid (2S)-(+)-serine ester A mixture of N-carbobenzyloxy-L-serine benzyl ester (Z-Ser-OBz1, 23.17 g, 70.34 mmole) and pyridine (30 mL) in anhydrous dichloromethane (500 mL) was cooled in an ice bath while under a nitrogen atmosphere. Acetylsalicyloyl chloride (21.07 g, 106.1 mmole) was added and the mixture was allowed to warm to room temperature and stir over two days. After 48 hours, the mixture was poured into ice-cold 2N
hydrochloric acid (400 mL). After mixing, the layers were separated and the dichloromethane fraction was washed water (500 mL), saturated sodium bicarbonate solution (500 mL), water (500 mL), brine (500 mL) and dried over sodium sulfate (25 g). After filtration, concentration under reduced pressure, and drying under high vacuum, the remaining brown solid (47.19 g) was purified by flash chromatography on silica gel (200 g, 0.035-0.070 min, 6 nm pore diameter), eluting with hexanes/ethyl acetate (3:1). After concentration of the product containing fractions under reduced pressure and drying under high vacuum until the weight was constant, the experiment produced the protected acetylsalicylic-L-serine ester SPIB0010101 (32.97 g, 95% yield) as a white solid.

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc 1.1 0 __________ /NI
H \C) 0\ 0 =

1H NMR (300 MHz, CDC13): ö = 7.74 (1H, d, J= 7.8 Hz), 7.55 (1H, dt, J= 7.8, 1.5 Hz), 7.33-7.21 (11H, m), 7.08 (1H, d, J= 7.5 Hz), 5.68 (1H, d, J= 8.4 Hz), 5.20 (2H, s), 5.12 (2H, s), 4.77 (1H, m), 4.66 (1H, dd, J= 11.4, 3.3 Hz), 4.57 (1H, dd, ./.=
11.4, 3.3 Hz), 2.30 (3H, s).
13C NMR (75 MHz, CDC13): 8 = 169.45, 169.09, 163.68, 163.35, 155.57, 150.77, 135.87, 134.75, 134.07, 131.44, 128.50, 128.43, 128.27, 128.14, 128.04, 125.92, 123.71, 122.18, 67.83, 67.27, 64.63, 53.55, 21.03.
The protected acetylsalicylic-L-serine ester SPEB0010101 (21.0 g, 42.7 mmole) was dissolved in ethanol (100 mL) and ethyl acetate (100 mL) at room temperature and added to a Parr bottle that contained 10% palladium on carbon (4.20 g, 50%
wet) under a nitrogen atmosphere. The nitrogen atmosphere was replaced with hydrogen gas (20 psi).
After 5 hours additional 10% palladium catalyst (4.26 g) was added and the hydrogen atmospere was returned (20 psi). After an additional 20 hours of shaking at room temperature, the palladium catalyst was removed by filtration through celite.
The remaining solids (palladium/celite and product) were washed with water (1500x2 mL) until the product was removed. The ethanol and water fractions were concentrated under reduced pressure at room temperature. The remaining solid (7.17 g) was dissolved in DIUF water (4.3 L), filtered through celite to remove insoluble material, and concentrated under high vacuum at room temperature. The white solid was then washed with 1,4-dioxane (100 mL) and DIUF water (50 mL) overnight. After 24 hours the solid was filtered and dried under high vacuum until the weight was constant (24 hours).

1-1:\work\1652\17690\SPEC\17690.spec without claimsII.doc The experiment produced the acetylsalicylic-L-serine ester SPIB00101 (6.17 g, 54%
yield) as a white solid.
o 0 C) -H'N H

11-1 NMR (300 MHz, D20-DC1): 8 = 8.05 (1H, dd, J= 7.8, 1.5 Hz), 7.75 (1H, dt, J 7.8, 1.5 Hz), 7.47 (1H, dt, J= 7.8, 0.9 Hz), 7.27 (1H, dd, J= 7.8, 0.9 Hz), 4.87 (1H, dd, J=
12.6, 4.2 Hz), 4.79 (1H, dd, J= 12.6, 3.0 Hz), 4.62 (1H, dd, J= 4.2, 3.0 Hz), 2.39 (3H, s).
13C NMR (75 MHz, D20-DC1): 5 = 173.01, 168.58, 164.54, 149.72, 135.39, 131.59, 126.87, 123.62, 121.15, 62.38, 52.05, 20.44.
HPLC analysis:
98.1% purity; r.t.= 5.839 min.; 65% TFA (0.1%)/35% methanol; 1 mL/min; 35 C;
Luna C18, 3u column (SN 184225-37), 4.6x250 min; 22 ul injection; DAD1B, Sig = 240, Ref= 550,100.
CHN analysis:
calc.: C 53.93, H 4.90, N 5.24; found: C 54.02, H 5.00, N 5.23.
Melting point: 147.0 C (dec.) 3) SPIB00103: 2-0-Acetylsalicylic acid (2S, 4R)-4-hydroxyproline ester A mixture of N-carbobenzyloxy-L-hydroxyproline benzyl ester (Z-Ser-OBz1, 21.5 g, 60.5 mmole)1 and pyridine (25 mL) in anhydrous dichloromethane (500 mL) was cooled in an ice bath while under a nitrogen atmosphere. Acetylsalicyloyl chloride (13.2 1-1:\work\1652\17690\SPEC\17690.spec without clahnslicloc g, 66.6 mmole) was added and the mixture was allowed to warm to room temperature and stir overnight. After 24 hours, additional acetylsalicyloyl chloride (5.0 g, 25.2 mmole) was added and the mixture was allowed to stir overnight. After 48 hours, the mixture was poured into ice-cold 1N hydrochloric acid (500 mL). After mixing, the layers were separated and the dichloroMethane fraction was washed with water (500 mL), saturated sodium bicarbonate solution (500 mL), water (500 mL), brine (500 mL) and dried over sodium sulfate (25 g). After filtration, concentration under reduced pressure, and drying under high vacuum, the remaining yellow oil (40.7 g) was purified by flash chromatography on silica gel (460 g, 0.035-0.070 mm, 6 nm pore diameter), eluting with heptane/ethyl acetate (3:1). After concentration of the product containing fractions under reduced pressure and drying under high vacuum until the weight was constant, the experiment produced the protected acetylsalicylic-L-hydroxyproline ester SPIB0010301 (21.31 g, 68% yield) as a colorless oil.
o 0 0 1.1 ìr o c)\

1H NMR (300 MHz, CDC13): 8 = 7.92 (1H, d, J= 7.8 Hz), 7.56 (1H, t, J= 7.8 Hz), 7.34-7.21 (10H, m), 7.09 (1H, d, J= 7.8 Hz), 5.48 (1H, s), 5.21 (2H, m), 5.03 (2H, d, J=15 Hz), 4.57 (1H, m), 3.85 (2H, m), 2.53 (1H, m), 2.28 (4H, m).
13C NMR (75 MHz, CDC13): 6= 171.72, 171.49, 169.25, 163.47, 163.30, 154.52, 153.93, 150.54, 136.05, 135.94, 135.21, 135.00, 134.17, 134.12, 128.43, 128.32, 128.28, 128.20, 128.05, 127.98, 127.94, 127.79, 125.89, 123.70, 122.46, 122.38, 73.24, 72.59, 67.33, 67.11, 66.97, 58.02, 57.69, 52.47, 52.15, 36.74, 35.65, 20.90.

1-1:\work\1652\17690\SPEC\17690.spec without clairnslI.doc The protected acetylsalicylic-L-hydroxyproline ester SPI110010301 (10.6 g, 20.5 mmole) was dissolved in ethanol (75 mL) and ethyl acetate (75 mL) at room temperature and added to a Parr bottle that contained 10% palladium on carbon (3.0 g, 50%
wet) under a nitrogen atmosphere. The nitrogen atmosphere was replaced with hydrogen gas (20 psi). After 17 hours of shaking at room temperature, the reaction mixture was washed with water (500 mL) for two hours. The organic layer (top) was removed via pipette and the aqueous layer was filtered through celite. The water fraction was concentrated under reduced pressure at room temperature. The remaining solid (6.71 g) was then washed with anhydrous dichloromethane (35 mL) overnight. After 24 hours the solid was filtered and dried under high vacuum until the weight was constant (24 hours). The experiment produced acetylsalicylic-L-hydroxyproline ester, (2.87 g, 47.7 % yield) as a white solid.

=
d\--OH
o 1H NMR (300 MHz, D20-DC1): 8 = 8.09 (1H, d, J= 7.5 Hz), 7.75 (1H, t, J= 7.5 Hz), 7.48 (1H, t, J= 7.5 Hz), 7.28 (1H, d, J= 7.5 Hz), 5.69 (1H, m), 4.76 (1H, t, J=7.5 Hz), 3.86 (1H, dd, J= 13.5, 3.9 Hz), 3.74 (1H, d, J= 13.5 Hz), 2.81 (1H, dd, J=
15.0, 7.5 Hz), 2.60 (1H, m), 2.40 (3H, s).
13C NMR (75 MHz, D20-DC1): 8 = 173.13, 170.25, 164.31, 149.65, 135.36, 131.54, 126.87, 123.54, 121.37, 73.86, 58.34, 50.95, 34.38, 20.48.
HPLC analysis:
98.3% purity; r.t.= 7.201 min.; 65% TFA (0.1%)/35% methanol; 1 mL/min; 35 C;
Luna C18, 3u column (SN 184225-37), 4.6x250 mm; 22 ul injection; DAD1B, Sig= 240, 4 Ref= 550,100.

FlAwork\1652117690 \SPEC \ 17690.spec without claimsII.doc CHN analysis:
calc.: C 57.34, H 5.16, N 4.78; found: C 57.09, H 5.23, N 4.91.
Melting point: 162 C (dec.) Gastric Mucosa irritation potential of the L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid compared to acetylsalicylic acid:-The present study was conducted to determine the relative potential of new formulations of aspirin (L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid) to cause gastric mucosal irritation/lesions in fasted male albino rats.
Aspirin served as reference control.
Different new formulations of aspirin and aspirin were administered by gavage to fasted male albino rats (Wistar strain), using 0.5% (w/v) Carboxymethylcellulose (CMC) in Phosphate Buffer (pH 2.6) solution as the vehicle. The study was conducted at two dose levels viz. 100mg and 200mg/kg body weight along with a vehicle control group.
At each dose level 5 animals were used. All the doses were expressed as aspirin molar equivalents. The doses used as well as the molar equivalents were presented below.
Table 11:Formulation: Molar equivalent Formulation Molar equivalent L-serine ester of acetylsalicylic 1.483 units are equivalent to 1 unit of aspirin acid L-Hydroxyproline ester of 1.628 units are equivalent to 1 unit of aspirin acetylsalicylic acid L-threonine ester of 1.561 units are equivalent to 1 unit of aspirin.
acetylsalicylic acid 11:\work\1652\17690\SPEC\17690.spec without claimslidoc Table 12: Test Item: Group: Dose (mg per kg) [in terms of acetylsalicylic acid] :
Equivalent weight of the Test item [mg]
Dose (mg per kg) Equivalent [in terms of Test Item Groupweight of the acetylsalicylic Test item [mg]
acid]
Vehicle control 0.0 Vehicle control Group L-serine ester of Test Group 1 100.0 148.3 acetylsalicylic Test Group 2 200.0 296.6 acid L-Hydroxyproline Test Group 1 100.0 162.8 ester of Test Group 2 200.0 325.6 acetylsalicylic acid L-threonine, ester Test Group 1 100.0 156.1 of acetylsalicylic Test Group 2 200.0 312.2 acid Reference control Test Group 1 100.0 100.0 acetylsalicylic Test Group 2 200.0 200.0 acid The rats were fasted for a period of 18 to 22 hours before dosing. The test item was administered as a single dose by gavage. Three hours after drug administration, the animals were killed humanely by CO2 gas inhalation. The stomach was dissected out and observed for = the quantity of mucous exudate, = degree of hyperemia and thickening of stomach wall, = hemorrhagic spots (focal or diffuse), nature of hemorrhages (petechial or ecchymotic) along with the size and = perforations The observations on gastric mucosal irritation of animals of various groups were summarized below H:\work\1652\17690\SPEC\17690.spec without claimsII.doc Table 13: Test Item: Group: Dose mg/kg (as acetylsalicylic acid): Observation Dose mg/kg (as Test Item GroupObservation acetylsalicylic acid None of the animals showed Vehicle Vehicle control 0.0 any evidence of gastric control Group mucosal irritation None of the dosed animals Test Group 1 100.0 showed any evidence of L-serine ester of gastric mucosal irritation acetylsalicylic acid None of the dosed animals Test Group 2 200.0 showed any evidence of gastric mucosal irritation.
None of the dosed animals Test Group 1 100.0 showed any evidence of L-Hydroxyprolin ester gastric mucosal irritation.
of acetylsalicylic acid None of the dosed animals Test Group 2 200.0 showed any evidence of gastric mucosal irritation None of the dosed animals Test Group 1 100.0 showed any evidence of L-threonine, ester of gastric mucosal irritation acetylsalicylic acid None of the dosed animals Test Group 2 200.0 showed any evidence of gastric mucosal irritation None of the dosed animals Test Group 1 100.0 showed any evidence of Reference control gastric mucosal irritation (acetylsalicylic acid) All the 5 animals dosed, Test Group 2 200.0 showed evidence of gastric mucosal irritation.
In conclusion it was observed that none of the L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid induced any evidence of irritation of gastric mucosa at the two doses tested viz., 100 and 200mg/kg body weight In contrast, aspirin (acetylsalicylic acid) has caused irritation of the gastric mucosal in all the fasted male albino rats at the dose level of 200mg/kg. However at the dose level of 100mg/kg aspirin failed to cause any evidence of gastric mucosal irritation in the male rats.

FlAwor1\1652\17690\SPEC\17690.spee without clahnsthdoc Further none of the animals of different test groups showed any clinical symptoms of toxicity through out the observation period of three hours.
Efficacy of L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid compared to acetylsalicylic acid on Clotting Time in rats estimated one hour after dosing Observations of blood clotting time The data on the mean clotting time (MCT) of the animals of low, intermediate and high dose groups of different formulations, vehicle control and positive control groups estimated one hour after dosing were presented below (Table 14):
Table 14: Summary of Mean Clotting Time ( S.D.) in Minutes - L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid and Aspirin (Positive control): Low dose: Intermediate dose: High dose Low Dose Intermediate Dose , High Dose Vehicle control 4.9 1.10 L-serine ester of 5.7 1.34 6.8 1.48 6.9 1.37 acetylsalicylic acid L-Hydroxyprolin ester 6.1 1.10 5.7 0.82 7.5 1.18 of acetylsalicylic acid _ L-threonine, ester of 5.2 1.14 5.6 0.84 7.4 0.97 acetylsalicylic acid Positive control 6.2 1.40 8.1 1.97 9.8 1.32 (acetylsalicylic acid) FIG. 3-6 depict the group mean data of animals regarding the dose relationship + mean clotting time in minutes for the L-series ester of aspirin and for the control.
The statistical analysis showed a significant improvement at 5% significance level in the efficacy for the high dose and mid dose when compared to the vehicle control group (Figure 7).

FlAwork\1652\176901SPEC\17690.spec without clairnsII.doc FIG. 4 shows the group mean data of animals. It provides the dose response relationship to mean clotting time (MCT) in minutes with respect to L-hydroxyproline ester of asperin. The statistical analysis of FIG. 4 showed a significant improvement at 5%
significance level in the efficacy for the high dose and low dose when compared to the vehicle control group (Figure 6) FIG. 5 depicts the dose response relationship to mean clotting time (MCT) in minutes of L-threonine ester of acetylsalicylic acid. The statistical analysis showed a significant improvement at 5% significance level in the efficacy for the high dose when compared to the vehicle control.
FIG. 6 depicts the dose response relationship to mean clotting time for acetylsalicylic acid. The statistical analysis showed a significant improvement at 5%
significance level in the efficacy for the intermediate and high dose when compared to the vehicle control.
The dose response effect were statistically significant and clearly evident (Figure 7).
CONCLUSION
The present study was conducted to evaluate the efficacy of new formulations of aspirin using blood clotting time as an index in albino rats. Aspirin served as positive control.
The study was conducted at three dose levels with the new formulations and positive control along with a vehicle control group.
Doses The doses for the main study were selected based on the dose range finding experiments with acetylsalicylic acid. All the doses were expressed as aspirin molar equivalents. The doses used for the main experiment for different formulations and positive control were same and presented below.

flAwork\1652\17690\SPEC\17690.spec without claimsII.doc Table 15: Test Item: Low Dose (mg/kg): Intermediate dose 9mg/kg): High dose (mg/kg) Low Dose Intermediate High Dose Test Item (mg/kg) Dose (mg/kg) (mg/kg) L-serine ester of 1.0 4.0 10.0 acetylsalicylic acid L-Hydroxyprolin ester of 1.0 4.0 10.0 acetylsalicylic acid L-threonine, ester of 1.0 4.0 10.0 acetylsalicylic acid Aspirin (Positive control) 1.0 4.0 10.0 Efficacy (Blood clotting time) The efficacy in terms of time required for the blood clotting time at different dose levels - low, intermediate and high dose for different formulations and acetylsalicylic acid are presented below.
Table 16: Low dose: Intermediate dose: High dose Low Dose Intermediate Dose High Dose Vehicle control 4.9 1.10 L-serine ester of 5.7 1.34 6.8 1.48 6.9 1.37 acetylsalicylic acid L-Hydroxyprolin ester 6.1 1.10 5.7 0.82 7.5 1.18 of acetylsalicylic acid L-threonine, ester of 5.2 1.14 5.6 0.84 7.4 0.97 acetylsalicylic acid Positive control 6.2 1.40 8.1 1.97 9.8 1.32 L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid are as significant as acetylsalicylic acid with respect to clotting time observed after one hour but are far superior in terms of the absence of gastric irritation at all levels compared to acetylsalicylic acid.
Efficacy of L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid compared to acetylsalicylic acid on Clotting Time in rats estimated two hours after dosing H:\work\1652\17690\SPEC\17690.spec without claimsILdoc The present study was conducted to evaluate the efficacy of L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid compared to acetylsalicylic acid using blood clotting time, estimated 2 hours ( 10 minutes) after dosing, as an index in albino rats. Aspirin served as positive control. Male albino rats were exposed to aspirin and to 3 new formulations of aspirin at one dose level of 20mg/kg body weight. No vehicle control group was used. The doses were expressed as aspirin molar equivalents.
The doses used for the main experiment for different formulations and positive control was presented below.
Table 17: Test Item: Dose in terms of Acetylsalicylic acid 9mg/kg) Dose in terms of Test Item Acetylsalicylic acid (mg/kg) L-serine ester of acetylsalicylic acid 20.0 L-Hydroxyproline ester of 20.0 acetylsalicylic acid L-threonine ester of acetylsalicylic acid 20.0 Aspirin (Positive control) 20.0 Efficacy (Blood clotting time) The efficacy in terms of time required for the blood clotting time at the dose level of 20 mg/kg body weight for different formulations and aspirin (positive control) are presented below.
Observations of Blood clotting time The data on the mean clotting time (MCT) of the animals, estimated 2 hours ( minutes) after dosing, at the dose level of 20mg/kg body weight for different formulations, vehicle control and positive control are presented below H:\work\1652\17690\SPEC\17690.spec without claimsII.doc Table 18: Summary of Mean Clotting Time ( S.D.) in Minutes of L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid compared to acetylsalicylic acid (Positive control) Dose (20mg/kg) L-serine ester of 3.8 0.92 acetylsalicylic acid L-Hydroxyproline 4.2 1.32 ester of acetylsalicylic acid L-threonine ester of 5.3 1.06 acetylsalicylic acid Positive control 5.4 1.17 (acetylsalicylic acid) L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid were found to be effective on clotting time.
In conclusion, it was observed that based on the time required for the blood to clot (clotting time), when estimated 2 hours after dosing, the amino acid prodrugs were efficacous. However, the L-threonine ester of acetylsalicyclic acid was found to have relatively better efficacy than the other two formulations.
As shown by FIG. 7 the statistical analysis showed that L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid are as effective as acetylsalicylic acid there is no significant difference at 5% significance level for L-Hydroxyproline ester of acetylsalicylic acid and L-threonine ester of acetylsalicylic with respect to positive control for the mean blood clotting time observed after two hours. However, combined with the gastric irritation potential, the L-serine, L-threonine, and L-Hydroxyproline esters of acetylsalicylic acid are far superior.

11:\work\1652\17690\SPEC\17690.speo without claintsadoc There are a number of screening tests to determine the utility of the prodrugs created according to the disclosed methods. These include both in vitro and in vivo screening methods.
The in vitro methods include acid/base hydrolysis of the prodrugs, hydrolysis in pig pancreas hydrolysis in rat intestinal fluid, hydrolysis in human gastric fluid, hydrolysis in human intestinal fluid, and hydrolysis in human blood plasma. These assays are described in Simmons, DM, Chandran, VR and Portmann, GA, Danazol Amino Acid Prodrugs: In Vitro and In Situ Biopharmaceutical Evaluation, Drug Development and Industrial Pharmacy, Vol 21, Issue 6, Page 687, 1995.
The compounds of the present invention are effective in treating diseases or conditions in which NSAIDs normally are used. The prodrugs disclosed herein are transformed within the body to release the active compound and enhances the therapeutic benefits of the NSAIDs by reducing or eliminating biopharmaceutical and pharmacokenetic barriers associated with each of them. However it should be noted that these prodrugs themselves will have sufficient activity without releasing any active drug in the mammals. Since the prodrugs is more soluble in water then Ibuprofen or other NSAIDs, it does not need to be associated with a carrier vehicle, such as alcohol or castor oil which may be toxic or produce unwanted side reactions. Moreover, oral formulations containing the NSAID
prodrugs are absorbed into the blood and are quite effective.
Thus, the prodrug of the present invention enhances the therapeutic benefits by removing biopharmaceutical and pharmacokenetic barriers of existing drugs.
Furthermore, the prodrugs are easily synthesized in high yields using reagents which are readily and commercially available.

IV. Proline Derivative of Acetaminophen Overview:
The procedure for the synthesis of the L-proline ester of acetaminophen is outlined in Synthetic Sequence section. The synthesis is exemplary. The complete procedure and analytical data is given in the Experimental Section. Acetaminophen (10 g) was coupled with Boc-L-proline with EDC in the presence of a catalytic amount of DMAP.
Once the reaction was complete (3 hours at room temperature), the solution was washed with water. After drying over sodium sulfate, filtration, and concentration the crude protected amino acid ester of acetaminophen was purified by flash chromatography on silica gel. The procedure generated the protected L-proline ester of acetaminophen in 72%. The protecting group was removed by dissolving the ester in dichloromethane and passing hydrogen chloride through the solution at room temperature. After filtration, the final salt was stirred in tetrahydrofuran until pure. The yield for the deprotection step was 91.4% after filtration and drying under high vacuum at 90 C for 4 hours.
Synthetic Sequence:

1-1:\work\1652 \17690\SPEC \17690.spec without clainisIi.doc PCT/oUS200,4/,00N24901 = OH a) HO
H, Acetaminophen boc-L-proline SP1001401 0 ,0 b) H,N
Cl- H
C) Synthesis of the L-proline ester of acetaminophen: a) EDC, DMAP, CH2C12; b) (g), CH2C12.
Experimental Section:
The synthesis of SPI0014 was conducted in one batch. Reagents mentioned in the experimental section were purchased at the highest obtainable purity from Lancaster, Sigma-Aldrich, or Acros, except for solvents, which were purchased from either Fisher Scientific or Mallinkrodt.
SPI0014: Pyrrolidine-2(S)-carboxylic acid 4-acetylamino-phenyl ester, hydrochloride A mixture of Boc-L-proline (14.39 g, 68.80 mmole), acetaminophen (10.02 g, 66.28 mmole), EDC (12.9 g, 67.29 mmole) and DMAP (1.10 g, 9.0 mmole) in anhydrous dichloromethane (100 mL) was stirred for 3 hours at room temperature under an argon H:\work\1652 \17690 \SPEC \17690.spec without claimsn.doc atmosphere. After 3 hours, water (120 mL) was added. After mixing for 5 minutes, the layers were separated and the dichloromethane fraction was washed with water (120 mL) and dried over sodium sulfate (5 g). After filtration, concentration under reduced pressure, and drying under high vacuum, the remaining oil (24.10 g) was purified by flash chromatography on silica gel (100 g, 0.035-0.070 mm, 6 nm pore diameter), eluting with hexanes/ethyl acetate (1:2). After concentration of the product containing fractions under reduced pressure and drying at high vacuum until the weight was constant, the experiment produced the protected acetaminophen-L-proline ester SPI001401 (16.71 g, 72:30: yield) as a white solid (foam).
o 0 ,i H,N 1.1 1H NMR (300 MHz, CDC13): 5 = 8.83 (1/2 H, s), 8.70 (1/2 H, s), 7.58 (1/2 H, d, J= 7.5 Hz), 7.46 (1/2 H, d, J= 7.5 Hz), 6.96 (2 H, m), 4.47 (1 H, m), 3.59-3.45 (2H, m), 2.36 (1 H, m), 2.17-1.90 (6 H, m), 1.46 (9 H, m).
13C NMR (75 MHz, CDC13): 5 = 171.91, 171.75, 169.02, 154.44, 153.78, 146.36, 146.21, 121.44, 121.23, 120.82, 80.41, 80.17, 59.16, 46.78, 46.55, 31.06, 30.11, 28.50, 24.57, 24.28, 23.78.
The protected acetaminophen-L-proline ester SPI001401 (16.60 g, 47.64 mmole) was dissolved in dichloromethane (400 mL) and hydrogen chloride gas was passed through the solution for 2 hours at room temperature. The remaining solids were allowed to settle (for 1 hour). The dichloromethane was carefully decanted away from the white precipitate. Tetrahydrofuran (200 mL) was added to the precipitate and the mixture stirred for 2 hours under an argon atmosphere. After filtration, the remaining white solid H:\work\1652\17690\SPEC\17690.spec without claimsII.doc was dried under high vacuum at 90 C until the product weight was constant (4 hours).
The experiment produced acetaminophen-L-proline ester, hydrochloride SPI0014 (12.4 g, 91.4% yield) as a white solid.
1HNMR (300 MHz, CDCL3-DMS0): 8 = 10.41 (1H, br s), 10.26 (1H, s), 9.55 (1H, br s), 7.70 (2H, d, J= 9 Hz), 7.12 (2H, d, J= 9 Hz), 4.66 (t, 1H, J= 8.4 Hz), 3.33 (2H, m), 2.43 (1H, m), 2.28 (1H, m), 2.08 (s, 3H), 2.04 (2H, m).
13C NMR (75 MHz, CDCL3-DMS0): 8 = 168.08, 167.25, 144.55, 137.40, 121.12, 119.64, 58.53, 45.33, 27.74, 23.86, 23.08.
HPLC analysis:
99.45% purity; rt= 5.733 min; Luna C18 5u column (sn 167917-13); 4.6x250 mm;

nm; 15% Me0H/85% hexane sulfonate buffer (110mMol, pH= 6); 35 C; 20 ul inj.;
lml/min; 5 mg/mL sample size.
CHN analysis:
calc.: C 54.84, H 6.02, N 9.84; found: C 54.66, H 5.98, N 9.65.
Melting point: 221-222 C
V. Amino Acid Derivative of Cyclosporine A
The macrocyclic immunosuppresants comprise a class of structurally distinctive, cyclic, poly, N-methylated undecaptides, and similar semi-synthetic macrolide structures commonly possessing pharmacological, in particular immunosuppressive, anti-inflammatory and/or anti-parasitic activity. The first of the cyclosporine to be isolated was the naturally occurring fungal metabolite Ciclosporin or Cyclosporine also known as cyclosporine A, which has the formula:

H:\work\1652\17690\SPEC\17690.spec without clainisadoc MeBmt-aAbu-Sar-MeLeu-Val-MeLeu-Ala-(D)Ala-MeLeu-MeLeu-MeVal r1 2 3 4 5 6 7 8 9 10 11 wherein MeBmt represents N-methyl-(4R)-4-but-2E-en-1-y1-4-methyl-(L) threonyl residue of the formula HO (R) ,CH
CH (R) CH3 ¨ N ¨CH-- CO
(S) in which ¨x-y- is CH=CH ¨(trans). Other similar products include, sirolimus (b), tacrolimus (c), and pimecrolimus (d), having the following structures:

\wor1\1652\17690\SPEC\17690.spec without claimsII.doc (b) 4scrOH
H
"4 0i/, H
a N CHs OH

= H3C /
H
OH

CH3, 0 H300 1 4..3 õ
I 'CH3 'bi^i3 Sirolimus (c) H3C0 si cii3 1 i OH
H3C .
0 i --CH

--H3C g , i (SCH3 00H3 Tacrolimus H:\work\1652\17690\SPEC\17690.spec without claimsII.doc (d) CI
=

01-f3 OH

1-13C q ba-13 OCH3 Pimecrolimus The class comprised by the cyclosporines is thus now very large indeed and includes, for example, [Thr]2-, [Va1]2-, [Nva]2- and [Nva]2-[Nva]5-Cielosporin (also known as cyclosporines C, D, G and M respectively), [Dihydrop-MeBmt]l-[Val]2-ciclosporin (also known as dihydro-cyclosporine D), [(D)Ser]8-Ciclosporin, [(D)MeVall11-Ciclosporin (also known as cyclosporine H), [MeAlar-Ciclosporin, [(D)Pre-Ciclosporin and so on.
In accordance with conventional nomenclature for cyclosporines, these are defined throughout the present specification and claims by reference to the structure of cyclosporine (i.e., Cyclosporine A). This is done by first indicating the amino acid residues present which differ from those present ion Ciclosporin (e.g., "[(D)Pro]3" to indicate that the cyclosporine in question has a ¨(D)Pro- rather than ¨Sar-residue at the 3-position) and then applying the term Cyclosporine to characterize remaining residues which are identical to those present in Cyclosporine A.

H:\work\1652\17690\SPEC\17690.spec without clahnsltdoc As used herein, the term "cyclosporines" refers to the various types of cyclosporines, in which x-y in the MeBmt residue has a cis or trans CH=CH or in which x-y therein is also included in those derivatives in which one or more of those amino acids in positions 2-11 of Cyclosporine A is replaced by a different amino acid. It is preferred;
however, that not more than two of the amino acids are replaced in the formula of cyclosporine A
and more preferentially not more than one of the amino acids is replaced by an amino acid.
In addition, amino acid residues referred to by abbreviation, e.g., -Ala-, -MeVal- and -aAbu-, are, in accordance with conventional practice, to be understood as having the (L)-configuration unless otherwise indicated, e.g. as in the case of "-(D)Ala-". Residue abbreviations preceded by "Me" as in the case of "-MeLeu-", represent a-N-methylated residues. Individual residues of the cyclosporine molecule are numbered, as in the art, clockwise and starting with the residue ¨MeBmt-, dihydro-MeBmt- etc...in position 1.
The same numerical sequence is employed throughout the present specification and claims.
Because of their unique pharmaceutical potential, the macrocyclic immunosuppressants have attracted considerable attention in the press. The term "macrocyclic immuno-suppressants" includes various natural and semi-synthetic derivatives of cyclosporine, and other macrolides such as sirolimus, tacrolimus and pimecrolimus. The primary area of clinical investigation for above drugs has been as immunosuppressive agents, in particular in relation to its application to recipients of organ transplants, e.g., heart, lung, combined heart-lung, liver, kidney, pancreatic, bone-marrow, skin and corneal transplants, and in particular allogenic organ transplants. These drugs are also used in the treatment of psoriasis, atompic dermatitis, rheumatoid arthritis and nephritic syndrome.
Macrocyclic immunosuppressants are also useful for treating various autoimmune diseases and inflammatory conditions and especially inflammatory conditions with an flAwork\1652 \17690 \SPEC\ 17690.spec without clairasEdoc aetiology, including an autoirnmune component, such as arthritis (for example, rheumatoid arthritis, arthritis chronica progredient and arthritis deformons) and rheumatic diseases. Specific autoinunune diseases for which cyclosporine therapy has been proposed or applied include, autoirrunune hematological disorder (including, e.g., hemolytic anemia, aplastic anemia, pure red cell anemia, and idiopathic thrombocytopaenia), systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease, including, e.g., ulcerative colitis and Crohn's disease), endocrine opthalmopathy Graves disease, sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), uvetis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstial lung fibrosis, psoriatic arthritis, atopic dermatitis and glomerulonephritis (with and without nephrotic syndrome, e.g., including idiopathic nephritic syndrome or minimal change nephropathy).
Furthermore, macrocyclic immunosuppressants also have applicability as an anti-parasitic, in particular anti-protozoal agent, and are suggested to be useful for treating malaria, coccidiomycosis and schistomsomiasis. More recently, they have been taught to be useful as an agent for reversing or abrogating anti-neoplastic agent resistance contumors, and the like.
Despite the very major contribution which macrocyclic immunosuppressants have made, difficulties have been encountered in providing more effective and convenient means of administration (e.g., galenic formulations, for example, oral dosage form, which are both convenient and for the patient as well as providing appropriate bioavailability and allowing dosaging at an appropriate and controlled dosage rate) as well as the reported occurrence of undesirable side reactions; in particular nephrotoxic reactions have been obvious serious impediments to its wider use or application.

HAwork\1652\17690\SPEC\17690.spec without claimsII.doc Moreover, the above mentioned macrocyclic immunosuppressants are characteristically highly hydrophobic and readily precipitate in the presence of even very minor amounts of water, e.g., on contact with the body (e.g., stomach fluids). It is accordingly extremely difficult to provide e.g., oral formulations which are acceptable to the patient in terms of form and taste, which are stable on storage and which can be administered on a regular basis to provide suitable and controlling patient dosaging.
Proposed liquid formulations, e.g., for oral administration of macrocyclic immunosuppressants, have heretofore been based primarily on the use of ethanol and oils or similar excipients as carrier media. Thus, the commercially available macrocyclic immunosupressant drink-solution employs ethanol and olive oil or corn-oil as carrier medium in conjunction with solvent systems comprising e.g., ethanol and LABR1FIL and equivalent excipients as carrier media. Thus, the commercially available macrocyclic immunosupressant drink solution employs ethanol and olive oil or corn-oil as carrier medium in conjunctions with a Labrffil as a surfactant. $ee e.g., U.S. Patent NO. 4,388,307. Use of the drink solution and similar composition as proposed in the art is however accompanied by a variety of difficulties.
Further, the palatability of the known oil based system has proved problematic. The taste of the known drink-solution is, in particular, unpleasant. Admixture with an appropriate flavored drink, for example, chocolate drink preparation, at high dilution immediately prior to ingestion has generally been practiced in order to make regular therapy at all acceptable. Adoption of oil based systems has also required the use of high ethanol concentrations to itself inherently undesirable, in particular where administration to children is forseen. In addition, evaporation of the ethanol, e.g., from capsules (adopted in large part, to meet problems of palatability, as discussed or other forms (e.g., when opened) results in the development of a macrocyclic immunosupressant precipitate. When such compositions are presented in, for example, soft gelatin encapsulated form an additional problem arises. This particular difficulty necessitates packaging of the encapsulated product in an air-tight component, for FlAwork\1652 \ 17690 \SPEC\17690.spec without claimsII.doc example, an air-tight blister or aluminum-foil blister package. This in turn renders the product both bulky and more expensive to produce. The storage characteristics of the aforesaid formulations are, in addition, far from ideal.
Bioavailability levels achieved using existing oral macrocyclic immunosupressant dosage system are also low and exhibit wide variation between individuals, individual patient types and even for single individuals at different times during the course of therapy. Reports in the literature indicates that currently available therapy employing the commercially available macrocyclic immunosupressant drink solution provides an average absolute bioavailability of approximately 30% only, with the marked variation between individual groups, e.g., between liver (relatively low bioavailability) and bone-marrow (relatively high bioavailability) transplant recipients. Reported variation in bioavailability between subjects has varied from one or a few percent for some patients, to as much as 90% or more for others. And as already noted, marked change in bioavailability for individuals with time is frequently observed. Thus, there is a need for a more uniform and high bioavailability of macrocyclic immunosupressant in patients.
Use of such dosage forms is also characterized by extreme variation in required patient dosaging. To achieve effective immunosuppressive therapy, blood or blood serum levels compounds of the cyclosporin have to be maintained within a specified range.
This required range can in turn, vary, depending on the particular condition being treated, e.g., whether therapy is to prevent transplant rejection or for the control of an autoimmune disease, or condition and on whether or not alternative immunosuppressive therapy is employed concomitantly with any of the immunosuppressants of the formula a-d therapy. Because of the wide variations in bioavailability levels achieved with conventional dosage forms, daily dosages needed to achieve required blood serum levels will also vary considerably from individual to individual and even for a single individual. For this reason it is necessary to monitor blood/blood-serum levels of patients receiving macrocyclic immunosuppressant therapy at regular and frequent intervals. Monitoring of blood/blood-serum levels, which is generally performed by H:\work\1652 \ 17690 \SPEC\ 17690.spec without claimsII.doc RIA or equivalent immunoassay technique, e.g. employing monoclonal antibody based technology, has to be carried out on a regular basis. This is inevitably time consuming and inconvenient and adds substantially to the overall cost of therapy.
It is also the case that blood/blood serum macrocyclic immunosuppressant levels achieved using available dosage systems exhibit extreme variation between peak and trough levels. That is for each patient, effective macrocyclic immunosuppressant levels in the blood vary widely between administrations of individual dosages.
There is also a need for providing macrocyclic immunosuppressant in a water soluble form for injection. It is well known that Cremephore L used in a current formulations of macrocyclic immunosuppressants is a polyoxyethylated derivative of castor oil and is a toxic vehicle. There have been a number of incidences of anaphylaxis due to the castor oil component. At present there is no formulation that would allow the macrocyclic immunosuppressants to be in aqueous solution at the concentrations needed due to poor water solubility of the drug.
Beyond all these very evident practical difficulties lies the occurrence of undesirable side reactions already alluded to, observed employing available oral dosage forms.
Several proposals to meet these various problems have been suggested in the art, including both solid and liquid oral dosage forms. An overriding difficulty which has however remained is the inherent insolubility of the macrocyclic immunosuppressants in aqueous media, hence preventing the use of a dosage form which can contain macrocyclic immunosuppressants in sufficiently high concentration to permit convenient use and yet meet the required criteria in terms of bioavailability, e.g.
enabling effective resorption from the stomach or gut lumen and achievement of consistent and appropriately high blood/blood-serum levels.

FlAwork\1652\17690\SPEC\17690.spec without claims11.doc The particular difficulties encountered in relation to oral dosaging with macrocyclic immunosuppressants have inevitably led to restrictions in the use of macrocyclic immunosuppressant therapy for the treatment of relatively less severe or endangering disease conditions. A particular area of difficulty in this respect has been the adoption of macrocyclic immunosuppressant therapy in the treatment of autoimmune diseases and other conditions affecting the skin, for example for the treatment of atopic dermatitis and psoriasis and, as also widely proposed in the art, for hair growth stimulation, e.g. in the treatment of alopecia due to ageing or disease.
Thus while oral macrocyclic immunosuppressant therapy has shown that the drug is of considerable potential benefit to patients suffering e.g. from psoriasis, the risk of side-reaction following oral therapy has prevented common use. Various proposals have been made in the art for application of macrocyclic immunosuppressants, e.g.
cyclosporine, in topical form and a number of topical delivery systems have been described. Attempts at topical application have however failed to provide any demonstrably effective therapy.
However, the present invention overcomes the problems described hereinabove.
More specifically, an embodiment of the present invention is a prodrug of macrocyclic immunosuppressant which significantly enhances its solubility in aqueous solutions, thereby avoiding the need to utilize a carrier, such as ethanol or castor oil when administered as a solution. Moreover, the prodrugs of macrocyclic immunosuppressant, in accordance with the present invention, do not exhibit the side effects of the prior art formulations. Further, the inventor has found that the macrocyclic immunosuppressant prodrugs of the present invention enhance its absorption when administered in the prodrug form to a patient, thereby enhancing significantly its bioavailability and its efficacy.
Accordingly, in one aspect, the present invention is directed to a prodrug of macrocyclic immunosuppressants. The prodrug consists of an amino acid esterified to the free FlAwork\1652\17690\SPEC\17690.spec without claimsII.doc hydroxy group present on the side chain of cyclospoiine, sirolimus, tacrolimus and either one of the hydroxyl groups of the pimecrolimus molecule.
For example, an aspect of the present invention is directed to, the compounds of the formulas (a) X

________________________ N¨CH¨CO¨CYCLO _________________ 1{:\work\1652\17690\SPEC\17690.spec without claimsll.doc (b) .s." AA or GLYAA
CH .-"-`0CH3 OH

OH

CH3 õ 0 H3C0 co õ,CH3 ''CF13 (c) AA-GLY or AA ¨ O. TACROL1MUS
1-11,,C0 cm3 ' OH

Cpuipc..6CH

oCH3 1-1:\work\ 1652 \17690\SPEC\17690.spec without claimsII.doc (d) Cl PIMECROLIMUS
H,co 9H, 0 ¨AA or GLY,AA

H3C q '0013 or pharmaceutically acceptable salts thereof;
wherein CYCLO represents the residues at positions 2-11 of the cyclosporine molecule;
x-y is CH=CH or CH2CH2 and AA is an amino acid or a dipeptide of the formula GLY-AA. In the latter case, GLY is glycine and AA is any a-amino acid. In the dipeptide structure, an AA is attached to the drug via OH group using glycine as the spacer.
Glycine is esterified to cyclospoiine and then glycine is bonded to any AA via amide linkage using amino group of glycine and carboxylic acid group of AA.
The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of the compounds of the Formulas a-d above and a pharmaceutical carrier therefor.
In another embodiment, the present invention is directed to a method of treating a patient in need of macrocyclic immunosuppressant therapy, which method comprises administering to said patient an effective amount of the compounds of Formulas a-d.

H:\work\1652\17690\SPEC\17690.spec without claimsILdoc In a further embodiment, the present invention is directed to a method of enhancing the solubility of macrocyclic immunosuppressant in an aqueous solution comprising reacting the hydroxy functionality in the MeBmt moiety at position 1 of the cyclosporine molecule as well as the specified hydroxyl functions in formulas b-d with an amino acid or acylating derivative thereof under ester forming conditions or by using a simple amino acid or a dipeptide structure wherein the AA is attached to drug using glycine as the spacer and isolating and isolating the product thereof.
In a still further embodiment, the present invention is directed to a method of enhancing the bioavailability of macrocyclic immunosuppressants when administered to a patient which comprises reacting the hydroxy functionality in the MeBmt moiety in position of the cyclospotine molecule with an amino acid or acylating derivative under ester forming conditions and as well as the specified hydroxyl functions in formulas b-d with an amino acid or acylating derivative thereof under ester forming conditions or by using a simple amino acid or a dipeptide structure wherein the AA is attached to drug using glycine as the spacer and isolating the product thereof and administering said product to the patient.
Overview:
The procedure for the synthesis of the N-(L-proline)-glycine and N-(L-lysine)-glycine esters of Cyclosporine A is outlined in Synthetic Sequence section. These examples are exemplary of the synthetic scheme using amino acids. The complete procedure and analytical data is given in the Experimental Section. Cyclosporine A (15 g) was coupled with chloroacetic anhydride (4 equivalent) in anhydrous pyridine. The experiment produced the chloroacetate ester of Cyclosporine A (SPI001201, 14 g, 88%
yield) in good yield. The chloroacetate ester (10.1 g) was then treated with sodium azide in DMF to generate the azidoacetate ester of Cyclosporine A (SPI001202, 9.9 g, 97%
yield). The azidoacetate (9.8 g) was then reduced with tin chloride (9 g) to prepare the glycine ester of Cyclosporine A (8.54 g, 89% yield). The glycine ester of Cyclosporine A (SPI001203) was then coupled with a two-fold excess of either boc-L-proline or Boc-H: \work\1652\17690 \SPEC \17690.spec without clahnsII.doc L-lysine using EDC as the coupling agent. After purification by column chromatography, the boc protecting groups were removed from the dipeptide esters of Cyclospotine A at low temperature (5 C) by treatment with 2M hydrochloric acid in diethyl ether. The L-lysine-glycine ester salt of Cyclosporine A did not require additional purification and was dried. The L-proline-glycine ester salt of Cyclosporine A required purification. The salt was converted to the free-base with sodium bicarbonate and purified by filtration through silica gel (eluting with acetone). The salt was then formed at low temperature with dilute anhydrous hydrochloric acid and dried.

11:\work\1652\17690\SPEC\17690.spec without claims1I.doc Synthetic Sequence:
N, NCI N /
ji 0:
r 1 0 I 0 i 3 ....0 N 0 N¨ a N 0 N¨

O + c====1-0-JUI --3.- o 0 \ 0 H.N...<1\....r 0 \ N
.../ 0 H
.44)N.1 14_,NN-1.),\
.... o Nx.. ;

Cyclosporin A
1 b ....õ/ o (3, N3L i ......, 0õ, r i c g7 . c-Nro 0 . . . \ro '0 N¨ N 0 N¨

0 \ .NICk"--( //. 0 H
\N=1),\1CCC--441/ 0 H O H N-.11---5,\
oNy.
oK,'N-y 1 d,f cwsLro H CI- H H HN,..31, H-.N
H = \--"NoriC4H 0 Cr-ci- HT1N-H ....v.., 04, C /
N 0 N¨

......\____µ".\A.i).-1011 0 Nrror N ..'c, 0 "N o 0 N =-= N-YJY 141H43Y1'4N -\
H.
__fr/0 0 0 \tsi____ci\..,r _ ---CONN

Synthesis of the N-(L-proline)-glycine and N-(L-Lysine)-glycine esters of Cyclosporine A: a) pyridine; b) NaN3, DMF; c) SnC12, methanol; d) boc-L-lysine, EDC; e) boc-L-proline, EDC; f) HC1, Et20.

H: \work\1652\17690 \SPEC \17690.spe,c without claimsadoc Experimental Section:
The synthesis of SPI0022 and SPI0023 was conducted in batches. Generally a small-scale experiment was performed first followed by a larger batch. Reagents mentioned in the experimental section were purchased at the highest obtainable purity from Aldrich, Acros, or Bachem, except for solvents, which were purchased from either Fisher Scientific or Mallincicrodt. The Cyclosporine A (USP grade) used in these procedures was provided by Signature Pharmaceuticals, Inc.
1) SPI001201 ci,_ jok /
01, 0 ro Cyclosporine A (15.01 g, 0.0124 moles) was dissolved in anhydrous pyridine (35 mL) at room temperature, under an argon atmosphere. The solution was cooled to 5 C
in an ice/water batch and chloroacetic anhydride (9.10 g, 0.053 moles) was added.
After stirring for 10 minutes, the ice bath was removed and the solution was allowed to stir under an argon atmosphere at room temperature for 17 hours. After 17 hours, diethyl ether (200 mL) was added. The ether was washed with water (2x100 mL) and dried for 1 hour over sodium sulfate (10 g). After filtration and concentration under reduced pressure, the remaining yellow foam was dried under high vacuum (1 hour at room temperature) and purified by flash chromatography on silica gel (200 g), eluting with heptane/acetone (2:1). After combining and concentrating the product containing fractions, the remaining light yellow foam (14.8 g) was purified a final time by crystallization from hot diethyl ether (140 mL). After cooling (-10 C, 2 hours), filtration, and drying under high vacuum, the procedure generated the chloroacetate ester of Cyclosporine A SPI001201 as a white solid (14.0 g, 88.3% yield).

H:\work\ 1652 \ 17690 \ SPEC\ 17690.spec without claimsII.doc Cyclosporine A chloroacetate ester:
1H NMR (300 MHz, CDC13):
5 = 8.50 (d, 1H, J= 9.6 Hz), 7.95 (d, 1H, J= 6.6 Hz), 7.46 (d, 1H, J= 9.0 Hz), 7.40 (d, 1H, J= 7.8 Hz), 5.35-4.52 (m, 15 H), 4.37 (t, 1H, J= 7.2 Hz), 4.12 (d, 1H, J= 14.7 Hz), 3.89 (d, 1H, J= 14.7 Hz), 3.45-3.0 (m, 15 H), 2.8-2.5 (m, 6H), 2.5-1.5 (m, 16H), 1.5-0.7 (m, 53 H).
13C NMR (75 MHz, CDC13):
ö= 173.78, 173.37, 172.86, 172.61, 171.28, 171.18, 170.91, 170.79, 168.78, 167.64, 167.18, 128.77, 126.68, 75.46, 65.95, 58.89, 57.47, 55.80, 55.31, 54.86, 54.34, 50.19, 48.91, 48.35, 48.02, 44.80, 40.96, 39.44, 37.07, 35.93, 33.85, 33.25, 32.40, 31.74, 31.50, 30.38, 30.12, 29.82, 29.53, 25.13, 24.92, 24.78, 24.40, 23.99, 23.75, 22.85, 21.94, 21.41, 21.25, 20.84, 19.85, 18.79, 18.32, 17.89, 17.82, 15.46, 15.24, 10.08.
2) SPI001202 0 \
The chloroacetate ester of Cyclosporine A SPI001201 (10.10 g, 7.89 mmole) was dissolved in anhydrous N,N-dimethlformamide (30 mL) at room temperature.
Sodium azide (2.15 g, 33.0 mmole) was added. The mixture was allowed to stir at room temperature for 24 hours in the dark, under an argon atmosphere. After 24 hours, diethyl ether (150 mL) was added and the precipitate was filtered. The ether was washed with water (2x100 mL), dried over sodium sulfate (15 g) for 30 minutes, filtered, and H:\work\1652\17690\SPEC\17690.spec without claimsli.doc concentrated under reduced pressure. The remaining white solid was dried under high vacuum for 1 hour at room temperature. The experiment produced the azidoacetate ester of Cyclosporine A SPI001202 (9.90 g, 97% yield) as a white solid, which was used without further purification.
Cyclosporine A azidoacetate ester:
1HNMR (300 MHz, CDC13):
8 = 8.48 (d, 1H, J= 9.3 Hz), 7.95 (d, 1H, J= 6.9 Hz), 7.45 (d, 111, J= 9.0 Hz), 7.39 (d, 1H, J= 7.8 Hz), 5.5-4.5 (m, 15 H), 4.31 (t, 1H, J= 6.6 Hz), 4.04 (d, 1H, J= 17.3 Hz), 3.53 (d, 1H, J= 17.3 Hz), 3.45-3.0 (m, 15 H), 2.8-2.5 (m, 6H), 2.5-1.5 (m, 16H), 1.5-0.7 (m, 53 H).
13C NMR (75 MHz, CDC13):
8 = 173.76, 173.32, 172.82, 172.53, 171.13, 170.89, 170.76, 170.69, 169.70, 168.20, 167.49, 128.63, 126.61, 74.96, 58.91, 57.39, 55.56, 55.21, 54.80, 54.23, 50.14, 48.99, 48.23, 48.24, 47.93, 44.71, 40.89, 39.33, 39.22, 37.02, 35.83, 33.81, 32.96, 32.31, 31.67, 31.42, 30.31, 30.09, 29.76, 29.47, 25.08, 24.92, 24.84, 24.67, 24.51, 24.40, 23.94, 23.82, 23.71, 21.85, 21.33, 21.25, 20.82, 19.79, 18.71, 18.25, 17.92, 17.81, 15.17, 10.03.
3) SPI001203 NE1,,.... A
/
tsil.--0 14 ¨
H
0 =
µ, oLy1:1;4õitisN
The azidoacetate ester of Cyclosporine A SPI001202 (9.80 g, 7.62 mmole) was dissolved in methanol (250 mL) at room temperature. Water (40 mL) was added H:\work\1652\17690\SPEC\17690.spec without clainislI.doc followed by tin (II) chloride (5 g, 26.3 nunole). The solution was allowed to stir for 1 hour at room temperature when an additional quantity of tin (II) chloride (4 g, 21.0 rnmole) was added. The solution was allowed to stir for an additional 2 hours at room temperature. Water (200 mL) containing ammonium hydroxide (40 mL, 29%) was added. After filtration, the solution was concentrated (to 200 mL) under reduced pressure. The remaining aqueous solution was extracted with ethyl acetate (2x200 mL).
The ethyl acetate fractions were combined, dried over sodium sulfate (20 g), filtered and concentrated under reduced pressure. The remaining clear foam was purified by filtration through silica gel (150 g), eluting with dichloromethane/methanol (20:1). The procedure generated the glycine ester of Cyclosporine A as a clear, solid foam (8.54g, 89% yield).
Glycine ester of Cyclosporine A:
1H NMR (300 MHz, CDC13):
= 8.60 (d, 1H, J= 9.6 Hz), 8.06 (d, 1H, J= 6.9 Hz), 7.53 (d, 1H, J= 8.4 Hz), 7.51 (d, 1H, J= 6.6 Hz), 5.7-4.52 (m, 15 H), 4.41 (t, 1H, J= 6.9 Hz), 3.5-3.0 (m, 17 H), 2.82-2.5 (m, 8H), 2.5-1.5 (m, 16H), 1.5-0.7 (m, 53 H).
13C NMR (75 MHz, CDC13):
8 = 174.10, 173.67, 173.23, 172.72, 172.55, 171.18, 171.10, 170.73, 170.61, 169.68, 167.77, 128.82, 126.42, 73.83, 58.57, 57.32, 55.99, 55.20, 54.74, 54.31, 50.08, 48.82, 48.28, 47.90, 44.70, 43.81, 40.74, 39.33, 39.24, 37.02, 35.84, 33.72, 33.07, 32.39, 31.72, 31.41, 30.25, 29.98, 29.74, 29.51, 25.05, 24.81, 24.73, 24.54, 24.31, 23.91, 23.78, 23.68, 21.86, 21.33, 21.25, 20.68, 19.76, 18.74, 18.24, 17.94, 17.79, 15.18, 10.03.
4) SPI0022 FI:\wor1\1652\176901SPEC\17690.spec without claitnsil.doc CI¨

H¨.N.

0õ, 0 N,H-Hcr, Nrc, N N-o'YjLrN
The glycine ester of Cyclosporine A (SPI001203, 2.0 g, 1.59 mmole) was dissolved in anhydrous dichloromethane (25 mL) with boc-L-lysine (1.31 g, 3.78 mmole) and EDC
(0.75 g, 3.9 mmole), under an argon atmosphere at room temperature. The boc-L-lysine was prepared from the dicyclohexylamine salt (2.0 g in 50 mL ether) by extraction with cold potassium hydrogen sulfate solution (1 g in 50 mL water) followed by cold water (2x50 mL). The ether containing the boc-L-lysine was dried over sodium sulfate (5 g), filtered, concentrated and dried under high vacuum for one hour at room temperature. A
few crystals of DMAP were added to the mixture of EDC, boc-L-lysine, and the glycine ester of Cyclosporine A and the solution was allowed to stir for 4 hours at room temperature. The dichloromethane solution was extracted with DIUF water (50 mL), 5% sodium bicarbonate solution (50 mL), and with DIUF water (50 mL). After drying over sodium sulfate (10 g), the dichloromethane solution was filtered and concentrated under reduced pressure. The remaining white foam (3.01 g) was purified by flash column chromatography on silica gel (50 g), eluting with heptane/acetone (2:1). The product containing fractions were combined, concentrated under reduced pressure, and dried under high vacuum. The purified protected intermediate (2.34 g white solid, 92.8% yield) was placed in a flask under an argon atmosphere, which was cooled in an ice-water bath. Cold anhydrous 2 M hydrochloric acid in diethyl ether (20 mL) was added and the solution stirred for 8 hours (at 5 C). The mixture was slowly allowed to warm to room temperature overnight. After stirring for a total of 20 hours, the flask was cooled again in an ice-water bath for 30 minutes. The product was filtered and dried under high vacuum for 1 hour at room temperature and then at 50 C for 4 hours. The FlAwork11652\17690\SPEC\17690.spec without claimsll.doc experiment produced Cyclosporine A N-(L-lysine)-glycine ester, dihydrochloride trihydrate (SPI0022, 1.59 g, 73.9% yield) as a white solid.
11-1NMR (300 MHz, CDC13, NMR data is for the free base):
5 = 8.58 (d, 111, J= 9.3 Hz), 8.04 (d, 1H, J= 6 Hz), 7.80 (d, 1H, J= 6 Hz), 7.49 (d, 2H, J=
8.4 Hz), 5.70-4.6 (m, 17 H), 4.41 (m, 1H), 4.28 (dd, 1H, J= 17, 7.2 Hz), 3.67 (d, 1H, J=
17 Hz), 3.46 (s 3H), 3.4-2.8 (m, 16 H), 2.8-2.5 (m, 8H), 2.5-1.35 (m, 24H), 1.5-0.7 (m, 50H).
13C NMR (75 MHz, CDC13, NMR data is for the free base):
5 = 175.23, 173.77, 173.34, 172.75, 172.63, 171.34, 171.22, 170.94, 170.84, 170.91, 169.89, 169.70, 128.74, 126.67, 74.41, 58.82, 57.43, 55.91, 55.21, 54.81, 54.42, 50.17, 48.89, 48.31, 47.98, 44.78, 41.92, 40.82, 40.69, 39.44, 39.32, 27.19, 35.91, 34.88, 33.71, , 33.25, 33.12, 32.44, 31.83, 31.50, 30.38, 30.06, 29.81, 29.55, 25.14, 24.90, 24.52, 24.43, 24.00, 23.76, 21.93, 21.42, 21.29, 20.81, 19.84, 18.82, 18.32, 17.96, 17.86, 15.21, 10.10.
= CHN analysis:
Calculated for C7011128a2N14015-3H20: C 55.50, H 8.92, and N 12.74; found: C
58.28, H 8.98, and N 13.16.
HPLC analysis:
99.60% purity; r.t.= 14.763 min.; 80% acetonitrile/20% Tris base in DIUF
water; 1 mL/min; 60C; Synergi Hydro RP, 4u column (serial # 163383-7), 4.6x250 mm; 20 ul;
UV= 210 nm.
Melting point: 196.0-198 C (uncorrected) H:\work\1652 \I7690 \SPEC \ 17690.spec without claintsILdoc 5) SPI0023 fo fr `ii HN.....ik I
N
\
H
.....<...t N" H H. 1,1=3')\-10.

The glycine ester of Cyclosporine A (SPI001203, 7.50 g, 5.95 mmole) was dissolved in anhydrous dichloromethane (50 mL) with boc-L-proline (2.56 g, 11.90 mmole) and EDC
(2.28 g, 11.9 mmole), under an argon atmosphere at room temperature. A few crystals of DMAP were added to the mixture of EDC, boc-L-proline, and the glycin.e ester of Cyclosporine A and the solution was allowed to stir for 3 hours at room temperature.
The dichloromethane solution was extracted with DIUF water (50 mL), 5% sodium bicarbonate solution (2x50 mL), and with DIUF water (50 mL). After drying over sodium sulfate (10 g), the dichloromethane was filtered and concentrated under reduced pressure. The remaining white foam (9.50 g) was purified by flash column chromatography on silica gel (150 g), eluting with heptane/acetone (2:1 followed by 1:1). The product containing fractions were combined, concentrated under reduced pressure, and dried under high vacuum (7.94 g white solid, 91.7% yield) for 10 minutes at room temperature.
The purified protected intermediate (6.46 g) was placed in a flask under an argon atmosphere, which was cooled in an ice-water bath. Cold anhydrous 2 M
hydrochloric acid in diethyl ether (150 mL) was added and the solution stirred for 8 hours (at 5 C).
The mixture was slowly allowed to warm to room temperature overnight. After stirring for a total of 20 hours, the flask was cooled again in an ice-water bath for 30 minutes.
The product was filtered and dried under high vacuum for 30 minutes at room temperature. The Cyclosporine A N-(L-proline)-glycine ester, hydrochloride (5.17 g, 84.6% yield, and 90% purity by HPLC) was converted to the free base by dissolving the H:\work\1652\17690\SPEC\17690.spec without claimsadoc salt in DIUF water (25 mL) that contained sodium bicarbonate (1 g). The free base was extracted with dichloromethane (3x25 mL), which was dried over sodium sulfate (5 g), filtered and concentrated. The remaining off-white solid (5 g) was purified by filtration through silica gel (100 g), eluting with acetone. The product containing fractions were combined, concentrated under reduced pressure, and dried under high vacuum for minutes at room temperature. The hydrochloride salt was regenerated by dissolving the free base (3.8 g) in diethyl ether (25 mL) and adding it to telydrous 2M
hydrochloric acid (5 mL) in heptarie (50 mL), while cooling in an ice-water bath. After 20 minutes at 5 C, the white solid was filtered and dried under high vacuum for 6 hours at room temperature. The experiment produced Cyclosporine A N-(L-proline)-glycine ester, hydrochloride (SPI0023, 3.8 g) as a white solid.
1H NMR (300 MHz, CDC13):
8 = 14.20 (br s, 2H), 8.62 (d, 1H, J= 10 Hz), 8.06 (d, 1H, J= 6.9 Hz), 7.61 (d, 1H, J= 8.1 Hz), 7.48 (d, 1H, J= 9 Hz), 5.70-5.50 (m, 3H), 5.40-4.60 (m, 12H), 4.37 (m, 1H), 4.20 (d, 1H, J= 18 Hz), 3.97 (d, 1H, J= 18 Hz), 3.70 (m, 1H), 3.45 (s, 3H), 3.23-3.08 (m, 12H), 2.66 (s, 3H), 2.60 (s, 3H), 2.50-1.80 (m, 15H), 1.78-1.20 (m, 15H), 1.15-0.66 (m, 46H).
13C NMR (75 MHz, CDC13):
= 174.15, 173.49, 172.67, 172.59, 171.86, 171.20, 171.13, 171.02, 170.83, 169.68, 168.77, 167.55, 128.30, 127.10, 80.09, 75.58, 62.65, 59.35, 57.36, 55.53, 55.30, 54.78, 54.35, 53.60, 50.25, 50.09, 48.92, 48.18, 48.12, 44.62, 40.59, 40.02, 39.43, 39.30, 37.13, 35.88, 33.74, 33.07, 32.19, 32.01, 31.86, 31.50, 31.43, 30.43, 29.93, 29.72, 29.30, 29.16, 27.56, 26.04, 25.00, 24.86, 24.74, 24.39, 20.96, 19.81, 18.71, 18.26, 18.09, 17.85, 17.79, 15.09, 14.30, 10.00.
CHN analysis:
Calculated for C691-1122C1N13014: C 59.48, H 8.83, and N 13.07; found: C
59.84, H 9.02, and N 12.65.

11:\work\ 1652\17690 \SPEC\17690.spec without claimsn.doc HPLC analysis:
99.59% purity; r.t.= 10.613 min.; 85% acetonitaile/15% Tris base in DIUF
water; 1.2 mL/min; 60C; Synergi Hydro RP, 4u column (serial # 163383-7), 4.6x250 mm; 20 ul;
UV= 210 nm.
Melting point: 197.0-199 C (uncorrected) These prodrugs of cyclosporin of the present invention are effective in treating diseases or conditions in which macrocyclic immunosuppressants normally are used. These prodrugs are transformed within the body to release the active compound and enhances the therapeutic benefits of the macrocyclic immunosuppressants by reducing or eliminating biopharmaceutical and pharmacokenetic barriers associated with each of them. However it should be noted that these prodrugs themselves will have sufficient activity without releasing any active drug in the mammals. Since the prodrugs are more soluble in water then cyclosporine or other macrocyclic immunosuppressants, it does not need to be associated with a carrier vehicle, such as alcohol or castor oil which may be toxic or produce unwanted side reactions. Moreover, oral formulations containing the prodrugs of the prodrugs are absorbed into the blood and are quite effective.
Thus, the prodrug of cyclosporin of the present invention enhances the therapeutic benefits by removing biopharmaceutical and pharmacokenetic barriers of existing drugs.
Furthermore, the prodrugs are easily synthesized in high yields using reagents which are readily and commercially available.
VI. Valproic Acid Esters Valproic acid (2-Propylpentanoic acid) is low molecular weight carboxylic acid derivative which is widely used as an anti-convulsive agent, useful in the treatment of epilepsy and also possess vasodilatation activity in the brain to relieve migraine H:\work\1652\17690\SPEC\17690.spec without claimsIl.doc headaches. It is administered orally to control epileptic episodes in humans and also alleviate severe pain associated with migraine headaches.

OH
o VALPROIC ACID
Valproic acid has been shown to have a large number of therapeutic applications, which are quite varying and somewhat surprising. For example, in addition to its efficacy in the treatment of epilepsy and migraine headaches, it has been shown to be effective in the treatment of certain psychiatric illnesses, such as bipolar disorder, mood stabilization, control of aggression, impulsivity in personality disorder, agitation in dementia, and has also been of use as adjunct therapy in the treatment of post traumatic stress disorder (PTSD).
Mechanism of Action:
In spite of being used in the treatment of epilepsy for a number of years, the exact mechanism of action of Valproic acid is still unknown. It has been postulated that it exerts its action by increasing concentration of gamma-amino butyric acid (GABA) in the brain. Gamma-amino butyric acid is a neurotransmitter, a chemical that nerves use to communicate with one another.
Valproate is the drug of choice in myoclonic epilepsy, with or without generalized tonic-clonic seizures, including juvenile myoclonic epilepsy of Janz that begins in adolescence or early adulthood. Photosensitive myoclonus is usually easily controlled.
Valproate also is effective in the treatment of benign myoclonic epilepsy, postanoxic myoclonus, and, with clonazepam, in severe progressive myoclonic epilepsy that is characterized by tonic-clonic seizures as well. It also may be preferred in certain stimulus-sensitive (reflex, startle) epilepsies.

11:\work\1652\17690\SPEC\17690.spee without clainisII.doc Although Valproate may be effective for infantile spasms; it is relatively contraindicated in children whose spasms are due to hyperglycinemia or other underlying metabolic (mitochondrial) abnormalities. In general, atonic and akinetic seizures in patients with Lennox-Gastaut syndrome are difficult to control, but Valproate is the drug of choice for treatment of mixed seizure types. Since this drug has been useful in some patients who are refractory to all other antiepileptic drugs, it may warrant a trial in nearly all nonresponsive patients regardless of seizure type.
In spite of it usefulness, hepatotoxicity may be fatal, but is idiosyncratic and not preventable by routinely monitoring liver enzymes. Hepatotoxicity occurs in very young children, most often those on multiple anticonvulsants. Valproate-induced cytopenias may be dose-related and warrant monitoring of complete blood counts during therapy.
Encephalopathy with hyperammonemia without liver function test abnormalities may occur. Pregnant women in first month are at risk for neural tube defects.
Valproic acid is a low molecular weight liquid with characteristic odor. Taken orally it has unpleasant taste and can severely irritate mouth and throat. In order to convert Valproic acid into a solid dosage form convenient for oral administration, a number of derivatives with covalent and ionic bond with the carboxylic acid have been made. A
simple sodium salt of Valproic acid, resulting in Valproate sodium is available as a solid.
However a stable coordination complex, know as Divalproex sodium was formed by partial neutralization of two molecules of Valproic acid with one atom of sodium. This product is the most widely available Valproic acid hemi salt marketed by Abbott Laboratories in the USA under the brand name Depakote . Depakote is also available in extended release formulation for oral administration.
A significant disadvantage of Valproic acid is that it in liquid form it is difficult to administer. Furthermore, administration of Valproic acid in different forms does not uniformly produce desired bioavailability. For example, the overall bioavailability of Valproate from Valproic acid, its sodium salt, Divalproex , and their extended release 11:\work\1652\176901SPEC\17690.spec without claimsII.doc formulations are not quite interchangeable. Since continuous monitoring of plasma profile of Valproic acid is essential, any change in plasma concentration due to changes in the formulation adversely affect overall therapeutic outcome.
In order to improve the therapeutic effectiveness, uniform blood profile, develop pharmaceutically elegant formulation and reduce first pass metabolism, present invention discusses prodrugs of Valproic acid which overcome some of the difficulties stated above.
Until now there has been no pharmaceutical preparation has been available in the market that can deliver Valproic acid with out harmful side effects. The present inventior.
however, has produced a number of water soluble, non-toxic derivatives of Valproic acid which are suitable for delivering Valproic acid consistently in the body without any harmful side effects and without the needs for expensive additives, and exepients.
Accordingly, in one aspect, the present invention is directed to a class of prodrugs of Valproic acid. The prodrug consists of the hydroxyl group of an amino acid esterified to the free carboxyl group present on the Valproic acid molecules. In another embodiment, the amine group of the amino acid is reacted with COOH group to form an amide linkage.
More specifically, an embodiment of the present invention is directed to, the compounds of the formula HC
VALPROIC ACID

1-1:\work\1652\17690\SPEC\17690.spec without claimsII.doc or pharmaceutically acceptable salts thereof; wherein R is either NH-AA or 0-AA and AA is an amino acid, in which either an amine group or the hydroxyl group is reacted_ with the carboxylic acid group of Valproic Acid.
The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of the various Valproic acid prodrugs above and a pharmaceutical carrier therefor.
In another embodiment, the present invention is directed to a method of treating a patient in need of Valproic acid therapy, which method comprises administering to said patient an effective amount of the Valproic acid.
In a further embodiment, the present invention is directed to a method of converting liquid Valproic acid into a solid powder by reacting the carboxyl functionality of the Valproic acid with either amine or hydroxyl functionality of an amino acid and isolating the products thereof.
In a still further embodiment, the present invention is directed to a method of substantially and in a therapeutically efficacious manner, reducing or eliminating the potential first pass metabolism thereby improving the consistent therapeutic effect by administering to a patient a prodrug which comprises reacting the COOH
functionality of the Valproic acid molecule with either NH2 or OH functionality of selected amino acids to form an ester or amide covalent bond respectively and isolating the product thereof and administering said product to the patient.
It has been found that when unsubstituted naturally occurring amino acids are esterified to Valproic acid, the resulting prodrugs are pharmaceutically elegant free flowing powders, and are rapidly absorbed into the body and release non-toxic amino acids upon cleavage in the body and require none of the emulsifiers, additives and other exepients.

H:\work\1652\17690\SPEC\17690.spec without clainisadoc Furthermore, it has been shown +11it the current invention also produced drugs, while they are prodrugs of Valproic acid; they were highly effective anti-epileptics and were exhibiting such effect intact. Thus the current amino acid prodrugs are effective anti-epileptics and useful in the treatment of a number of psychiatric illnesses and exhibit such potential with or without releasing the active parent drug.
The Valproic acid prodrug bulk density is much higher than the corresponding sodium salts, and they are suitable for compacting large weight tablets and capsules.
Furthermore, their do not exhibit bitter taste and unusual odor of the Valproic acid.
While the prodrugs my invention are not supposed to possess any acidic activity due to blockage of the carboxylic acid group responsible for such, however it has been shown that the prodrugs are effective anti-epileptics with or without releasing Valproic acid.
However, all of the Valproic acid prodrugs described are released in vivo the active drug with all its pharmacological and psychoactive properties.
The prodrug of Valproic acid clearly provides a number of advantages over Valproic acid, for example, all of the side chains cleaved from these prodrugs are naturally occurring essential amino acids hence are non-toxic. This results in high therapeutic index. Secondly all the prodrugs are readily cleaved in the body to release Valproic acid.
Furthermore, due their high water solubility, they can be easily administered by either forming an in-situ solution just before IV administration using lyophilized sterile powder or providing the drug in solution in prefilled syringe or bottles for infusion. The aminoacid esters are more stable than Valproic acid since COOH group in Valproic acid is blocked to reaction with bases. Thus the Valproic acid prodrugs invented here are more effective then Valproic acid itself without the toxicity and other pharmaceutical problems associated with current marketed formulations.
The procedure for the synthesis of the L-serine, L-threonine, and L-hydroxyproline 30= esters of valproic acid (2-propylpentanoic acid) is outlined in Synthetic Sequence FlAwork\1652\17690\SPEC\17690.speo without claiinsIl.doc section and is exemplary for alai preparation of the various prodrugs of the present invention. The complete procedure and analytical data is given in the Experimental Section. In general, valproic acid (2-8 g, in batches) was coupled with the N-benzyloxy/benzyl ester protected amino acids using EDC in the presence of a catalytic amount of DMAP. Once the reactions were complete (20 hours at room temperature), the mixture was extracted with DIUF water, dried over sodium sulfate, and concentrated under reduced pressure. The crude material was either used directly for the deprotection step or purified by column chromatography. The procedure generated the protected amino acid esters of valproic acid in yields ranging from 72% to 92%. The protecting groups were removed by hydrogenation (30 psi H2) in the presence of 10%
palladium on carbon. The amino acid esters of valproic acid were extracted away from the palladium catalyst with ethanol, concentrated, and dried. The final salts were formed by acidification with hydrochloric acid. The crude salts (yields ranging from 57%
to 92%) were then purified by the methods described in the Experimental Section.

H:\wor1\1652\17690\SPEC\17690.spec without claiins11.doc Synthetic Sequence:
1. SPIC001 O o o 4. HO.---CLOBz1 a" b) 1L'O 0 -4 OH ,.. r IYICE3zI YCH
z c) H c.
,N
H 'cbz H I H
CI
H
Valproic acid Z-Ser-OBzI SPIC00101 SPIC001 2. SPIC002 O 0 li + r r .crioszi cyLoBzi b) N
\cbz a) )((:) N

k.

0,tcr-koH
N
H
Valproic acid Z-Hyp-OBzI SPIC00201 SPIC002 3. SPIC003 a) ecm + HO;"¨jOM ....:bz ----"-H c II, 1 0 0:0Bz1 b) N
Hõcbz c) ( H I H -H Cl Valproic acid 2-Thr-OBzI SPIC00301 SPIC003 Synthesis of the L-serine, L-threonine, and L-hydroxyproline esters of valproicacid: a) EDC, DMAP, CH2C12; b) H2, 10% Pd/C, Et0H, Et0Ac; c) HC1.
, H:\work\1652\17690\SPEC\17690.spec without claiinsILdoc Experimental Section:
The synthesis of SPIC001, SPIC002 and SPIC003 was conducted in one or two batches. Reagents mentioned in the experimental section were purchased at the highest obtainable purity from Lancaster, Sigma-Aldrich, Acros, or Bachem, except for solvents, which were purchased from either Fisher Scientific or Mallinkrodt.
1) SPIC001: 2-Propylpentanoic acid 2(S)-amino-2-carboxy-ethyl ester, hydrochloride (L-Serine-valproic acid ester, hydrochloride) A mixture of 2-propylpentanoic acid (valproic acid, 6.48 g, 44.93 mmole), N-carbobenzyloxy-L-serine benzyl ester (Z-Ser-OBz1, 14.80 g, 44.93 mmole), EDC
(8.61 g, 44.91mmole), and DMAP (549 mg, 4.49 mmole) in anhydrous dichloromethane (50 mL) was stirred under an argon atmosphere at room temperature for 20 hours.
After 20 hours, the dichloromethane was washed with water (3x50 mL), dried over magnesium sulfate (5 g), filtered and concentrated under reduced pressure. The remaining colorless oil (20.87 g) was purified by column chromatography on silica gel (150 g, 0.035-0.070 mm, 6 nm pore diameter), eluting with hexanes/ethyl acetate (3:1). After concentration of the product containing fractions under reduced pressure and drying under high vacuum until the weight was constant, the experiment produced the protected L-serine-valproate ester SPIC00101 (18.9 g, 92% yield) as a colorless oil.

o HNsr0 SPIC00101 0 A ik H:\work\1652\17690\SPEC\17690.spec without clairnsILdoc IHNMR (300 MHz, DMS0): 8 = 7.96 (1H, d, J= 8.1 Hz), 7.35 (10H, m), 5.14 (2H, s), 5.05 (2H, s), 4.51 (1H, m), 4.29 (2H, m), 2.29 (1H, m), 1.50-1.25 (4H, m), 1.25-1.10 (4H, m), 0.80 (6H, t, J= 6.6 Hz).
13C NMR (75 MHz, DMS0): 8 = 174.88, 169.15, 155.85, 136.58, 135.45, 128.26, 128.18, 127.47, 127.71, 127.57, 66.32, 65.66, 62.47, 53.09, 44.20, 33.86, 33.79, 19.95,

13.85.
The protected L-serine-valproate ester SPIC00101 (18.9 g, 41.48 mmole) was dissolved in ethanol (60 mL) and ethyl acetate (60 mL) at room temperature and added to a Parr bottle (500 mL) that contained 10% palladium on carbon (3.0 g, 50% wet) under a nitrogen atmosphere. The nitrogen atmosphere was replaced with hydrogen gas (30 psi).
After 4 hours of shaking, additional palladium catalyst (1.0 g) in ethanol\ethyl acetate (1:1, 100 mL) was added and the reaction mixture shook overnight under hydrogen gas (30 psi) at room temperature. After 24 hours the catalyst was removed by filtration through a thin layer of activated carbon. The ethanol and ethyl acetate were concentrated under reduced pressure at room temperature. After drying under high vacuum, the remaining solids were acidified with hydrochloric acid in diethyl ether (2M, 24.6 mL).
The mixture was stored in a refrigerator for two hours before filtration and washing with additional cold diethyl ether (10 mL). After filtration, the remaining white solid was dried at room temperature under high vacuum until the product weight was constant (24 hours). The experiment produced L-serine-valproic acid ester, hydrochloride (6.34 g, 57% yield) as a white solid.

N
I 1-1 Cl FlAwork\1652\17690\SPEC\17690.spec without claimsII.doc 1HNMR (300 MHz, DMS0): 8 = 8.73 (br s, 3H), 4.47 (dd, 111, J= 12.9, 4.5 Hz), 4.31 (dd, 2H, J= 12.9, 3.6 Hz), 2.36 (m, 1H), 1.50 (m, 2H), 1.39 (m, 2H), 1.20 (m, 4H), 0.84 (t, 6H, J= 7 Hz).
13C NMR (75 MHz, DMS0): 8 = 174.67, 168.19, 61.84, 51.16, 44.12, 33.76, 33.58, 20.07, 19.92, 13.97, 13.89.
HPLC analysis:
98.49% purity; rt= 4.767 min; Luna C18 5u column (sn 167917-13); 4.6x250 mm;

nm; 33% ACN/66% DIUF water; 35 C; 20 ul inj.; lml/min; 20 mg/mL sample size;
sample dissolved in mobile phase.
CHN analysis:
calc.: C 49.34, H 8.28, N 5.23; found: C 49.22, H 8.35, N 5.24.
Melting point: 159-160 C
2) SPIC002: 4(R)-(2-Propyl-pentanoyloxy)-pyrrolidine-2(S)-carboxylic acid (L-Hydroxyproline-valproic acid ester) A mixture of 2-propylpentanoic acid (valproic acid, 4.32 g, 30 mmole), N-carbobenzyloxy-L-hydroxyproline benzyl ester (Z-Hyp-OBz1, 10.66 g, 30 mmole)', EDC (5.74 g, 30 mmole), and DMAP (366 mg, 3 mmole) in anhydrous dichloromethane (30 mL) was stirred under an argon atmosphere at room temperature for 20 hours. After 20 hours, the dichloromethane was washed with water (3x30 mL), dried over magnesium sulfate (5 g), filtered and concentrated under reduced pressure. The remaining colorless oil SPIC00201 (11.95 g, 24.7 mmole, 82.4% yield) was used without purification.

11:\work\1652\17690\SPEC\17690.spec without claimsll.doc 0 ,,,CYLO
0 *I

1H NMR (300 MHz, CDC13): = 7.29 (10H, m), 5.28-5.00 (5H, m), 4.55 (1/2H, t, J--= 8 Hz), 4.46 (1/2H, t, J= 8 Hz), 3.80-3.60 (2H, m), 2.43-2.16 (3H, m), 1.60-1.45 (2H, m), 1.40-1.32 (2H, m), 1.28-1.20 (4H, m), 0.86 (6H, m).
13C NMR (75 MHz, DMS0): 8 = 174.74, 171.40, 171.05, 153.79, 153.31, 136.34, 136.20, 135.57, 135.38, 128.24, 128.13, 127.95, 127.87, 127.67, 127.52, 127.28, 127.10, 72.29, 71.53, 66.34, 66.10, 57.66, 57.19, 52.27, 51.89, 44.13, 40.33, 35.78, 34.79, 34.04, 33.92, 33.35, 20.00, 19.91, 13.79, 13.73.
The protected L-hydroxyproline-valproate ester SPIC00201 (17.24 g, 35.79 mmole) was dissolved in ethanol (50 mL) and ethyl acetate (100 mL) at room temperature and added to a Parr bottle (500 mL) that contained 10% palladium on carbon (3.5 g, 50%
wet) under a nitrogen atmosphere. The nitrogen atmosphere was replaced with hydrogen gas (30 psi). After 15 hours of shaking, the catalyst was removed by filtration through a thin layer of celite and activated carbon. The ethanol and ethyl acetate mixture was concentrated under reduced pressure at room temperature. After drying overnight under high vacuum at room temperature, the experiment produced L-hydroxyproline-valproic acid ester SPIC002 (9.2 g, 99.8% yield) as a white solid. In order to remove trace impurities, the zwitterion was purified by reverse-phase column chromatography (50 g ODS silica gel) in two batches. The zwitterion was placed on the column in DIUF water and eluted with mixture of DIUF water/methanol (2:1, 1:1, 1:2, 100% methanol).

11:\work\1652\17690\SPEC\17690,spec without claitnsEdoc The product containing fractions were combined, concentrated under reduced pressure at 20 C (or less), and dried under high vacuum at room temperature until the weight was constant (24 hours, 6.4 g white solid recovered).
0 +.0)LOH
Ns 1H NMR (300 MHz, CDC13): = 12.40 (br s, 1H), 8.32 (br s, 1H), 5.28 (m, 1H), 4.11 (t, 1H, Jr= 7.2 Hz), 3.59 (m, 1H), 3.34 (br d, 1H, Jr= 10.5 Hz), 2.50-2.22 (m, 3H), 1.62-1.50 (m, 2H), 1.50-1.32 (m, 2H), 1.32-1.19 (m, 4H), 0.88 (t, 6H, Jr= 7.2 Hz).
13C NMR (75 MHz, CDC13): 8 = 175.99, 173.35, 71.83, 59.56, 49.77, 45.08, 36.19, 34.51, 20.87, 14.31.
HPLC analysis:
99.20% purity; r.t.= 7.228 min.; 70% DIUF water/30% acetonitrile; 1 mL/min;
36.8C;
Luna C18, 5u column (serial # 167917-13), 4.6x250 mm; 22 ul injection; sample dissolved in mobile phase.
CHN analysis:
calc.: C 60.68, H 9.01, N 5.44; found: C 60.58, H 9.12, N 5.48.
Melting point: 179.0-180.0 C
3) SPIC003: 2-Propyl-pentanoic acid 2(S)-amino-2-carboxy-1(R)-methy1-ethy1 ester, hydrochloride FlAwork\1652\17690\SPEC\17690.spec without claimsII.doe (L-Threonine-valproic acid ester, hydrochloride) A mixture of 2-propylpentanoic acid (valproic acid, 4.32 g, 30 mmole), N-carbobenzyloxy-L-threonine benzyl ester (Z-Thr-OBz1, 10.30 g, 30 mmole), EDC
(5.74 g, 30 mmole), and DMAP (366 mg, 3.0 mmole) in anhydrous dichloromethane (30 mL) was stirred under an argon atmosphere at room temperature for 20 hours. After hours, the dichloromethane was washed with water (3x30 mL), dried over magnesium sulfate (5 g), filtered and concentrated under reduced pressure. The remaining colorless oil (13.44 g) was purified by column chromatography on silica gel (100 g, 0.035-0.070 mm, 6 nm pore diameter), eluting with hexanes/ethyl acetate (4:1).
After concentration of the product containing fractions under reduced pressure and drying under high vacuum until the weight was constant, the experiment produced the protected L-threonine-valproate ester SPIC00301 (12.65 g, 89.8% yield) as a colorless oil.
0 t: 0 -)L0).Y0 Ny O

111 NMR (300 MHz, CDC13): 8 = 7.40-7.05 (11H, m), 5.45 (1H, m), 5.17-5.02 (4H, m), 4.53 (1H, d, J= 9.6 Hz), 2.24 (1H, m), 1.58-1.40 (2H, m), 1.40-1.15 (9H, m), 0.86 (6H, m).
13C NMR (75 MHz, DMS0): ô = 174.24, 169.29, 156.48, 136.61, 135.34, 128.26, 128.20, 127.74, 127.67, 127.58, 69.04, 66.33, 65.78, 57.62, 44.50, 33.89, 33.80, 20.03, 19.91, 16.40, 13.87.

H:\work\1652\17690\SPEC\17690.spec without clairnsII.doc The protected L-threonine-valproate ester SPIC00301 (12.65 g, 26.9 mmole) was dissolved in ethanol (50 mL) and ethyl acetate (50 mL) at room temperature and added to a Parr bottle (500 mL) that contained 10% palladium on carbon (2.53 g, 50%
wet) under a nitrogen atmosphere. The nitrogen atmosphere was replaced with hydrogen gas (30 psi). After 20 hours the catalyst was removed by filtration through a thin layer of activated carbon, washing with ethanol (25 mL). The ethanol and ethyl acetate were concentrated under reduced pressure at room temperature. After drying under high vacuum, the remaining solids (6.13 g) were acidified with hydrochloric acid (3.1 mL
conc.) in DIUF water (50 mL). The solution was filtered a second time through activated carbon and dried overnight in a freeze-dryer. The experiment produced L-threonine-valproic acid ester, hydrochloride SPIC003 (6.52 g, 86.0 % yield) as a white solid.
The combined batches of the L-threonine-valproic acid ester, hydrochloride (8.8 g) were purified by crystallization form acetonitrile. After the salt was dissolved in hot acetonitrile (225 mL), the material was treated activated acrbon, filtered, and placed in a 5 C refrigerator overnight. The white solids were filtered after 18 hours, washed with cold acetonitrile (10 mL), and dried under high vacuum at room temperature until the product weight was constant (24 hours). The process recovered L-threonine-valproic acid ester, hydrochloride SPIC003 (6.82 g, 77.5 % recovery) as a white solid.

1-Bwork\1652\17690\SPEC\17690.spec without claimsILdoc OOH
H I H ¨
H CI

111NMR (300 MHz, DMS0): 8 = 8.71 (br s, 3H), 5.28 (m, 1H), 4.16 (d, 1H, J=
2.7Hz), 2.33 (m, 1H), 1.56-1.40 (m, 2 H), 1.37-1.27 (m, 5H), 1.21-1.13 (m, 4H), 0.84 (t, 6H, J=
6.6 Hz).
13C NMR (75 MHz, DMS0): 8 = 173.97, 168.19, 67.69, 55.42, 44.43, 33.95, 33.78, 20.07, 19.95, 16.54, 13.94.
HPLC analysis:
98.88% purity; r.t.= 4.864 min.; 70% DIUF water/30% acetonitrile; 1 mL/min;
40C;
Luna C18, 5u column (serial # 211739-42), 4.6x250 mm; 20 ul injection; sample dissolved in mobile phase.
CHN analysis:
calc.: C 51.15, H 8.59, N 4.97; found: C 51.29, H 8.59, N 4.98.
Melting point: 144 C
Solubility of the above esters wee determined in water at room temperature by dissolving excess of each of the drug and allowing them to settle for a few hours. The resulting solutions were centrifuged at 150Orpm for 3 min and the supernatant liquid was analyzed. It was shown that these esters possess solubility in water in excess of 50 mg/mL.

11:\work\1652\17690\SPEC\17690.spec without claimsII.doc There are a number of screening tests to determine the utility of the prodrugs created according to the disclosed methods. These include both in vitro and in vivo screening methods.
The in vitro methods include acid/base hydrolysis of the prodrugs, hydrolysis in pig pancreas, hydrolysis in rat intesetinal fluid, hydrolysis in human gastric fluid, hydrolysis in human intestinal fluid, and hydrolysis in human blood plasma. These assays are described in Simmons, DM, Chandran, VR and Portmann, GA, Danazol, Amino Acid Prodrugs: In Vitro and In Situ Biopharmaceutical Evaluation, Drug Development and Industrial Pharmacy, Vol. 21, Issue 6, Page 687, 1995,.
Prodrugs of Valproic acid of the present invention are effective in treating diseases or condidiotns in which Valproic acid normally are used. The prodrugs disclosed herein are transformed within the body to release the active compond and enhances the therapeutic benefits of the Valproic acid by reducing or eliminating biopharmaceutical and pharmacokinetic barriers associated with each of them. However it should be noted that these prodrugs themselves will have sufficient activity without releasing any active drug in the mammals.
Thus, the prodrug of the present invention enhances the therapeutic benefits by removing biopharmaceutical and pharmacokenetic barriers of existing drugs.
Furthermore, the prodrugs are easily synthesized in high yields using reagents which are readily and commercially available.
VII WATER SOLUBLE PRODRUGS OF FIBRIC ACID DERIVATIVES
Fibric acid derivatives are useful anti-hyperlipidemic drugs useful in the treatment of hyperlipidemia in mammals where the symptoms are elevated triglycerides, low HDL
(High density lipoproteins or "good" cholesterol, and elevated cholesterol.
Fibric Acid derivatives are also useful in reducing LDL (Low density lipoproteins, or "bad"

cholesterol). The general structure of the filmic acid analogs is represented below, where X is various mixed aliphatic and aromatic functionalities. Specific derivatives included in this formula are clofibric acid, fenofibric acid, ciprfibrate and gemfibrozil and the like.
X xl,L, OH

FIBRIC ACID ANALOGS
Typical examples of the chemical moiety X in the above structure are shown below.

=Ciprofibric Acid a a Clofibric Acid Çl cl 0, Fenofibric Acid o ei,3 Gemfibrozil H3c IT: \work\ 1652 \17690 \SPEC\17690.spec without claimsIl.doc Fibric acid analogs shown in the structure above have been shown to have a large number of therapeutic applications, which are quite varying and somewhat surprising.
Broadly, these derivatives are useful in the treatment dyslipidemia and dyslipoproteinemia. Dyslipidemia and dyslipoproteinemia are herein defined to include the group selected from hypercholesterolemia, abnormal and elevated levels of cholesterol, abnormal and elevated levels of LDL cholesterol, abnormal and elevated levels of total cholesterol, abnormal and elevated levels of plasma cholesterol, abnormal and elevated levels of triglycerides, hypertrigylceridaemia, abnormal levels of lipoproteins, abnormal and elevated levels of low density lipoproteins (LDLs), abnormal and elevated levels of very low density lipoproteins, abnormal and elevated levels of very low intermediate density lipoproteins, abnormal levels of high density lipoproteins, hyperlipidemia, hyperchylomicronemia, abnormal levels of chylomicrons, related disorders, and combinations thereof such as those described in The ILIB Lipid Handbook for Clinical Practice, Blood Lipids and Coronary Heart Disease, Second Edition, A. M. Gotto et al, International Lipid Information Bureau, New York, N.Y., 2000,.
Mechanism of Action:
The mechanism of action of Fibric acid derivatives seen in clinical practice have been explained in-vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor alpha (PPAR-alpha).
Through this mechanism, Fibric acid derivatives increase lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity).
The resulting fall in ttiglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due their susceptibility to oxidation), to large buoyant particles. These larger particles have greater affinity for cholesterol receptors and are catabolized rapidly. Activation of PPAR-alpha also induces an increase in the synthesis of apoproteins A-I, A-II, and HDL
cholesterol.

Fibric Acid derivatives are also useful in the treatment of gout, as they reduce serum uric acid levels in hyperurecemic patients.
Hyperlipidemia types include type I, type IIa, type Ilb, type III, type IV, and type V.
These types can be characterized according to the levels relative to normal of lipids (cholesterol and triglycerides) and lipoproteins described above. Different classifications are derived from Drug Facts and Comparisons, 52nd Edition (1998) page 1066 .
Many of the fibric acid derivatives when administered orally do not have sufficient bioavilability and absorption are variable, erratic and depended upon food. In fact absolute bioavialbility of many of the fibric acid derivatives is not possible since the prodrugs of fibric acids currently marketed as insoluble in water, hence a parenteral formuation is difficult or not available. Furthermore, since these drugs usually administered as esters, they are in fact prodrugs. These prodrugs have to be metabolized in the body to release active drug, which are the filmic acids. However, due to the ester formation of these drugs, they are quite insoluble in water, hence are difficult to formulate, and are not easily broken down in the body to release active drugs.
Many of the Fibric acid derivatives are low to medium molecular weight solids with characteristic odor. Taken orally it has unpleasant taste and can severely irritate mouth and throat. Taken with food provides more blood concentration compared to fasting.
This fed/fast difference in bioavailability is more pronounced when Filmic acid derivatives are compared against their corresponding prodrug derivatives.
Overall bioavailability has been reported anywhere between 40-60 and quite variable among patients.
One of the significant problems associated with currently marketed fibric acid derivatives being that when these prodrugs are cleaved in the body, they release the prodrug moiety, which themselves are highly toxic. For example, in the case of fenofibrate and gemfibrozil isopropyl alcohol is released as the esterase enzyme cleave the pro-moiety from the fenofibric acid. It is well know isopropanol is highly toxic when released into any of the mammalian tissues.
In order to improve the therapeutic effectiveness, uniform blood profile, develop pharmaceutically elegant formulation and improve the solubility of the drug in water, present invention discusses alternative prodrugs of Fibric acid derivatives which overcome many of the difficulties stated above.
Accordingly, in one aspect, the present invention is directed to alternate class of prodrugs of Fibric acid derivatives. The prodrug consists of the hydroxyl group of an amino acid esterffied to the free carboxyl group present on the Fibric acid derivatives molecules. In another embodiment, the amine group of the amino acid is reacted with COOH of the filmic acids to form an amide linkage.
More specifically, in one aspect of the present invention is directed to, the compounds of the formulas H><
tise FIBRIC ACID ANALOGS
where x is as defined hereinabove or pharmaceutically acceptable salts thereof; wherein R is either NH-AA or 0-AA and AA is an amino acid, in which either an amine group or the hydroxyl group is reacted with the carboxylic acid group of Fibric acid derivatives.

H:\work\1652\17690\SPEC\17690.spec without claimslicloc The present invention is also directed in an embodiment to a pharmaceutical composition comprising a therapeutically effective amount of the various Fibric acid derivatives prodrugs above and a pharmaceutical carrier therefor.
In another embodiment, the present invention is directed to a method of treating a patient in need of Fibric acid derivatives therapy, which method comprises administering to said patient an effective amount of the Fibric acid derivatives.
In a further embodiment, the present invention is directed to a method of converting liquid Fibric acid derivatives into a solid powder by reacting the carboxyl functionality of the Fibric acid derivatives with either amine or hydroxyl functionality of an amino acid and isolating the products thereof.
In a still further embodiment, the present invention is directed to a method of substantially and in a therapeutically efficacious manner, make the derivatives absorbed easily upon oral administration thereby improving the consistent therapeutic effect by administering to a patient a prodrug which comprises reacting the COOH
functionality of the Fibric acid derivatives molecule with either NH2 or OH functionality of selected amino acids to form an ester or amide covalent bond respectively and isolating the product thereof and administering said product to the patient.
It was determined that when unsubstituted naturally occurring amino acids are esterified to Fibric acid derivatives, the resulting prodrugs are pharmaceutically elegant free flowing powders, and are rapidly absorbed into the body and release non-toxic amino acids upon cleavage in the body and require none of the emulsifiers, additives and other exepients.
Furthermore, it has been found that the current invention also produced drugs, while they are prodrugs of Fibric acid derivatives; they were highly effective anti-hyperlipidemics and were exhibiting such effect intact. Thus the current amino acid prodrugs are H:\work\1652\17690\SPEC\17690.spec without claims11.cloc effective anti-hyperlipidemics and useful in the treatment of a number of high cholesterol related illnesses and exhibit such potential with or without releasing the active parent drug.
While the prodrugs of fibric acidn of the present invention are not expected to possess any acidic activity due to blockage of the carboxylic acid group responsible for such, however it has been shown that the prodrugs of fibric acid are effective anti-hyperlipidemics with or without releasing Fibric acid derivatives. However, all of the Fibric acid derivatives prodrugs described are released in vivo the active drug with all its pharmacological and cholesterol lowering properties.
The present invention clearly provides a number of advantages over Fibric acid derivatives, for example, all of the side chains cleaved from these prodrugs are naturally occurring essential amino acids hence are non-toxic. This results in high therapeutic index. Secondly all the prodrugs are readily cleaved in the body to release Fibric acid derivatives. Furthermore, due their high water solubility, they can be easily administered by either forming an in-situ solution just before IV administration using lyophilized sterile powder or providing the drug in solution in prefilled syringe or bottles for infusion. The aminoacid esters are more stable than Fibric acid derivatives since COOH
group in Fibric acid derivatives is blocked to reaction with bases. Thus the Fibric acid derivatives prodrugs described here are more effective then Fibric acid derivatives itself without the toxicity and other pharmaceutical problems associated with current marketed formulations.
The prodrugs of this invention are anti-hyperlipidemic drugs useful in the treatment of hyperlipidemia in mammals where the symptoms are elevated triglycerides, low HDL
(High density lipoproteins or "good" cholesterol, and elevated cholesterol.
Fibric Acid derivatives are also useful in reducing LDL (Low density lipoproteins, or "bad"
cholesterol).

H:\work\1652\17690\SPEC\17690.spec without clahnsil.doc Typical examples of synthesis of L-threonine, L-hydroxyproline and L-serine esters of Fibric acid derivatives are shown in the synthetic processes outlined below.
These procedures are applicable to all other compounds of the Fibric acid derivatives class as well.
Synthesis of Fibric acid derivatives Prodrugs The procedure for the synthesis of the L-serine, L-threonine, and L-hydroxyproline esters of fenofibric acid is outlined in Synthetic Sequence section and is exemplary.
The complete procedure and analytical data is given in the Experimental Section. In general, fenofibric acid (100 g batches) was prepared from 4-chloro-4'-hydroxybezophenone in accordane with the procedures in the literature.
Fenofibric acid was coupled with the t-butyl esters of N-Boc protected amino acid (L-serine, L-threonine, and L-hydroxyproline) using EDC as the coupling agents and a catalytic amount of DMAP. The protecting groups were removed at low temperature (5 C, 3-days) with a mixture of hydrochloric acid in acetic acid (1M) with dichloromethane.
The amino acid ester salts of fenofibric acid were purified by crystallization from ethyl acetate, and dried under high vacuum.
Synthetic Sequence:

H:\work\1652\17690\SPEC\17690.spec without claimsII.doc D
0 to + A + CHID. + Na0N
a OH
V

ci 1><TrOH

Fenotibric Acid o \Nõ, [ b ,ti 0 0 ci Itill 110 oXi -,----iir -.),_ CI 110 itill oxõ...e.
N
o I µ
o SP1130D20101 H A )4, 0 '14 0 SPI130020301 )Cr-C 0I 11 I 1110 xe0 ' 0 1 d - II ri µ-l<
o i SPI90020201 d o 0 H CI-H,4,_H i d 0.
01 AO ISO y....r. µ on 01 0 ni 0 CI- o .1.1 o H
H..4..H a-SP1800201 ur ir Off SPIB00203 CI
o i O

Synthesis of the L-serine, L-threonine, and L-hydroxyproline esters of fenofibric acid: a) Boc-Ser-OtBu, EDC, DMAP, CH2C12; b) Boc-Thr-OtBu, EDC, DMAP, CH2C12; c) Boc-Hyp-OtBu, EDC, DMAP, CH2C12; d) HC1, AcOH, CH2C12.
, H:\work\1652\17690\SPEC\17690.spec without clairnsII.doe Experimental Section:
The synthesis of SPIB00201, SPIB00202 and SPIB00203 was conducted in one or two batches. Reagents mentioned in the experimental section were purchased at the highest obtainable purity from Lancaster, Sigma-Aldrich, Acros, or Bachem, except for solvents, which were purchased from either Fisher Scientific or Mallinkrodt.
1) Synthesis of fenofibric acid:
C1OOOfOH

A mixture of 4-chloro-4'-hydroxybezophenone (116 g, 0.500 mole) and sodium hydroxide (120 g, 3.00 mole) in acetone (1 L) was heated to reflux for 2 hours. The heating was stopped and the heating source was removed. A mixture of chloroform (179 g, 1.50 mole) in acetone (300 mL) was added drop-wise. The reaction mixture was stirred overnight without heating. The mixture was heated to reflux for 8 hours and then allowed to cool to room temperature. The precipitate was removed by filtration and washed with acetone (100 mL). The filtrate was concentrated under reduced pressure to give a brown oil. Water (200 mL) was added to the brown oil and was acidified (to pH=1) with 1N hydrochloric acid. The precipitate, which formed was filtered and dried under high vacuum. The remaining yellow solid (268 g) was recrystallized from toluene in 4 batches (400 mL toluene each). After filtration and drying under high vacuum, the experiment produced fenofibric acid (116 g, 73% yield) as a light yellow solid.
NMR (300 MHz, DMSO-d6): 6 = 13.22 (1H, s, br), 7.72 (4H, d, J= 8.4 Hz), 7.61 (2H, d, J= 7.8 Hz), 6.93 (2H, d, J= 7.8 Hz), 1.60 (6H, s).
I3C NMR (75 MHz, DMSO-d6): 8 = 192.96, 174.18, 159.35, 136.84, 136.12, 131.67, 131.02, 129.12, 128.43, 116.91, 78.87, 25.13.

H:\work\1652 \17690 \SPEC \17690.spec without clairnsli.doc 2) SPIB00201: L-serine-fenofibric acid ester To a mixture of fenofibric acid (11.6 g, 36.3 mmol), N-carbobenzyloxy-L-serine t-butyl ester (Boc-Ser-OtBu, 8.62 g, 33.0 mmol), EDC (7.59 g, 39.6 mmol), and DMAP
(484 mg, 3.96 mmol) cooled in an ice-water bath was added anhydrous dichloromethane (150 mL) dropwise. After the addition was complete, the ice bath was removed and the reaction mixture was stirred under an argon atmosphere at room temperature for hours. After 20 hours, the additional dichloromethane (200 mL) was added and the solution was washed with water (2x200 mL) and brine (200 mL). After drying over sodium sulfate and filtration, the solution was concentrated under reduced pressure. The remaining yellow oil (21.2 g) was purified by column chromatography on silica gel (400 g, 0.035-0.070 mm, 6 nm pore diameter), eluting with heptane/ethyl acetate (3:1). After concentration of the product-containing fractions under reduced pressure and drying under high vacuum until the weight was constant, the experiment produced the protected L-serine-fenofibric acid ester SPIB0020101 (16.2 g, 87% yield) as a light yellow oil.
o o _ 10 =
o 1HNMR (300 MHz, CDC13): = 7.75 (2H, d, J= 9.0 Hz), 7.72 (211, d, J= 9.0 Hz), 7.45 (2H, d, J= 8.7 Hz), 6.86 (2H, d, ./.= 8.7 Hz), 5.04 (1H, d, J= 6.9 Hz), 4.55-4.42 (3H, m), 1.66 (3H, s), 1.65 (3H, s), 1.43 (9H, s), 1.39 (9H, s).
13C NMR (75 MHz, CDC13): 8 = 193.92, 172.99, 168.07, 159.24, 154.87, 138.24, 136.19, 131.94, 131.06, 130.40, 128.41, 117.26, 82.88, 80.13, 79.24, 65.44, 53.44, 28.27, 27.92, 25.70, 25.30.
To a stirred solution of the protected L-serine-fenofibric acid ester SPEB0020101 (16.2 g, 28.8 mmol) in anhydrous dichloromethane (100 mL) cooled to 5 C, under an argon atmosphere was added a solution of hydrogen chloride in acetic acid (400 mL, 1M, 400 H:\work\1652 \17690 \SPEC \17690.spec without claimsII.doc minol) drop-wise. The reaction mixture stirred for 3 days at 5 C. After three days the mixture was concentrated under reduced pressure and dried under high vacuum to remove acetic acid. To the remaining light yellow oil (24.7 g) was added ethyl acetate (100 mL). The solution was concentrated and dried a second time. To the remaining light yellow oil (17.0 g) was added ethyl acetate (65 mL). The mixture was heated to reflux for 5 minutes and cooled to room temperature. The precipitate was removed by filtration and dried under high vacuum overnight at room temperature, then at 43 C for one hour. The experiment produced the L-serine-fenofibric acid ester, hydrochloride SPLB00201 (7.66 g, 60% yield) as a white solid.
Cl 110 c>rOjirF1 1.-H OH
CI

NMR (300 MHz, DMSO-d6): 8 = 14.12 (1H, s, br), 8.77 (3H, s, br), 7.72 (411, m), 7.62 (2H, d, J= 8.4 Hz), 6.92 (2H, d, J= 9.0 Hz), 4.62 (1H, dd, .,T= 12.0, 4.2 Hz), 4.50 (1H, dd, J= 12.0, 2.4 Hz), 4.41 (1H, m), 1.64 (3H, s), 1.63 (3H, s).
13C NMR (75 MHz, DMSO-d6): 8 = 193.06, 171.70, 168.06, 158.72, 136.93, 136.06, 131 .73, 131.09, 129.62, 128.49, 117.64, 79.02, 62.99, 51.11, 25.04, 24.94.
HPL,C analysis:
100% purity; r.t.= 4.361 min.; 55% TFA (0.1%), 45% ACN; 1 mL/min; 32.3 C, Luna C18, serial # 167917-13; 20 ul inj., NB275-49.
CHN analysis:
cale.: C 54.31, H 4.79, N 3.17; found: C 54.37, H 4.78, N 3.12.
Melting point: 151 C (dec.) H:\work\1652\17690\SPEC\17690.spec without claimsIl.doc 3) SPI1300202: L-threonine-fenofibric acid ester To a mixture of fenofibric acid (25.5 g, 79.9 mmol), N-carbobenzyloxy-L-threonine t-butyl ester (Boc-Thr-OtBu, 20.0 g, 72.6 mmol, prepared by the literature method), EDC
(16.7 g, 87.1 mmol), and DMAP (1.06 g, 8.71 mmol) cooled in an ice-water bath was added anhydrous dichloromethane (200 mL), dropwise. After the addition was complete, the ice bath was removed and the reaction mixture was stirred under an argon atmosphere at room temperature for 20 hours. After 20 hours, additional EDC
(1.39 g, 7.26 mmol) was added and the experiment was allowed to stir over the weekend at room temperature under an argon atmosphere. After 4 days, additional dichloromethane (300 mL,) was added and the solution was washed with water (300 mL) and brine (300 mL).
After drying over sodium sulfate and filtration, the solution was concentrated under reduced pressure. The remaining yellow oil (53.5 g) was purified by column chromatography on silica gel (500 g, 0.035-0.070 mm, 6 nm pore diameter), eluting with heptane/ethyl acetate (3:1). After concentration of the product-containing fractions under reduced pressure and drying under high vacuum until the weight was constant, the experiment produced the protected L-threonine-fenofibric acid ester SPIB0020201 (34.1 g, 82% yield) as a white foam.
H,o31--ok CI 1. 0 0 I ti 1H INIMR (300 MHz, CDC13): 6 = 7.74 (211, d, J= 8.4 Hz), 7.72 (2H, d, J= 8.4 Hz), 7.45 (2R, d, J= 8.4 Hz), 6.87 (2H, d, J= 8.4 Hz), 5.47 (1H, m), 4.98 (1H, d, .1-=
9.9 Hz), 4,31 (1R, d, J= 9.9 Hz), 1.65 (3H, s), 1.64 (3H, s), 1.45 (9H, s), 1.42 (9H, s), 1.22 (3H, d, 6.3 Hz).
13C NMR (75 MHz, CDC13): 8 = 193.94, 172.14, 168.70, 159.26, 155.62, 138.28, 136.18, 131.90, 131.08, 130.37, 128.43, 117.40, 82.70, 80.17, 79.38, 72.02, 57.46, 28.30, 27.99, 26.44, 24.79, 16.90.

1-1:\wor111652\17690\SPEC\17690.spec without clahnsil.doc To a stirred solution of the protected L-threonine-fenofibric acid ester (34.1 g, 59.2 mtnol) in anhydrous dichloromethane (100 mL) cooled to 5 C, under an argon atmosphere was added a solution of hydrogen chloride in acetic acid (600 mL, 1M, 600 mmol) drop-wise. The reaction mixture was kept for 6 days at 5 C. The mixture was concentrated under reduced pressure and dried under high vacuum to remove acetic acid. To the remaining white solid (45.8 g) was added ethyl acetate (500 mL). The mixture was heated to reflux for 10 minutes and cooled to room temperature.
The precipitate was removed by filtration and dried under high vacuum overnight at room temperature. The experiment produced the L-threonine-fenofibric acid ester, hydrochloride SPD300202 (26.3 g, 97% yield) as a white solid.
Cl--CX/r H

1H NMR (300 MHz, DMSO-d6): 8 = 14.10 (1H, s, br), 8.84 (3H, s, br), 7.73 (4H, m), 7.63 (2H, d, J= 8.1 Hz), 6.89 (2H, d, J= 8.7 Hz), 5.44 (1H, m), 4.31 (1H, s), 1.64 (3H, s), 1.62 (3H, s), 1.38 (3H, d, J= 6.3 Hz).
13C NMR (75 MHz, DMSO-d6): 8 = 193.04, 171.00, 168.13, 158.76, 136.90, 136.08, 131.70, 131.06, 129.49, 128.48, 117.41, 78.99, 69.40, 55.21, 25.59, 24.22, 16.06.
HPLC analysis:
98.59% purity; r.t.= 4.687 min.; 55% TFA (0.1%), 45% ACN; 1 mL/min; 32.3 C, Luna C18, serial # 167917-13; 20 ul inj., NB275-49, DAD1 B, Sig--210.4, Ref=550,100.
CHN analysis:
calc.: C 55.27, H 5.08, N 3.07; found: C 54.98, H 5.13, N 3.03.
Melting point: 160.5 C (dec.) H:\work\1652\17690\SPEC\17690.spec without olaimsll.doc 4) SP1B00203: L-hydroxyproline-fenofibric acid ester To a mixture of fenodbric acid (24.9 g, 78.1 mmol), N-carbobenzyloxy-L-hydroxyproline t-butyl ester (Boc-Hyp-OtBu, 20.4 g, 71.0 mmole, prepared in accordance with the procedure in the literature), EDC (16.3 g, 85.2 mmol), and DMAP
(1.04 g, 8.52 rnmol) cooled in an ice-water bath was added anhydrous dichloromethane (200 mL) dropwise. After the addition was complete, the ice bath was removed and the reaction mixture was stirred under an argon atmosphere at room temperature for hours. After 20 hours, additional EDC (1.63 g, 8.52 nnnol) was added and the experiment was allowed to stir over the weekend at room temperature under an argon atmosphere. After 4 days the solution was washed with water (200 mL) and brine (200 mL). After drying over sodium sulfate and filtration, the solution was concentrated under reduced pressure. The remaining yellow oil (49.4 g) was purified by column chromatography on silica gel (500 g, 0.035-0.070 mm, 6 nm pore diameter), eluting with heptane/ethyl acetate (2:1). After concentration of the product containing fractions under reduced pressure and drying under high vacuum until the weight was constant, the experiment produced the protected L-hydroxyproline-fenofibric acid ester (26.4 g, 63% yield) as a colorless oil.
ci 0 \O

i\
NMR (300 MHz, CDC13): S = 7.76 (2H, d, J= 8.1 Hz), 7.73 (2H, d, J= 8.1 Hz), 7.46 (2H, d, J= 8.1 Hz), 6..84 (2H, d, J= 8.1 Hz), 5.32 (1H, m), 4.13 (0.38H, t, Je= 7.8 Hz), 4.00 (0.62H, t, J= 7.8 Hz), 3.67 (1.62H, m), 3.46 (0.38H, d, J=12.6 Hz), 2.29 (1H, m), 2.15 (1H, m), 1.68 (3H, s), 1.66 (3H, s), 1.44-1.38 (18H, m).

FlAwork\1652\17690\SPEC\17690.spec without clainisII.doc 13C NMR (75 MHz, CDC13): 8 = 193.88, 172.98, 171.14, 159.25, 153.48, 138.23, 136.16, 131.99, 131.08, 130.36, 128.44, 117.03, 116.91, 81.48, 80.32, 80.20, 79.19, 74.03, 73.26, 58.23, 51.88, 51.58, 36.33, 35.31, 31.92, 28.29, 28.00, 25.89, 24.95.
To a stirred solution of the protected L-hydroxyproline-fenofibric acid ester SPIB0020301 (26.0 g, 44.2 mmol) in anhydrous dichloromethane (100 mL) cooled to 5 C, under an argon atmosphere was added a solution of hydrogen chloride in acetic acid (450 mL, 1M, 450 mmol) drop-wise. The reaction mixture stirred for 4 days at 5 C.
After four days the mixture was concentrated under reduced pressure and dried under high vacuum to remove acetic acid. To the remaining yellow oil (31.5 g) was added ethyl acetate (200 mL). The mixture was sonicated and then concentrated under reduced pressure and dried under high vacuum. To the remaining white solid (23.2 g) was added ethyl acetate (300 mL). The ethyl acetate mixture was heated to reflux for 10 minutes and cooled to room temperature. The precipitate was removed by filtration and dried under high vacuum overnight at room temperature. The experiment produced the L-hydroxyproline-fenoftbric acid ester, hydrochloride SPII300203 (15.8 g, 76%
yield) as a white solid.
o ci 40 40 Xiroõ,,Qc_H OH

1H NMR (300 MHz, DMSO-d6): 8 = 14.07 (1H, s, br), 10.75 (1H, s, br), 9.40 (1H, s, br), 7.71 (4H, d, J= 8.1 Hz), 7.60 (2H, d, J= 8.1 Hz), 6.96 (2H, d, J= 8.1 Hz), 5.42 (1H, m), 4.24 (1H, t, J= 9.0 Hz), 3.61 (1H, dd, J= 13.2, 4.2 Hz), 3.28 (1H, d, J= 13.2 Hz), 2.35 (2H, m), 1.66 (3H, s), 1.64 (3H, s).
13C NMR (75 MHz, DMSO-d6): 8 = 193.00, 171.52, 169.14, 158.81, 136.87, 136.09, 131.81, 131.05, 129.48, 128.46, 117.28, 78.99, 73.79, 57.54, 50.23, 34.13, 25.69, 24.49.
HPLC analysis:

H:\work\1652\17690\SPEC\17690.spec without claimadoc 100% purity; r.t.= 8.369 min.; 60% DRJF water (0.1% TFA)/40% acetonitrile; 1 mL/min; 36.4 C; Luna Cl 8, 5u column (serial # 191070-3), 4.6x250 mm; 20 ul injection; DAD1 A, Sig =- 210.4, Ref= 550,100.
HPLC-MS (ESI): calculated: M+ = 431; found M+H= 432.3 Melting point: 187.5 C (dec.) Solubility of the above esters were determined in water at room temperature by dissolving excess of each of the drug and let them settle for few hours. The resulting solutions were centrifuged at 150Orpm for 3 min and the supernatant liquid was analyzed. It was shown that these esters possess solubility in water in excess of 50 mg/mL.
EXPERIMENTAL
Rats were checked for time zero tiiglyceride level in blood. Then the rats were set on high sugar diet, such as 30% surcorse in water for 1 week. Then at the end of 1 week, rats were tested for triglycerides, and were put on normal diet. From day 7-14 the rats were administered either test or control drug. Triglycerides were again tested on the 14th day in rat blood.
In the Fenofibrate (control) vs L-Serine Ester of Fenofibric acid (test drug), 3 rats each for each of the drug and control at equivalent doses of 50, 100 and 200 mg/kg were tested.
The results are shown below.

H: \work\ 1652 \17690\SPEC\17690.spec without claimsII.doc SUMMARY ¨ DOSE RANGE FINDING STUDY ¨ HYPOLIPIDEMIC
PROPERTY ¨ FENOFLBRATE AND ITS FORMULATION
Test Substance: L-Serine Ester of Fenofibric Acid Vehicle: 1% Tween 80 in milli Q -water Dose.
Test Item Animal No. Triglycerides (mg/di) Mg/kg) Day zero Day 7 Day 14 Vehicle 0 2 88 171 222 Reference control 7 110 204 62 Fenofibrate 100 8 115 195 69 --L-Serine Ester of 16 109 46 Fenofibric Acid 100 17 129 100 69 From the above results, it can be concluded the highly water soluble serine ester was effectively performed.
10 There are a number of screening tests to determine the utility of the prodrugs created according tio the disclosed methods. These include both in vitro and in vivo Iscreening methods.

H:\work\1652 \17690 \SPEC \17690.spec without claimsll.doc The in vitro methods include acid/base hydrolysis of the prodrugs, hydrolysis in pig pancreas hydrolysis in rat intestinal fluid, hydrolysis in human gastric fluid, hydrolysis in human intestinal fluid, and hydrolysis in human blood plasma. These assays are dscribed in Simmons, DM, Chandran, VR and Portmann, GA, Danazol Amino Acid Prodrugs: In Vitro and In Situ Biopharmaaceutical Evaluation, Drug Development and Industrial Pharmacy, Vol 21, Issue 6, Page 687, 1995.
The prodrugs of Fibric Acid of the present invention are effective in treating diseases or conditions in which Fibric acid derivatives normally are used. The prodrugs disclosed herein are transformed within the body to release the active compound and enhances the therapeutic benefits of the Fibric acid derivatices by reducing or eliminating biopharmaceutical and pharmacoldnetic barriers associated with each of them.
However it should be noted that these prodrugs themselves will have sufficient activity without releasing any active drug in the mammals.
Thus, the prodrug of the present invention enhances the therapeutic benefits by removing biopharmaceutical and pharmacokenetic barriers of existing drugs.
Furtheremore, the prodrugs are easily synthesized in high yields using reagents which are readily and commercially available.
The prodrugs of Fibric acid of the present invention are effective in treating diseases or conditions in which Fibric acid derivatives normally are used. The prodrugs disclosed herein are transformed within the body to release the active compound and enhances the therapeutic benefits of the Fibric acid derivatives by reducing or eliminating biopharmaceutical and pharmacokenetic barriers associated with each of them.
However it should be noted that these prodrugs themselves will have sufficient activity without releasing any active drug in the mammals.

Thus, the prodrug of fibric acid of the present invention enhances the therapeutic benefits by removing biopharmaceutical and pharmacokenetic barriers of existing drugs.
Furthermore, the prodrugs are easily synthesized in high yields using reagents which are readily and commercially available.
In the formula hereinabove and in the claims it is to be understood that the AA has the following definition in the following contents I I
1) ¨ C ¨NH ¨AA ¨
AA in this definition refers to the amino acid residue without an amino group either on the main chain or the side chain.
¨ ¨ 0 ¨AA ¨

2) AA in this definition is an amino acid residue less the hydroxy group on the side chain.
NH ¨ ¨ AA
3) 0 AA refers to an amino acid group without the carboxy group, either on the main chain or side group.

H:\work\1652\17690\SPEC\17690.spec without claimsadoc 4) OAA- This is a ester bond between the hydroxy group of the drug and the carboxy group of the amino acid either on the main chain or side chain. Thus, as written OAA is H

Ro wherein Ro is the side chain amino acid as defined hereinabove.
Alternatively, it may refer to an ester bond between the carboxy group of the drug and the hydroxy group on the side chain of those amino acids which have a hydroxy group thereon such as threonine, serine, hydroxyprofine, tyrosine and the like. The hydroxy group forms part of the ester linkage which is depicted hereinabove with O.
Thus, as written, the AA refers to an amino acid with a hydroxy group on the side chain, but as depicted OAAõ the AA is without the hydroxy group since the oxygen atom is depicted in the formula.
The scope of the claims shot'. ld not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
=

Claims (293)

1. A use of a compound for the preparation of a medicament, said compound being the product of the reaction between an amino acid or an acylating derivative thereof and a drug having a functionality group selected from the group consisting of hydroxy, amino, carboxy and an acylating derivative of said carboxy group under conditions effective to form a covalent bond between the drug and the amino acid, said drug being selected from the group consisting of of 5-HETE, Abacavir, Acarbose, Acebutolol, Acetaminophen, Adefovir, Albuterol, Alfaprostol acid, Amlodipine, Amoxicillin, Amphotericin B, Amprenavir, Arachidonic Acid, Aspirin, Atenolol, Atorvastatin, Atropine, Atovaquone, Baclofen, Benazeprilat, Beraprost, Betaxolol, Bexarotene, Bicalutamide, Biperiden, Bisoprolol, Bitolterol, Brinzolamide, Bupivacaine, Buprenorphine, Bupropion, Butorphanol, Candesartan, Capacitabine, Captopril, Carbidopa, Carboprost, Carnitine, Carteolol, Carvedilol, Cefdinir, Cefditoren, Ceftazidime, Cefpodoxime, Cefuroxime, Cerivastatin, Chloramphenicol, Cisapride, Clofibrate, Clopidogrel Acid, Cloprostenol, Clorazepic Acid, Cycloserine, Cyclosporine, Cytarabine, Dextroamphetamine, Diclofenac, Didanosine, Divalproex, Docetaxel, Dorzolamide, Dyphylline, Dysopyramide, Efavirenz, Enalaprilat, Ephedrine, Eplerenone, Eprosartan, Esmolol, Estramustine, Ethambutol, Ethchlorvynol, Ethosuximide, Ethotoin, Etidocaine, Etoposide, Ezetimibe, Famciclovir, Fenofibrate, Fenoprofen, Fenprostalene acid, Fexofenadine, Fibric acid derivatives, Finasteride, Flavoxate, Fluprostenol, Fluoxetine, Flurbiprofen, Fluticasone, Fluvastatin, Fosinoprilat, Frovatriptan, Fulvestrant, Gemprost Acid, Glimepiride, Goserelin, Hydroxychloroquine, Hydroxyzine, Hyoscyamine, Ibuprofen, Ibutilide, Indapamide, Indinavir, Ipratropium, Irinotecan, Isosorbide, Isradipine, Ketoprofen, Ketorolac, Labetalol, Lamivudine, Lansoprazole, Latanoprost Acid, Leukotrienes (LTA4, LTB4, LTC4, LTD4 and LTE4) Leuprolide, Levobunolol, Levodopa, Levorphanol, Limaprost, .gamma.-Linolenic Acid, Liothyronine, Lisinopril, Lopinavir, Lorazepam, Lovastatin, Medroxyprogesterone, Mefloquine, Megestrol, Mephobarbital, Mepivacaine, Metaproterenol, Metformin, Methamphetamine, Methohexital, Methotrexate, Methylphenidate, Methylprednisolone, Metolazone, Metoprolol, Mexiletine, Miglitol, Moexiprilat, Mometasone, Montelukast, Mycophenolate Acid, Nadolol, Nalbuphine, Naproxen, Naratriptan, Nateglinide, Nelfinavir, Niacin, Nicotinic Acid, Nicotinamide, Nicardipine, Nimidipine, Nisoldipine, Norgestimate, Octreotide, Ofloxacin, Olmesartan, Omeprazole, Ozagrel, Paclitaxel, Pantothenic Acid, Paroxetine, Pemoline, Penbutolol, Penciclovir, Pentazocine, Pentobarbital, Perindoprilat, Phenylephrine, Phenylpropanolamine, Pindolol, Pioglitazone, Pirbuterol, Pramipexole, Pravastatin, Propafenone, Propofol, Propoxyphene, Propranolol, Prostacyclin, Prostaglandins (E1, E2 and F2.alpha.), Prostanoic Acid, Pseudoephedrine, Quinacrine, Quinaprilat, Quinethazone, Quinidine, Quinine, Ramiprilat, Reboxetine, Repaglinide, Ribavirin, Ritonavir, Ropivacaine, Rosaprostol, Rosuvastatin, Salmeterol, Salsalate, Sertraline, Simavastatin, Sotalol, Sulfa Drugs, Sulfasalazine, Sumatriptan, Tacrolimus, Tazarotene, Telmesartan, Tenofovir, Terbutaline, Tiagabine, Timolol, Tirofiban, Tocainide, Tramadol, Trandolaprilat, Tranylcypromine, Treprostinil, Triamcinolone, Trimoprostil, Troglitazone, Unoprostone, Valproic Acid, Valsartan, Venlafaxine, Vidarabine, Warfarin, Zalcitabine, Zidovudine, Zileuton, Zolmitriptan and pharmaceutically acceptable salts thereof wherein the amino acid is L-Thr.

2. The use according to claim 1 wherein the compound is:

R8N=N-AA5-COOH, SULFO DRUG AZO DERIVATIVE , SULFA DRUG AMIDE DERIVATIVE
or a pharmaceutically acceptable salt thereof, wherein AA is an amino acid without the hydroxyl group on the carboxy group, R is NHAA or OAA1, CYCLO represents the residues at positions 2 ¨ 11 of a cyclosporin molecule;
AA1 is an amino acid without the hydroxy group on the carboxy group;
AA6 is an amino acid residue having a hydroxy group on the side less said hydroxyl group, and wherein AA6 is attached via an ester bond through its side chain hydroxy group;
R2 is R5 is AA2, AA2 is an amino acid residue less the hydroxy group on the carboxy group;
AA3 is an amino acid less the hydrogen atom on the amino group;
R6 is COAA1, R7 is O-AA1;
AA5 is an amino acid without the amino and carboxy group;
R8 is a sulfanilamide moiety of the general class of sulfa drugs; and R9 is NHAA or OAA6, and AA, AA1, AA2, AA3, AA5, and AA6 are Thr.

3. The use according to claim 2, wherein the compound has the formula

4. A compound which is the product from a reaction between a drug having a functionality selected from the group consisting of hydroxy, amino, carboxy or an acylating derivative of said carboxy group and an amino acid or an acylating derivative thereof under conditions sufficient to form a covalent bond from the reaction of said functional group and said amino acid or said compound, or the pharmaceutically acceptable salt thereof, wherein the drug is selected from the group consisting of 5-HETE, Abacavir, Acarbose, Acebutolol, Acetaminophen, Adefovir, Albuterol, Alfaprostol acid, Amlodipine, Amoxicillin, Amphotericin B, Amprenavir, Arachidonic Acid, Aspirin, Atenolol, Atorvastatin, Atropine, Atovaquone, Baclofen, Benazeprilat, Beraprost, Betaxolol, Bexarotene, Bicalutamide, Biperiden, Bisoprolol, Bitolterol, Brinzolamide, Bupivacaine, Buprenorphine, Bupropion, Butorphanol, Candesartan, Capacitabine, Captopril, Carbidopa, Carboprost, Carnitine, Carteolol, Carvedilol, Cefdinir, Cefditoren, Ceftazidime, Cefpodoxime, Cefuroxime, Cerivastatin, Chloramphenicol, Cisapride, Clofibrate, Clopidogrel Acid, Cloprostenol, Clorazepic Acid, Cycloserine, Cyclosporine, Cytarabine, Dextroamphetamine, Diclofenac, Didanosine, Divalproex, Docetaxel, Dorzolamide, Dyphylline, Dysopyramide, Efavirenz, Enalaprilat, Ephedrine, Eplerenone, Eprosartan, Esmolol, Estramustine, Ethambutol, Ethchlorvynol, Ethosuximide, Ethotoin, Etidocaine, Etoposide, Ezetimibe, Famciclovir, Fenofibrate, Fenoprofen, Fenprostalene acid, Fexofenadine, Fibric acid derivatives, Finasteride, Flavoxate, Fluprostenol, Fluoxetine, Flurbiprofen, Fluticasone, Fluvastatin, Fosinoprilat, Frovatriptan, Fulvestrant, Gemprost Acid, Glimepiride, Goserelin, Hydroxychloroquine, Hydroxyzine, Hyoscyamine, Ibuprofen, Ibutilide, Indapamide, Indinavir, Ipratropium, Irinotecan, Isosorbide, Isradipine, Ketoprofen, Ketorolac, Labetalol, Lamivudine, Lansoprazole, Latanoprost Acid, Leukotrienes (LTA4, LTB4, LTC4, LTD4 and LTE4) Leuprolide, Levobunolol, Levodopa, Levorphanol, Limaprost, .gamma.-Linolenic Acid, Liothyronine, Lisinopril, Lopinavir, Lorazepam, Lovastatin, Medroxyprogesterone, Mefloquine, Megestrol, Mephobarbital, Mepivacaine, Metaproterenol, Metformin, Methamphetamine, Methohexital, Methotrexate, Methylphenidate, Methylprednisolone, Metolazone, Metoprolol, Mexiletine, Miglitol, Moexiprilat, Mometasone, Montelukast, Mycophenolate Acid, Nadolol, Nalbuphine, Naproxen, Naratriptan, Nateglinide, Nelfinavir, Niacin, Nicotinic Acid, Nicotinamide, Nicardipine, Nimidipine, Nisoldipine, Norgestimate, Octreotide, Ofloxacin, Olmesartan, Omeprazole, Ozagrel, Paclitaxel, Pantothenic Acid, Paroxetine, Pemoline, Penbutolol, Penciclovir, Pentazocine, Pentobarbital, Perindoprilat, Phenylephrine, Phenylpropanolamine, Pindolol, Pioglitazone, Pirbuterol, Pramipexole, Pravastatin, Propafenone, Propofol, Propoxyphene, Propranolol, Prostacyclin, Prostaglandins (E1, E2 and F2.alpha.), Prostanoic Acid, Pseudoephedrine, Quinacrine, Quinaprilat, Quinethazone, Quinidine, Quinine, Ramiprilat, Reboxetine, Repaglinide, Ribavirin, Ritonavir, Ropivacaine, Rosaprostol, Rosuvastatin, Salmeterol, Salsalate, Sertraline, Simavastatin, Sotalol, Sulfa Drugs, Sulfasalazine, Sumatriptan, Tacrolimus, Tazarotene, Telmesartan, Tenofovir, Terbutaline, Tiagabine, Timolol, Tirofiban, Tocainide, Tramadol, Trandolaprilat, Tranylcypromine, Treprostinil, Triamcinolone, Trimoprostil, Troglitazone, Unoprostone, Valproic Acid, Valsartan, Venlafaxine, Vidarabine, Warfarin, Zalcitabine, Zidovudine, Zileuton, Zolmitriptan, and pharmaceutically acceptable salts thereof and wherein the amino acid is L-Thr.

5. The compound according to claim 4 which is:
R8N=N-AA5-COOH, SULFO DRUG AZO DERIVATIVE , SULFA DRUG AMIDE DERIVATIVE
or a pharmaceutically acceptable salt thereof, wherein AA is an amino acid without the hydroxyl group on the carboxy group, R is NHAA or OAA1, CYCLO represents the residues at positions 2 ¨ 11 of a cyclosporin molecule;
AA1 is an amino acid without the hydroxy group on the carboxy group;
AA6 is an amino acid residue having a hydroxy group on the side less said hydroxyl group, and wherein AA6 is attached via an ester bond through its side chain hydroxy group;
R2 is R5 is AA2, AA2 is an amino acid residue less the hydroxy group on the carboxy group;
AA3 is an amino acid less the hydrogen atom on the amino group;
R6 is COAA1, R7 is O-AA1;
AA5 is an amino acid without the amino and carboxy group;
R8 is a sulfanilamide moiety of the general class of sulfa drugs; and R9 is NHAA or OAA6, and AA, AA1, AA2, AA3, AA5, and AA6 are Thr.

6. The compound according to claim 5, wherein the compound has the formula

7. A pharmaceutical composition comprising a compound according to any one of claims 4 to 6 and a pharmaceutical carrier thereof.

8. Use of a compound for the preparation of a medicament for enhancing the bioavailability of a drug, said compound being the reaction product of an amino acid or an acylating derivative thereof with a drug having a functionality group selected from the group consisting of hydroxy, amino, carboxy or an acylating derivative of said caboxy group, said drug being selected from 5-HETE, Abacavir, Acarbose, Acebutolol, Acetaminophen, Adefovir, Albuterol, Alfaprostol acid, Amlodipine, Amoxicillin, Amphotericin B, Amprenavir, Arachidonic Acid, Aspirin, Atenolol, Atorvastatin, Atropine, Atovaquone, Baclofen, Benazeprilat, Beraprost, Betaxolol, Bexarotene, Bicalutamide, Biperiden, Bisoprolol, Bitolterol, Brinzolamide, Bupivacaine, Buprenorphine, Bupropion, Butorphanol, Candesartan, Capacitabine, Captopril, Carbidopa, Carboprost, Carnitine, Carteolol, Carvedilol, Cefdinir, Cefditoren, Ceftazidime, Cefpodoxime, Cefuroxime, Cerivastatin, Chloramphenicol, Cisapride, Clofibrate, Clopidogrel Acid, Cloprostenol, Clorazepic Acid, Cycloserine, Cyclosporine, Cytarabine, Dextroamphetamine, Diclofenac, Didanosine, Divalproex, Docetaxel, Dorzolamide, Dyphylline, Dysopyramide, Efavirenz, Enalaprilat, Ephedrine, Eplerenone, Eprosartan, Esmolol, Estramustine, Ethambutol, Ethchlorvynol, Ethosuximide, Ethotoin, Etidocaine, Etoposide, Ezetimibe, Famciclovir, Fenofibrate, Fenoprofen, Fenprostalene acid, Fexofenadine, Fibric acid derivatives, Finasteride, Flavoxate, Fluprostenol, Fluoxetine, Flurbiprofen, Fluticasone, Fluvastatin, Fosinoprilat, Frovatriptan, Fulvestrant, Gemprost Acid, Glimepiride, Goserelin, Hydroxychloroquine, Hydroxyzine, Hyoscyamine, Ibuprofen, Ibutilide, Indapamide, Indinavir, Ipratropium, Irinotecan, Isosorbide, Isradipine, Ketoprofen, Ketorolac, Labetalol, Lamivudine, Lansoprazole, Latanoprost Acid, Leukotrienes (LTA4, LTB4, LTC4, LTD4 and LTE4) Leuprolide, Levobunolol, Levodopa, Levorphanol, Limaprost, .gamma.-Linolenic Acid, Liothyronine, Lisinopril, Lopinavir, Lorazepam, Lovastatin, Medroxyprogesterone, Mefloquine, Megestrol, Mephobarbital, Mepivacaine, Metaproterenol, Metformin, Methamphetamine, Methohexital, Methotrexate, Methylphenidate, Methylprednisolone, Metolazone, Metoprolol, Mexiletine, Miglitol, Moexiprilat, Mometasone, Montelukast, Mycophenolate Acid, Nadolol, Nalbuphine, Naproxen, Naratriptan, Nateglinide, Nelfinavir, Niacin, Nicotinic Acid, Nicotinamide, Nicardipine, Nimidipine, Nisoldipine, Norgestimate, Octreotide, Ofloxacin, Olmesartan, Omeprazole, Ozagrel, Paclitaxel, Pantothenic Acid, Paroxetine, Pemoline, Penbutolol, Penciclovir, Pentazocine, Pentobarbital, Perindoprilat, Phenylephrine, Phenylpropanolamine, Pindolol, Pioglitazone, Pirbuterol, Pramipexole, Pravastatin, Propafenone, Propofol, Propoxyphene, Propranolol, Prostacyclin, Prostaglandins (E1 , E2 and F2.alpha.), Prostanoic Acid, Pseudoephedrine, Quinacrine, Quinaprilat, Quinethazone, Quinidine, Quinine, Ramiprilat, Reboxetine, Repaglinide, Ribavirin, Ritonavir, Ropivacaine, Rosaprostol, Rosuvastatin, Salmeterol, Salsalate, Sertraline, Simavastatin, Sotalol, Sulfa Drugs, Sulfasalazine, Sumatriptan, Tacrolimus, Tazarotene, Telmesartan, Tenofovir, Terbutaline, Tiagabine, Timolol, Tirofiban, Tocainide, Tramadol, Trandolaprilat, Tranylcypromine, Treprostinil, Triamcinolone, Trimoprostil, Troglitazone, Unoprostone, Valproic Acid, Valsartan, Venlafaxine, Vidarabine, Warfarin, Zalcitabine, Zidovudine, Zileuton, Zolmitriptan, and pharmaceutically acceptable salts thereof and wherein the amino acid is L-Thr.

9. Use of a compound for enhancing the bioavailability of a drug, said compound being the reaction product of an amino acid or an acylating derivative thereof with a drug having a functionality group selected from the group consisting of hydroxy, amino, carboxy or an acylating derivative of said caboxy group, said drug being selected from 5-HETE, Abacavir, Acarbose, Acebutolol, Acetaminophen, Adefovir, Albuterol, Alfaprostol acid, Amlodipine, Amoxicillin, Amphotericin B, Amprenavir, Arachidonic Acid, Aspirin, Atenolol, Atorvastatin, Atropine, Atovaquone, Baclofen, Benazeprilat, Beraprost, Betaxolol, Bexarotene, Bicalutamide, Biperiden, Bisoprolol, Bitolterol, Brinzolamide, Bupivacaine, Buprenorphine, Bupropion, Butorphanol, Candesartan, Capacitabine, Captopril, Carbidopa, Carboprost, Carnitine, Carteolol, Carvedilol, Cefdinir, Cefditoren, Ceftazidime, Cefpodoxime, Cefuroxime, Cerivastatin, Chloramphenicol, Cisapride, Clofibrate, Clopidogrel Acid, Cloprostenol, Clorazepic Acid, Cycloserine, Cyclosporine, Cytarabine, Dextroamphetamine, Diclofenac, Didanosine, Divalproex, Docetaxel, Dorzolamide, Dyphylline, Dysopyramide, Efavirenz, Enalaprilat, Ephedrine, Eplerenone, Eprosartan, Esmolol, Estramustine, Ethambutol, Ethchlorvynol, Ethosuximide, Ethotoin, Etidocaine, Etoposide, Ezetimibe, Famciclovir, Fenofibrate, Fenoprofen, Fenprostalene acid, Fexofenadine, Fibric acid derivatives, Finasteride, Flavoxate, Fluprostenol, Fluoxetine, Flurbiprofen, Fluticasone, Fluvastatin, Fosinoprilat, Frovatriptan, Fulvestrant, Gemprost Acid, Glimepiride, Goserelin, Hydroxychloroquine, Hydroxyzine, Hyoscyamine, Ibuprofen, Ibutilide, Indapamide, Indinavir, Ipratropium, Irinotecan, Isosorbide, Isradipine, Ketoprofen, Ketorolac, Labetalol, Lamivudine, Lansoprazole, Latanoprost Acid, Leukotrienes (LTA4, LTB4, LTC4, LTD4 and LTE4) Leuprolide, Levobunolol, Levodopa, Levorphanol, Limaprost, .gamma.-Linolenic Acid, Liothyronine, Lisinopril, Lopinavir, Lorazepam, Lovastatin, Medroxyprogesterone, Mefloquine, Megestrol, Mephobarbital, Mepivacaine, Metaproterenol, Metformin, Methamphetamine, Methohexital, Methotrexate, Methylphenidate, Methylprednisolone, Metolazone, Metoprolol, Mexiletine, Miglitol, Moexiprilat, Mometasone, Montelukast, Mycophenolate Acid, Nadolol, Nalbuphine, Naproxen, Naratriptan, Nateglinide, Nelfinavir, Niacin, Nicotinic Acid, Nicotinamide, Nicardipine, Nimidipine, Nisoldipine, Norgestimate, Octreotide, Ofloxacin, Olmesartan, Omeprazole, Ozagrel, Paclitaxel, Pantothenic Acid, Paroxetine, Pemoline, Penbutolol, Penciclovir, Pentazocine, Pentobarbital, Perindoprilat, Phenylephrine, Phenylpropanolamine, Pindolol, Pioglitazone, Pirbuterol, Pramipexole, Pravastatin, Propafenone, Propofol, Propoxyphene, Propranolol, Prostacyclin, Prostaglandins (E1, E2 and F2.alpha.), Prostanoic Acid, Pseudoephedrine, Quinacrine, Quinaprilat, Quinethazone, Quinidine, Quinine, Ramiprilat, Reboxetine, Repaglinide, Ribavirin, Ritonavir, Ropivacaine, Rosaprostol, Rosuvastatin, Salmeterol, Salsalate, Sertraline, Simavastatin, Sotalol, Sulfa Drugs, Sulfasalazine, Sumatriptan, Tacrolimus, Tazarotene, Telmesartan, Tenofovir, Terbutaline, Tiagabine, Timolol, Tirofiban, Tocainide, Tramadol, Trandolaprilat, Tranylcypromine, Treprostinil, Triamcinolone, Trimoprostil, Troglitazone, Unoprostone, Valproic Acid, Valsartan, Venlafaxine, Vidarabine, Warfarin, Zalcitabine, Zidovudine, Zileuton, Zolmitriptan, and pharmaceutically acceptable salts thereof and wherein the amino acid is L-Thr.

10. A method of enhancing the solubility in an aqueous solution of a drug having a functionality selected from the group consisting of hydroxy, amino, carboxy or an acylating derivative of said carboxy group comprising:
selecting said drug from the group consisting of 5-HETE, Abacavir, Acarbose, Acebutolol, Acetaminophen, Adefovir, Albuterol, Alfaprostol acid, Amlodipine, Amoxicillin, Amphotericin B, Amprenavir, Arachidonic Acid, Aspirin, Atenolol, Atorvastatin, Atropine, Atovaquone, Baclofen, Benazeprilat, Beraprost, Betaxolol, Bexarotene, Bicalutamide, Biperiden, Bisoprolol, Bitolterol, Brinzolamide, Bupivacaine, Buprenorphine, Bupropion, Butorphanol, Candesartan, Capacitabine, Captopril, Carbidopa, Carboprost, Carnitine, Carteolol, Carvedilol, Cefdinir, Cefditoren, Ceftazidime, Cefpodoxime, Cefuroxime, Cerivastatin, Chloramphenicol, Cisapride, Clofibrate, Clopidogrel Acid, Cloprostenol, Clorazepic Acid, Cycloserine, Cyclosporine, Cytarabine, Dextroamphetamine, Diclofenac, Didanosine, Divalproex, Docetaxel, Dorzolamide, Dyphylline, Dysopyramide, Efavirenz, Enalaprilat, Ephedrine, Eplerenone, Eprosartan, Esmolol, Estramustine, Ethambutol, Ethchlorvynol, Ethosuximide, Ethotoin, Etidocaine, Etoposide, Ezetimibe, Famciclovir, Fenofibrate, Fenoprofen, Fenprostalene acid, Fexofenadine, Fibric acid derivatives, Finasteride, Flavoxate, Fluprostenol, Fluoxetine, Flurbiprofen, Fluticasone, Fluvastatin, Fosinoprilat, Frovatriptan, Fulvestrant, Gemprost Acid, Glimepiride, Goserelin, Hydroxychloroquine, Hydroxyzine, Hyoscyamine, Ibuprofen, Ibutilide, Indapamide, Indinavir, Ipratropium, Irinotecan, Isosorbide, Isradipine, Ketoprofen, Ketorolac, Labetalol, Lamivudine, Lansoprazole, Latanoprost Acid, Leukotrienes (LTA4, LTB4, LTC4, LTD4 and LTE4) Leuprolide, Levobunolol, Levodopa, Levorphanol, Limaprost, .gamma.-Linolenic Acid, Liothyronine, Lisinopril, Lopinavir, Lorazepam, Lovastatin, Medroxyprogesterone, Mefloquine, Megestrol, Mephobarbital, Mepivacaine, Metaproterenol, Metformin, Methamphetamine, Methohexital, Methotrexate, Methylphenidate, Methylprednisolone, Metolazone, Metoprolol, Mexiletine, Miglitol, Moexiprilat, Mometasone, Montelukast, Mycophenolate Acid, Nadolol, Nalbuphine, Naproxen, Naratriptan, Nateglinide, Nelfinavir, Niacin, Nicotinic Acid, Nicotinamide, Nicardipine, Nimidipine, Nisoldipine, Norgestimate, Octreotide, Ofloxacin, Olmesartan, Omeprazole, Ozagrel, Paclitaxel, Pantothenic Acid, Paroxetine, Pemoline, Penbutolol, Penciclovir, Pentazocine, Pentobarbital, Perindoprilat, Phenylephrine, Phenylpropanolamine, Pindolol, Pioglitazone, Pirbuterol, Pramipexole, Pravastatin, Propafenone, Propofol, Propoxyphene, Propranolol, Prostacyclin, Prostaglandins (E1, E2 and Fat), Prostanoic Acid, Pseudoephedrine, Quinacrine, Quinaprilat, Quinethazone, Quinidine, Quinine, Ramiprilat, Reboxetine, Repaglinide, Ribavirin, Ritonavir, Ropivacaine, Rosaprostol, Rosuvastatin, Salmeterol, Salsalate, Sertraline, Simavastatin, Sotalol, Sulfa Drugs, Sulfasalazine, Sumatriptan, Tacrolimus, Tazarotene, Telmesartan, Tenofovir, Terbutaline, Tiagabine, Timolol, Tirofiban, Tocainide, Tramadol, Trandolaprilat, Tranylcypromine, Treprostinil, Triamcinolone, Trimoprostil, Troglitazone, Unoprostone, Valproic Acid, Valsartan, Venlafaxine, Vidarabine, Warfarin, Zalcitabine, Zidovudine, Zileuton, Zolmitriptan, and pharmaceutically acceptable salts thereof; and reacting said drug with an amino acid or an acylating derivative thereof, wherein the amino acid is L-Thr.

11. Use of a compound for the preparation of a medicament for treating infectious diseases in mammals caused by pathogenic microorganisms, said compound being the reaction product of the carboxylic acid functionality of the cefdinir molecule with an amino acid or an acylating derivative under ester or amide forming conditions, wherein said amino acid is L-Thr.

12. Use of a compound for treating infectious diseases in mammals caused by pathogenic microorganisms, said compound being the reaction product of the carboxylic acid functionality of the cefdinir molecule with an amino acid or an acylating derivative under ester or amide forming conditions, wherein said amino acid is L-Thr.

13. Use of a compound for the preparation of a medicament of enhancing the safety profile with longer anesthetic effect of propofol in an aqueous solution, said compound being the reaction product of the the hydroxy functionality of the propofol molecule with an amino acid or an acylating derivative thereof under ester forming conditions, wherein said amino acid is L-Thr.

14. Use of a compound for enhancing the safety profile with longer anesthetic effect of propofol in an aqueous solution, said compound being the reaction product of the hydroxy functionality of the propofol molecule with an amino acid or an acylating derivative thereof under ester forming conditions, wherein said amino acid is L-Thr.

15. Use of a compound for the preparation of a medicament for treating a microorgamism infection, said compound being the reaction product of a drug selected from the group consisting of amoxicillin, cefuroxime, ceftazidime and cexpodoxine and an amino acid or an acylating derivative thereof, wherein said amino acid is L-Thr.

16. Use of a compound for treating a microorgamism infection, said compound being the reaction product of a drug selected from the group consisting of amoxicillin, cefuroxime, ceftazidime and cexpodoxine and an amino acid or an acylating derivative thereof, wherein said amino acid is L-Thr.

17. Use of a compound for preparation of a medicament for reducing the gastric irritation of ibuprofen, said compound being the reaction product of the ibuprofen molecule or an acylating derivative thereof with an amino acid or an acylating derivative under either ester or amide forming conditions, wherein said amino acid is L-Thr.

18. Use of a compound for reducing the gastric irritation of ibuprofen, said compound being the reaction product of the ibuprofen molecule or an acylating derivative thereof with an amino acid or an acylating derivative under either ester or amide forming conditions, wherein said amino acid is L-Thr.

19. Use of a compound for preparation of a medicament for reducing the gastric irritability in the stomach, said compound being the reaction product of the aspirin molecule or an acylating derivative thereof with L-Thr or an acylating derivative thereof under either amide or ester forming conditions.

20. Use of a compound for reducing the gastric irritability in the stomach, said compound being the reaction product of the aspirin molecule or an acylating derivative thereof with L-Thr or an acylating derivative thereof under either amide or ester forming conditions.

21. The product from a reaction between a drug having a functionality selected from the group consisting of hydroxy, amino, carboxy or an acylating derivative of said carboxy group and an amino acid or an acylating derivative thereof under conditions sufficient to form a covalent bond from the reaction of said functional group and said amino acid or said compound, or the pharmaceutically acceptable salt thereof, wherein the drug is selected from the group consisting of 5-HETE, Abacavir, Acarbose, Acebutolol, Acetaminophen, Adefovir, Albuterol, Alfaprostol acid, Amlodipine, Amoxicillin, Amphotericin B, Amprenavir, Arachidonic Acid, Aspirin, Atenolol, Atorvastatin, Atropine, Atovaquone, Baclofen, Benazeprilat, Beraprost, Betaxolol, Bexarotene, Bicalutamide, Biperiden, Bisoprolol, Bitolterol, Brinzolamide, Bupivacaine, Buprenorphine, Bupropion, Butorphanol, Candesartan, Capacitabine, Captopril, Carbidopa, Carboprost, Carnitine, Carteolol, Carvedilol, Cefdinir, Cefditoren, Ceftazidime, Cefpodoxime, Cefuroxime, Cerivastatin, Chloramphenicol, Cisapride, Clofibrate, Clopidogrel Acid, Cloprostenol, Clorazepic Acid, Cycloserine, Cyclosporine, Cytarabine, Dextroamphetamine, Diclofenac, Didanosine, Divalproex, Docetaxel, Dorzolamide, Dyphylline, Dysopyramide, Efavirenz, Enalaprilat, Ephedrine, Eplerenone, Eprosartan, Esmolol, Estramustine, Ethambutol, Ethchlorvynol, Ethosuximide, Ethotoin, Etidocaine, Etoposide, Ezetimibe, Famciclovir, Fenofibrate, Fenoprofen, Fenprostalene acid, Fexofenadine, Fibric acid derivatives, Finasteride, Flavoxate, Fluprostenol, Fluoxetine, Flurbiprofen, Fluticasone, Fluvastatin, Fosinoprilat, Frovatriptan, Fulvestrant, Gemprost Acid, Glimepiride, Goserelin, Hydroxychloroquine, Hydroxyzine, Hyoscyamine, Ibuprofen, Ibutilide, Indapamide, Indinavir, Ipratropium, Irinotecan, Isosorbide, Isradipine, Ketoprofen, Ketorolac, Labetalol, Lamivudine, Lansoprazole, Latanoprost Acid, Leukotrienes (LTA4, LTB4, LTC4, LTD4 and LTE4) Leuprolide, Levobunolol, Levodopa, Levorphanol, Limaprost, .gamma.-Linolenic Acid, Liothyronine, Lisinopril, Lopinavir, Lorazepam, Lovastatin, Medroxyprogesterone, Mefloquine, Megestrol, Mephobarbital, Mepivacaine, Metaproterenol, Metformin, Methamphetamine, Methohexital, Methotrexate, Methylphenidate, Methylprednisolone, Metolazone, Metoprolol, Mexiletine, Miglitol, Moexiprilat, Mometasone, Montelukast, Mycophenolate Acid, Nadolol, Nalbuphine, Naproxen, Naratriptan, Nateglinide, Nelfinavir, Niacin, Nicotinic Acid, Nicotinamide, Nicardipine, Nimidipine, Nisoldipine, Norgestimate, Octreotide, Ofloxacin, Olmesartan, Omeprazole, Ozagrel, Paclitaxel, Pantothenic Acid, Paroxetine, Pemoline, Penbutolol, Penciclovir, Pentazocine, Pentobarbital, Perindoprilat, Phenylephrine, Phenylpropanolamine, Pindolol, Pioglitazone, Pirbuterol, Pramipexole, Pravastatin, Propafenone, Propofol, Propoxyphene, Propranolol, Prostacyclin, Prostaglandins (E1, E2 and F2.alpha.), Prostanoic Acid, Pseudoephedrine, Quinacrine, Quinaprilat, Quinethazone, Quinidine, Quinine, Ramiprilat, Reboxetine, Repaglinide, Ribavirin, Ritonavir, Ropivacaine, Rosaprostol, Rosuvastatin, Salmeterol, Salsalate, Sertraline, Simavastatin, Sotalol, Sulfa Drugs, Sulfasalazine, Sumatriptan, Tacrolimus, Tazarotene, Telmesartan, Tenofovir, Terbutaline, Tiagabine, Timolol, Tirofiban, Tocainide, Tramadol, Trandolaprilat, Tranylcypromine, Treprostinil, Triamcinolone, Trimoprostil, Troglitazone, Unoprostone, Valproic Acid, Valsartan, Venlafaxine, Vidarabine, Warfarin, Zalcitabine, Zidovudine, Zileuton, Zolmitriptan, and pharmaceutically acceptable salts thereof and wherein the amino acid is L-Thr, with the proviso that if there is an amide linkage between the drug and amino acid, the amide linkage is between the amino group of the drug and the carboxy group on the side chain of the amino acid or the amide linkage is between the carboxy group of the drug and the amino group of the side chain of the amino acid or between the carboxy group of the drug and the amino group on the main chain of the amino acid.

22. The compound of claim 4 wherein the drug is covalently bound to the L-Thr via an ester linkage.

23. The compound of claim 22, wherein the drug is 5-HETE.

24. The compound of claim 22, wherein the drug is Abacavir.

25. The compound of claim 22, wherein the drug is Acarbose.

26. The compound of claim 22, wherein the drug is Acebutolol.

27. The compound of claim 22, wherein the drug is Acetaminophen.

28. The compound of claim 22, wherein the drug is Adefovir.

29. The compound of claim 22, wherein the drug is Albuterol.

30. The compound of claim 22, wherein the drug is Alfaprostol acid.

31. The compound of claim 22, wherein the drug is Amlodipine.

32. The compound of claim 22, wherein the drug is Amoxicillin.

33. The compound of claim 22, wherein the drug is Amphotericin B.

34. The compound of claim 22, wherein the drug is Amprenavir.

35. The compound of claim 22, wherein the drug is Arachidonic Acid.

36. The compound of claim 22, wherein the drug is Aspirin.

37. The compound of claim 22, wherein the drug is Atenolol.

38. The compound of claim 22, wherein the drug is Atorvastatin.

39. The compound of claim 22, wherein the drug is Atropine.

40. The compound of claim 22, wherein the drug is Atovaquone.

41. The compound of claim 22, wherein the drug is Baclofen.

42. The compound of claim 22, wherein the drug is Benazeprilat.

43. The compound of claim 22, wherein the drug is Beraprost.

44. The compound of claim 22, wherein the drug is Betaxolol.

45. The compound of claim 22, wherein the drug is Bexarotene.

46. The compound of claim 22, wherein the drug is Bicalutamide.

47. The compound of claim 22, wherein the drug is Biperiden.

48. The compound of claim 22, wherein the drug is Bisoprolol.

49. The compound of claim 22, wherein the drug is Bitolterol.

50. The compound of claim 22, wherein the drug is Brinzolamide.

51. The compound of claim 22, wherein the drug is Bupivacaine.

52. The compound of claim 22, wherein the drug is Buprenorphine.

53. The compound of claim 22, wherein the drug is Bupropion.

54. The compound of claim 22, wherein the drug is Butorphanol.

55. The compound of claim 22, wherein the drug is Candesartan.

56. The compound of claim 22, wherein the drug is Capacitabine.

57. The compound of claim 22, wherein the drug is Captopril.

58. The compound of claim 22, wherein the drug is Carbidopa.

59. The compound of claim 22, wherein the drug is Carboprost.

60. The compound of claim 22, wherein the drug is Carnitine.

61. The compound of claim 22, wherein the drug is Carteolol.

62. The compound of claim 22, wherein the drug is Carvedilol.

63. The compound of claim 22, wherein the drug is Cefdinir.

64. The compound of claim 22, wherein the drug is Cefditoren.

65. The compound of claim 22, wherein the drug is Ceftazidime.

66. The compound of claim 22, wherein the drug is Cefpodoxime.

67. The compound of claim 22, wherein the drug is Cefuroxime.

68. The compound of claim 22, wherein the drug is Cerivastatin.

69. The compound of claim 22, wherein the drug is Chloramphenicol.

70. The compound of claim 22, wherein the drug is Cisapride.

71. The compound of claim 22, wherein the drug is Clofibrate.

72. The compound of claim 22, wherein the drug is Clopidogrel Acid.

73. The compound of claim 22, wherein the drug is Cloprostenol.

74. The compound of claim 22, wherein the drug is Clorazepic Acid.

75. The compound of claim 22, wherein the drug is Cycloserine.

76. The compound of claim 22, wherein the drug is Cyclosporine.

77. The compound of claim 22, wherein the drug is Cytarabine.

78. The compound of claim 22, wherein the drug is Dextroamphetamine.

79. The compound of claim 22, wherein the drug is Diclofenac.

80. The compound of claim 22, wherein the drug is Didanosine.

81. The compound of claim 22, wherein the drug is Divalproex.

82. The compound of claim 22, wherein the drug is Docetaxel.

83. The compound of claim 22, wherein the drug is Dorzolamide.

84. The compound of claim 22, wherein the drug is Dyphylline.

85. The compound of claim 22, wherein the drug is Dysopyramide.

86. The compound of claim 22, wherein the drug is Efavirenz.

87. The compound of claim 22, wherein the drug is Enalaprilat.

88. The compound of claim 22, wherein the drug is Ephedrine.

89. The compound of claim 22, wherein the drug is Eplerenone.

90. The compound of claim 22, wherein the drug is Eprosartan.

91. The compound of claim 22, wherein the drug is Esmolol.

92. The compound of claim 22, wherein the drug is Estramustine.

93. The compound of claim 22, wherein the drug is Ethambutol.

94. The compound of claim 22, wherein the drug is Ethchlorvynol.

95. The compound of claim 22, wherein the drug is Ethosuximide.

96. The compound of claim 22, wherein the drug is Ethotoin.

97. The compound of claim 22, wherein the drug is Etidocaine.

98. The compound of claim 22, wherein the drug is Etoposide.

99. The compound of claim 22, wherein the drug is Ezetimibe.

100. The compound of claim 22, wherein the drug is Famciclovir.

101. The compound of claim 22, wherein the drug is Fenofibrate.

102. The compound of claim 22, wherein the drug is Fenoprofen.

103. The compound of claim 22, wherein the drug is Fenprostalene acid.

104. The compound of claim 22, wherein the drug is Fexofenadine.

105. The compound of claim 22, wherein the drug is Fibric acid derivatives.

106. The compound of claim 22, wherein the drug is Finasteride.

107. The compound of claim 22, wherein the drug is Flavoxate.

108. The compound of claim 22, wherein the drug is Fluprostenol.

109. The compound of claim 22, wherein the drug is Fluoxetine.

110. The compound of claim 22, wherein the drug is Flurbiprofen.

111. The compound of claim 22, wherein the drug is Fluticasone.

112. The compound of claim 22, wherein the drug is Fluvastatin.

113. The compound of claim 22, wherein the drug is Fosinoprilat.

114. The compound of claim 22, wherein the drug is Frovatriptan.

115. The compound of claim 22, wherein the drug is Fulvestrant.

116. The compound of claim 22, wherein the drug is Gemprost Acid.

117. The compound of claim 22, wherein the drug is Glimepiride.

118. The compound of claim 22, wherein the drug is Goserelin.

119. The compound of claim 22, wherein the drug is Hydroxychloroquine.

120. The compound of claim 22, wherein the drug is Hydroxyzine.

121. The compound of claim 22, wherein the drug is Hyoscyamine.

122. The compound of claim 22, wherein the drug is Ibuprofen.

123. The compound of claim 22, wherein the drug is Ibutilide.

124. The compound of claim 22, wherein the drug is Indapamide.

125. The compound of claim 22, wherein the drug is Indinavir.

126. The compound of claim 22, wherein the drug is Ipratropium.

127. The compound of claim 22, wherein the drug is Irinotecan.

128. The compound of claim 22, wherein the drug is Isosorbide.

129. The compound of claim 22, wherein the drug is Isradipine.

130. The compound of claim 22, wherein the drug is Ketoprofen.

131. The compound of claim 22, wherein the drug is Ketorolac.

132. The compound of claim 22, wherein the drug is Labetalol.

133. The compound of claim 22, wherein the drug is Lamivudine.

134. The compound of claim 22, wherein the drug is Lansoprazole.

135. The compound of claim 22, wherein the drug is Latanoprost Acid.

136. The compound of claim 22, wherein the drug is a Leukotriene.

137. The compound of claim 136, wherein the Leukotriene is LTA4.

138. The compound of claim 137, wherein the Leukotriene is LTB4.

139. The compound of claim 137, wherein the Leukotriene is LTC4.

140. The compound of claim 137, wherein the Leukotriene is LTD4.

141. The compound of claim 137, wherein the Leukotriene is LTE4.

142. The compound of claim 22, wherein the drug is Leuprolide.

143. The compound of claim 22, wherein the drug is Levobunolol.

144. The compound of claim 22, wherein the drug is Levodopa.

145. The compound of claim 22, wherein the drug is Levorphanol.

146. The compound of claim 22, wherein the drug is Limaprost.

147. The compound of claim 22, wherein the drug is .gamma.-Linolenic Acid.

148. The compound of claim 22, wherein the drug is Liothyronine.

149. The compound of claim 22, wherein the drug is Lisinopril.

150. The compound of claim 22, wherein the drug is Lopinavir.

151. The compound of claim 22, wherein the drug is Lorazepam.

152. The compound of claim 22, wherein the drug is Lovastatin.

153. The compound of claim 22, wherein the drug is Medroxyprogesterone.

154. The compound of claim 22, wherein the drug is Mefloquine.

155. The compound of claim 22, wherein the drug is Megestrol.

156. The compound of claim 22, wherein the drug is Mephobarbital.

157. The compound of claim 22, wherein the drug is Mepivacaine.

158. The compound of claim 22, wherein the drug is Metaproterenol.

159. The compound of claim 22, wherein the drug is Metformin.

160. The compound of claim 22, wherein the drug is Methamphetamine.

161. The compound of claim 22, wherein the drug is Methohexital.

162. The compound of claim 22, wherein the drug is Methotrexate.

163. The compound of claim 22, wherein the drug is Methylphenidate.

164. The compound of claim 22, wherein the drug is Methylprednisolone.

165. The compound of claim 22, wherein the drug is Metolazone.

166. The compound of claim 22, wherein the drug is Metoprolol.

167. The compound of claim 22, wherein the drug is Mexiletine.

168. The compound of claim 22, wherein the drug is Miglitol.

169. The compound of claim 22, wherein the drug is Moexiprilat.

170. The compound of claim 22, wherein the drug is Mometasone.

171. The compound of claim 22, wherein the drug is Montelukast.

172. The compound of claim 22, wherein the drug is Mycophenolate Acid.

173. The compound of claim 22, wherein the drug is Nadolol.

174. The compound of claim 22, wherein the drug is Nalbuphine.

175. The compound of claim 22, wherein the drug is Naproxen.

176. The compound of claim 22, wherein the drug is Naratriptan.

177. The compound of claim 22, wherein the drug is Nateglinide.

178. The compound of claim 22, wherein the drug is Nelfinavir.

179. The compound of claim 22, wherein the drug is Niacin.

180. The compound of claim 22, wherein the drug is Nicotinic Acid.

181. The compound of claim 22, wherein the drug is Nicotinamide.

182. The compound of claim 22, wherein the drug is Nicardipine.

183. The compound of claim 22, wherein the drug is Nimidipine.

184. The compound of claim 22, wherein the drug is Nisoldipine.

185. The compound of claim 22, wherein the drug is Norgestimate.

186. The compound of claim 22, wherein the drug is Octreotide.

187. The compound of claim 22, wherein the drug is Ofloxacin.

188. The compound of claim 22, wherein the drug is Olmesartan.

189. The compound of claim 22, wherein the drug is Omeprazole.

190. The compound of claim 22, wherein the drug is Ozagrel.

191. The compound of claim 22, wherein the drug is Paclitaxel.

192. The compound of claim 22, wherein the drug is Pantothenic Acid.

193. The compound of claim 22, wherein the drug is Paroxetine.

194. The compound of claim 22, wherein the drug is Pemoline.

195. The compound of claim 22, wherein the drug is Penbutolol.

196. The compound of claim 22, wherein the drug is Penciclovir.

197. The compound of claim 22, wherein the drug is Pentazocine.

198. The compound of claim 22, wherein the drug is Pentobarbital.

199. The compound of claim 22, wherein the drug is Perindoprilat.

200. The compound of claim 22, wherein the drug is Phenylephrine.

201. The compound of claim 22, wherein the drug is Phenylpropanolamine.

202. The compound of claim 22, wherein the drug is Pindolol.

203. The compound of claim 22, wherein the drug is Pirbuterol.

204. The compound of claim 22, wherein the drug is Pramipexole.

205. The compound of claim 22, wherein the drug is Pravastatin.

206. The compound of claim 22, wherein the drug is Propafenone.

207. The compound of claim 22, wherein the drug is Propofol.

208. The compound of claim 22, wherein the drug is Propoxyphene.

209. The compound of claim 22, wherein the drug is Propranolol.

210. The compound of claim 22, wherein the drug is Prostacyclin.

211. The compound of claim 22, wherein the drug is a prostaglandin.

212. The compound of claim 211, wherein the prostaglandin is E1.

213. The compound of claim 211, wherein the prostaglandin is E2.

214. The compound of claim 211, wherein the prostaglandin is F2.alpha..

215. The compound of claim 22, wherein the drug is Prostanoic Acid.

216. The compound of claim 22, wherein the drug is Pseudoephedrine.

217. The compound of claim 22, wherein the drug is Quinacrine.

218. The compound of claim 22, wherein the drug is Quinaprilat.

219. The compound of claim 22, wherein the drug is Quinethazone.

220. The compound of claim 22, wherein the drug is Quinidine.

221. The compound of claim 22, wherein the drug is Quinine.

222. The compound of claim 22, wherein the drug is Ramiprilat.

223. The compound of claim 22, wherein the drug is Reboxetine.

224. The compound of claim 22, wherein the drug is Repaglinide.

225. The compound of claim 22, wherein the drug is Ribavirin.

226. The compound of claim 22, wherein the drug is Ritonavir.

227. The compound of claim 22, wherein the drug is Ropivacaine.

228. The compound of claim 22, wherein the drug is Rosaprostol.

229. The compound of claim 22, wherein the drug is Rosuvastatin.

230. The compound of claim 22, wherein the drug is Salmeterol.

231. The compound of claim 22, wherein the drug is Salsalate.

232. The compound of claim 22, wherein the drug is Sertraline.

233. The compound of claim 22, wherein the drug is Simavastatin.

234. The compound of claim 22, wherein the drug is Sotalol.

235. The compound of claim 22, wherein the drug is Sulfa Drugs.

236. The compound of claim 22, wherein the drug is Sulfasalazine.

237. The compound of claim 22, wherein the drug is Sumatriptan.

238. The compound of claim 22, wherein the drug is Tacrolimus.

239. The compound of claim 22, wherein the drug is Tazarotene.

240. The compound of claim 22, wherein the drug is Telmesartan.

241. The compound of claim 22, wherein the drug is Tenofovir.

242. The compound of claim 22, wherein the drug is Terbutaline.

243. The compound of claim 22, wherein the drug is Tiagabine.

244. The compound of claim 22, wherein the drug is Timolol.

245. The compound of claim 22, wherein the drug is Tirofiban.

246. The compound of claim 22, wherein the drug is Tocainide.

247. The compound of claim 22, wherein the drug is Tramadol.

248. The compound of claim 22, wherein the drug is Trandolaprilat.

249. The compound of claim 22, wherein the drug is Tranylcypromine.

250. The compound of claim 22, wherein the drug is Treprostinil.

251. The compound of claim 22, wherein the drug is Triamcinolone.

252. The compound of claim 22, wherein the drug is Trimoprostil.

253. The compound of claim 22, wherein the drug is Troglitazone.

254. The compound of claim 22, wherein the drug is Unoprostone.

255. The compound of claim 22, wherein the drug is Valproic Acid.

256. The compound of claim 22, wherein the drug is Valsartan.

257. The compound of claim 22, wherein the drug is Venlafaxine.

258. The compound of claim 22, wherein the drug is Vidarabine.

259. The compound of claim 22, wherein the drug is Warfarin.

260. The compound of claim 22, wherein the drug is Zalcitabine.

261. The compound of claim 22, wherein the drug is Zidovudine.

262. The compound of claim 22, wherein the drug is Zileuton.

263. The compound of claim 22, wherein the drug is Zolmitriptan.

264. The compound of claim 22, wherein the drug is Acetylsalicylic acid.

265. The compound of claim 22, wherein the drug is fenoflbric acid.

266. The compound of claim 22, wherein the drug is Ciproflxacin.

267. The compound of claim 22, wherein the drug is Ramipril.

268. The compound of claim 22, wherein the drug is Trandolapril.

269. The compound of claim 22, wherein the drug is Fosinopril.

270. The compound of claim 22, wherein the drug is Enalapril.

271. The compound of claim 22, wherein the drug is Benazepril.

272. The compound of claim 22, wherein the drug is Perindopril.

273. The compound of claim 22, wherein the drug is Moexipril.

274. The compound of claim 22, wherein the drug is Cromolyn.

275. The compound of claim 22, wherein the drug is Acyclovir.

276. The compound of claim 22, wherein the drug is Gancyclovir.

277. The compound of claim 22, wherein the drug is Trovafloxacin.

278. The compound of claim 22, wherein the drug is 5-Amino-Salicylic acid (5-AS).

279. The compound of claim 22, wherein the drug is Danazol.

280. The compound of claim 22, wherein the drug is Gabapentin.

281. The compound of claim 22, wherein the drug is Sirolimus.

282. The compound of claim 22, wherein the drug is Pimecrolimus.

283. The compound of claim 22, wherein the drug is Pioglitazone.

284. The compound of claim 22, wherein the drug is Salicyclic acid.

285. The compound of claim 22, wherein the drug is Diflunisal.

286. The compound of claim 22, wherein the drug is Carprofen.

287. The compound of claim 22, wherein the drug is Etodolac.

288. The compound of claim 22, wherein the drug is Sulindac.

289. The compound of claim 22, wherein the drug is Indomethacin.

290. The compound of claim 22, wherein the drug is Tolmetin.

291. The compound of claim 22, wherein the drug is Cefdinir.

292. The compound of claim 22, wherein the drug is Valsartan.

293. The compound of claim 22, wherein the drug is Cefditoren.